U.S. patent application number 15/699948 was filed with the patent office on 2018-12-13 for hydrophobically tagged small molecules as inducers of protein degradation.
This patent application is currently assigned to Dana-Farber Cancer Institute, Inc.. The applicant listed for this patent is Dana-Farber Cancer Institute, Inc., Yale University. Invention is credited to Craig M. Crews, Nathanael S. Gray, Pasi A. Janne, Sang Min Lim, Ting Xie.
Application Number | 20180354954 15/699948 |
Document ID | / |
Family ID | 50488791 |
Filed Date | 2018-12-13 |
United States Patent
Application |
20180354954 |
Kind Code |
A9 |
Gray; Nathanael S. ; et
al. |
December 13, 2018 |
HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN
DEGRADATION
Abstract
Provided are bifunctional small molecules of Formula (I):
##STR00001## or pharmaceutically acceptable salts thereof, wherein
M represents a small organic molecule which binds, covalently or
non-covalently, a kinase, such as Her3 protein kinase; L.sup.1
represents a linker; and R.sup.H represents a hydrophobic group. An
example of a compound of Formula (I) is a compound of Formula (II):
##STR00002## Also provided are pharmaceutical compositions
comprising a compound of Formula (I) or (II) and methods of using
such compounds for treating proliferative diseases.
Inventors: |
Gray; Nathanael S.; (Boston,
MA) ; Xie; Ting; (Boston, MA) ; Lim; Sang
Min; (San Diego, CA) ; Janne; Pasi A.;
(Needham, MA) ; Crews; Craig M.; (New Haven,
CT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Dana-Farber Cancer Institute, Inc.
Yale University |
Boston
New Haven |
MA
CT |
US
US |
|
|
Assignee: |
Dana-Farber Cancer Institute,
Inc.
Boston
MA
Yale University
New Haven
CT
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20180093990 A1 |
April 5, 2018 |
|
|
Family ID: |
50488791 |
Appl. No.: |
15/699948 |
Filed: |
September 8, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14436657 |
Apr 17, 2015 |
9758522 |
|
|
PCT/US2013/065698 |
Oct 18, 2013 |
|
|
|
15699948 |
|
|
|
|
61716305 |
Oct 19, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
A61K 31/519 20130101; C07D 487/04 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; A61K 31/519 20060101 A61K031/519 |
Claims
1-39. (canceled)
40. A compound of Formula (II): ##STR00171## or a pharmaceutically
acceptable salt thereof; wherein: Ring A is substituted or
unsubstituted carbocyclyl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl; L.sup.1 represents a linker selected from
the group consisting of substituted and unsubstituted alkylene;
substituted and unsubstituted alkenylene; substituted and
unsubstituted alkynylene; substituted and unsubstituted
heteroalkylene; substituted and unsubstituted heteroalkenylene;
substituted and unsubstituted heteroalkynylene; substituted and
unsubstituted heterocyclylene; substituted and unsubstituted
carbocyclylene; substituted and unsubstituted arylene; substituted
and unsubstituted heteroarylene; and combinations thereof; R.sup.H
represents a hydrophobic group selected from the group consisting
of substituted and unsubstituted aryl, substituted and
unsubstituted heteroaryl, substituted and unsubstituted
carbocyclyl, substituted and unsubstituted heterocyclyl,
substituted and unsubstituted aralkyl, substituted and
unsubstituted heteroarylalkyl, substituted and unsubstituted
carbocycylalkyl, and substituted and unsubstituted
heterocyclylalkyl L.sup.2 represents a bond or a linker selected
from the group consisting of substituted and unsubstituted
alkylene; substituted and unsubstituted alkenylene; substituted and
unsubstituted alkynylene; substituted and unsubstituted
heteroalkylene; substituted and unsubstituted heteroalkenylene;
substituted and unsubstituted heteroalkynylene; substituted and
unsubstituted heterocyclylene; substituted and unsubstituted
carbocyclylene; substituted and unsubstituted arylene; substituted
and unsubstituted heteroarylene; and combinations thereof; and
R.sup.D is of formula: ##STR00172## ##STR00173## ##STR00174##
wherein: R.sup.D1 is hydrogen, halogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--CN, --NO.sub.2, --OR.sup.D1a, --N(R.sup.D1a).sub.2, --SR.sup.D1a,
--CH.sub.2OR.sup.D1a, --CH.sub.2N(R.sup.D1a).sub.2,
--CH.sub.2SR.sup.D1a, --C(.dbd.O)R.sup.D1a, --C(.dbd.O)OR.sup.D1a,
--C(.dbd.O)SR.sup.D1a, --C(.dbd.O)N(R.sup.D1a).sub.2,
--C(.dbd.S)R.sup.D1a, --C(.dbd.S)OR.sup.D1a, --C(.dbd.S)SR.sup.D1a,
--C(.dbd.S)N(R.sup.D1a).sub.2, --C(.dbd.NR.sup.D1a)R.sup.D1a,
--C(.dbd.NR.sup.D1a)OR.sup.D1a, --C(.dbd.NR.sup.D1a)SR.sup.D1a, or
--C(.dbd.NR.sup.D1a)N(R.sup.D1a).sub.2, wherein each occurrence of
R.sup.D1a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
or two R.sup.D1a groups are joined to form an substituted or
unsubstituted heterocyclic ring; R.sup.D2 is hydrogen, halogen,
acyl, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --CN, --NO.sub.2,
--OR.sup.D2a, --N(R.sup.D2a).sub.2, --SR.sup.D2a,
--CH.sub.2OR.sup.D2a, --CH.sub.2N(R.sup.D2a).sub.2,
--CH.sub.2SR.sup.D2a, --C(.dbd.O)R.sup.D2a, --C(.dbd.O)OR.sup.D2a,
--C(.dbd.O)SR.sup.D2a, --C(.dbd.O)N(R.sup.D2a).sub.2,
--C(.dbd.S)R.sup.D2a, --C(.dbd.S)OR.sup.D2a, --C(.dbd.S)SR.sup.D2a,
--C(.dbd.S)N(R.sup.D2a).sub.2, --C(.dbd.NR.sup.D2a)R.sup.D2a,
--C(.dbd.NR.sup.D2a)OR.sup.D2a, --C(.dbd.NR.sup.D2a)SR.sup.D2a, and
--C(.dbd.NR.sup.D2a)N(R.sup.D2a).sub.2, wherein each occurrence of
R.sup.D2a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
or two R.sup.D2a groups are joined to form an substituted or
unsubstituted heterocyclic ring; R.sup.D3 is hydrogen, halogen,
acyl, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.D3a,
--N(R.sup.D3a).sub.2, --SR.sup.D3a, --CH.sub.2OR.sup.D3a,
--CH.sub.2N(R.sup.D3a).sub.2, --CH.sub.2SR.sup.D3a,
--C(.dbd.O)R.sup.D3a, --C(.dbd.O)OR.sup.D3a, --C(.dbd.O)SR.sup.D3a,
--C(.dbd.O)N(R.sup.D3a).sub.2, --C(.dbd.S)R.sup.D3a,
--C(.dbd.S)OR.sup.D3a, --C(.dbd.S)SR.sup.D3a,
--C(.dbd.S)N(R.sup.D3a).sub.2, --C(.dbd.NR.sup.D3a)R.sup.D3a,
--C(.dbd.NR.sup.D3a)OR.sup.D3a, --C(.dbd.NR.sup.D3a)SR.sup.D3a, or
--C(.dbd.NR.sup.D3a)N(R.sup.D3a).sub.2 wherein each occurrence of
R.sup.D3a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
or two R.sup.D3a groups are joined to form an substituted or
unsubstituted heterocyclic ring; optionally R.sup.D1 and R.sup.D3,
or R.sup.D2 and R.sup.D3, or R.sup.D1 and R.sup.D2 are joined to
form an substituted or unsubstituted carbocyclic or substituted or
unsubstituted heterocyclic ring; R.sup.D4 is a leaving group
selected from the group consisting of --Br, --Cl, --I, and
--OS(.dbd.O).sub.wR.sup.D4a, wherein w is 1 or 2, and R.sup.D4a is
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted carbocyclyl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl; each occurrence of R.sup.B is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or a nitrogen protecting
group, or two R.sup.B groups are joined to form an substituted or
unsubstituted heterocyclic or substituted or unsubstituted
heteroaryl ring; each occurrence of R.sup.C is independently
hydrogen, halogen, substituted or unsubstituted alkyl, substituted
or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.C1,
--N(R.sup.C1).sub.2, --SR.sup.C1, --C(.dbd.O)R.sup.C1,
--C(.dbd.O)OR.sup.C1, --C(.dbd.O)SR.sup.C1,
--C(.dbd.O)N(R.sup.C1).sub.2, --NR.sup.C1C(.dbd.O)R.sup.C1,
--NR.sup.C1C(.dbd.O)OR.sup.C1, --NR.sup.C1C(.dbd.O)SR.sup.C1, or
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2, wherein each occurrence of
R.sup.C1 is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl, a
nitrogen protecting group when attached to a nitrogen atom, an
oxygen protecting group when attached to an oxygen atom, or a
sulfur protecting group when attached to a sulfur atom, or two
R.sup.C1 groups are joined to form a substituted or unsubstituted
heterocyclic or substituted or unsubstituted heteroaryl ring; a is
0, 1, 2, 3, or 4; and b is 0 or 1.
41. The compound of claim 40 of Formula (II-a): ##STR00175## or a
pharmaceutically acceptable salt thereof.
42. The compound of claim 40 of Formula (II-b): ##STR00176## or a
pharmaceutically acceptable salt thereof.
43. The compound of claim 40, wherein Ring A is a substituted or
unsubstituted phenyl.
44. The compound of claim 40, wherein Ring A is a substituted or
unsubstituted 5- to 6-membered heteroaryl ring.
45. The compound of claim 40, wherein Ring A is a substituted or
unsubstituted C.sub.3-C.sub.8 carbocyclyl ring.
46. The compound of claim 40, wherein Ring A is a substituted or
unsubstituted 3- to 8-membered heterocyclyl ring.
47. The compound of claim 40 of Formula (II-c): ##STR00177## or a
pharmaceutically acceptable salt thereof; wherein: each occurrence
of R.sup.A is, independently, hydrogen, halogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.A1, --N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1,
or --C(.dbd.O)OR.sup.A1 wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and c is 0 or 1.
48. The compound of claim 40 of Formula (II-d): ##STR00178## or a
pharmaceutically acceptable salt thereof; wherein: each occurrence
of R.sup.A is, independently, hydrogen, halogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.A1, --N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1,
or --C(.dbd.O)OR.sup.A1 wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and c is 0 or 1.
49. The compound of claim 40 of Formula (II-e): ##STR00179## or a
pharmaceutically acceptable salt thereof; wherein: each occurrence
of R.sup.A is, independently, hydrogen, halogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.A1, --N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1,
or --C(.dbd.O)OR.sup.A1 wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; c is 0 or 1; and d is 0, 1, 2, 3, 4,
or 5.
50. The compound of claim 40 of Formula (II-f): ##STR00180## or a
pharmaceutically acceptable salt thereof; wherein: each occurrence
of R.sup.A is, independently, hydrogen, halogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.A1, --N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1,
or --C(.dbd.O)OR.sup.A1 wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and c is 0 or 1.
51. The compound of claim 40, wherein L.sup.1 represents a linker 4
to 20 consecutive covalently bonded atoms in length, inclusive.
52. The compound of claim 40, wherein L.sup.1 represents a linker
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive covalently
bonded atoms in length.
53. The compound of claim 40, wherein L.sup.1 represents a linker
consisting of a combination of one or more groups of the formula:
##STR00181## ##STR00182## wherein: each instance of n is
independently an integer between 1 to 10, inclusive; each instance
of m is independently 0, 1 or 2; each instance of Q is
independently --NR.sup.W1--; --NR.sup.W1--NR.sup.W1--;
--O--NR.sup.W1--; --NR.sup.W1--O--; --S--; or --O--; each instance
of W is independently O, S, or NR.sup.W1; each instance of G.sub.1
and G.sub.2 are independently N or CH; each instance of R.sup.W1 is
independently hydrogen; substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; a nitrogen protecting
group if attached to a nitrogen atom, or an oxygen protecting group
if attached to an oxygen atom; each instance of R.sup.W2 is
independently hydrogen; substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or two R.sup.W2 groups are
joined to form a 5-6 membered ring; and each instance of R.sup.W3
is independently hydrogen; halogen; substituted or unsubstituted
alkyl; substituted or unsubstituted alkenyl; substituted or
unsubstituted alkynyl; substituted or unsubstituted carbocyclyl;
substituted or unsubstituted heterocyclyl; substituted or
unsubstituted aryl; or substituted or unsubstituted heteroaryl, or
two R.sup.W3 groups are joined to form a 3-6 membered ring; or
R.sup.W1 and R.sup.W3 are joined to form a 5-6 membered
heterocyclic ring.
54. The compound of claim 40, wherein R.sup.H is a group of
formula: ##STR00183## wherein each occurrence of R.sup.H1,
R.sup.H2, and R.sup.H3 is independently halogen, alkyl, haloalkyl,
alkoxy, or dialkylamino; and p and q are independently 0, 1, 2, or
3.
55. The compound of claim 40, wherein R.sup.H is a group of
formula: ##STR00184## wherein each occurrence of R.sup.H1 and
R.sup.H2 is independently halogen, alkyl, haloalkyl, alkoxy, or
dialkylamino; and p and q are independently 0, 1, 2, or 3.
56. The compound of claim 52, wherein -L.sup.1-R.sup.H represents a
group of the formula: ##STR00185## wherein each instance of G.sub.1
and G.sub.2 are independently N or CH.
57. The compound of claim 52, wherein -L.sup.1-R.sup.H represents a
group of the formula: ##STR00186## ##STR00187## wherein each
instance of G.sub.1 and G.sub.2 are independently N or CH.
58. A pharmaceutical composition comprising a compound of claim 40,
or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable excipient.
59. A method of treating a cancer associated with aberrant activity
of a Her3 protein kinase, the method comprising administering a
compound of claim 40 or pharmaceutical composition thereof to a
subject in need thereof in an amount sufficient to reduce Her3
protein kinase activity.
Description
RELATED APPLICATIONS
[0001] The present application claims priority under 35 U.S.C.
.sctn. 119(e) to U.S. provisional patent application, U.S. Ser. No.
61/716,305, filed Oct. 19, 2012, the entirety of which is
incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Inducing protein degradation using hydrophobic tags is a
strategy that has recently received active attention from the
scientific community. For example, Crews and co-workers discovered
that covalent attachment of a hydrophobic tag to a dehalogenase
fusion protein is effective in modulating the level of the
transgenic fusion protein. See, e.g., Neklesa et al., Nature
Chemical Biology (2011) 7:538-543. Hydrophobic tags used to induce
protein degradation may eventually be found useful in a variety of
applications, such as, for example, tagged therapeutic agents and
tagged research tools for inducing protein degradation in vivo and
in vitro. However, the development of such hydrophobically tagged
agents and tools is underrealized and continues to remain of great
interest.
SUMMARY OF THE INVENTION
[0003] The present invention is based on the development of
bifunctional compounds (i.e., a kinase binding small molecule
tagged with a hydrophobic moiety) that can induce the degradation
of a kinase of interest. These bifunctional compounds possess a
kinase recognition element that can bind either covalently or
non-covalently and a `hydrophobic` tag element that signals to the
intracellular protein homeostasis machinery to induce degradation
of the targeted kinase. In contrast to all currently reported small
molecule approaches to modulating kinase activity which typically
involve inhibition of enzymatic activity, these bifunctional
compounds are designed to induce the physical elimination of the
protein from the cell. Without wishing to be bound by any
particular theory, the protein degradation induced by the
bifunctional compounds studied appears to be dependent upon the
molecular chaperone protein Hsp90 and/or on the proteasome, the
central proteolytic enzyme in the cell.
[0004] Bifunctional compounds contemplated herein are generally
represented by Formula (I):
##STR00003##
or a pharmaceutically acceptable salt thereof; wherein:
[0005] M represents a small organic molecule which binds to a
kinase;
[0006] L.sup.1 represents a linker selected from the group
consisting of substituted and unsubstituted alkylene, substituted
and unsubstituted alkenylene, substituted and unsubstituted
alkynylene, substituted and unsubstituted heteroalkylene,
substituted and unsubstituted heteroalkenylene, substituted and
unsubstituted heteroalkynylene, substituted and unsubstituted
heterocyclylene, substituted and unsubstituted carbocyclylene,
substituted and unsubstituted arylene; substituted and
unsubstituted heteroarylene, and combinations thereof; and
[0007] R.sup.H represents a hydrophobic group selected from the
group consisting of substituted and unsubstituted aryl, substituted
and unsubstituted heteroaryl, substituted and unsubstituted
carbocyclyl, substituted and unsubstituted heterocyclyl,
substituted and unsubstituted aralkyl, substituted and
unsubstituted heteroarylalkyl, substituted and unsubstituted
carbocycylalkyl, and substituted and unsubstituted
heterocyclylalkyl.
[0008] Binding of a small molecule M refers to covalent or
non-covalent binding to a kinase, e.g., a protein kinase. In
certain embodiments, M covalently binds a protein kinase. In other
embodiments, M non-covalently binds a protein kinase. Exemplary
kinases are listed herein. In certain embodiments, M represents a
small organic molecule which covalently or non-covalently binds to
Her3 kinase.
[0009] The small organic molecule M is substituted with a group
-L.sup.2-R.sup.D, wherein:
[0010] L.sup.2 represents a bond or a linker selected from the
group consisting of substituted and unsubstituted alkylene;
substituted and unsubstituted alkenylene; substituted and
unsubstituted alkynylene; substituted and unsubstituted
heteroalkylene; substituted and unsubstituted heteroalkenylene;
substituted and unsubstituted heteroalkynylene; substituted and
unsubstituted heterocyclylene; substituted and unsubstituted
carbocyclylene; substituted and unsubstituted arylene; substituted
and unsubstituted heteroarylene; and combinations thereof; and
[0011] R.sup.D is of the formula:
##STR00004## ##STR00005## ##STR00006##
wherein Y, X.sup.1, R.sup.D1, R.sup.D2, R.sup.D3, R.sup.D4, and z
are as define herein.
[0012] In certain embodiments, the compound of Formula (I) is a
compound of Formula (II):
##STR00007##
or a pharmaceutically acceptable salt thereof; wherein Ring A,
R.sup.B, R.sup.C, R.sup.D, R.sup.H, L.sup.1, L.sup.2, a, and b are
as defined herein.
[0013] In certain embodiments, Ring A is substituted or
unsubstituted phenyl. In certain embodiments, Ring A is a
substituted or unsubstituted 5- to 6-membered heteroaryl ring. In
certain embodiments, Ring A is a substituted or unsubstituted
C.sub.3-8 carbocyclyl ring. In certain embodiments, Ring A is a
substituted or unsubstituted 3- to 8-membered heterocyclyl
ring.
[0014] In certain embodiments, R.sup.H is a substituted or
unsubstituted hydrophobic group of formula:
##STR00008##
wherein R.sup.H1, R.sup.H2, R.sup.H3, q, and p are as defined
herein.
[0015] In certain embodiments, L.sup.1 represents a linker 4 to 20
consecutive covalently bonded atoms in length, inclusive. In
certain embodiments, L.sup.1 represents a linker 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, or 15 consecutive covalently bonded atoms in
length.
[0016] In certain embodiments, L.sup.1 represents a linker
consisting of a combination of one or more groups of the
formulae:
##STR00009## ##STR00010##
wherein n, m, Q, W, G.sub.1, G.sub.2, R.sup.W1, R.sup.W2, and
R.sup.W3 are as defined herein.
[0017] In certain embodiments, the compound of Formula (I) has a
molecular weight of between about 200 to about 800 g/mol,
inclusive. In certain embodiments, the compound has a c Log P less
than 5, e.g., between about -8 to about 4.9 c Log P, inclusive. In
certain embodiments, the compound has 0, 1, 2, 3, 4, or 5 hydrogen
bond donors. In certain embodiments, the compound has 0, 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10 hydrogen bond acceptors.
[0018] In another aspect, provided are pharmaceutical compositions
comprising a compound of Formula (I), or a pharmaceutically
acceptable salt thereof, and optionally a pharmaceutically
acceptable excipient. The pharmaceutical composition may be useful
in treating proliferative diseases, such as cancer.
[0019] In yet another aspect, provided are methods of treating a
condition associated with aberrant activity of a kinase, e.g., a
protein kinase, the method comprising administering a compound of
Formula (I), or a pharmaceutical composition thereof, to a subject
in need thereof in an amount sufficient to reduce kinase activity.
In certain embodiments, the compound reduces kinase activity by
targeted degradation of the protein kinase. In certain embodiments,
the compound reduces kinase activity by inducing unfolding of the
protein kinase. In certain embodiments, the compound reduces kinase
activity by covalently binding to the protein kinase. In certain
embodiments, the compound reduces kinase activity by non-covalently
binding to the protein kinase. In certain embodiments, the
condition being treated is a proliferative disorder. In certain
embodiments, the proliferative disorder is cancer.
[0020] The details of one or more embodiments of the invention are
set forth in the accompanying Figures, the Detailed Description,
and the Examples. Other features, objects, and advantages of the
invention will be apparent from the description and from the
claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] FIG. 1 depicts the general hydrophobic tagging induced
degradation strategy.
[0022] FIG. 2 depicts the results of a Invitrogen LanthaScreen.TM.
Eu kinase binding assay of TX2-112-1, TX2-113-1, TX2-114-1,
TX2-120-1, and TX2-121-1 (depicted in Table 1).
[0023] FIG. 3 depicts results of a CellTiter-Glo.RTM. Luminescent
Assay (anti-proliferation assay) of TX2-112-1, TX2-113-1,
TX2-114-1, TX2-120-1, and TX2-121-1 (depicted in Table 1).
[0024] FIGS. 4A and 4B depict electrophoretic gel image (SDS-PAGE)
results of compounds TX2-112-1, TX2-113-1, TX2-114-1, TX2-120-1,
and TX2-121-1 (FIG. 4A) and SML-11-124-1 and TX2-126-1 (FIG. 4B)
immunoblotted against various antibodies; line 1: ErbB3 antibody;
line 2: Phospho-Akt (Ser473) antibody; line 3: p44/42 MAPK
(p-Erk1/2) antibody; line 4: T-Akt antibody; and line 5:
Phospho-p44/42 MAPK (T-Erk1/2) (Thr202/Thr204) antibody.
DEFINITIONS
Chemical Definitions
[0025] Definitions of specific functional groups and chemical terms
are described in more detail below. The chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed.,
inside cover, and specific functional groups are generally defined
as described therein. Additionally, general principles of organic
chemistry, as well as specific functional moieties and reactivity,
are described in Organic Chemistry, Thomas Sorrell, University
Science Books, Sausalito, 1999; Smith and March March's Advanced
Organic Chemistry, 5.sup.th Edition, John Wiley & Sons, Inc.,
New York, 2001; Larock, Comprehensive Organic Transformations, VCH
Publishers, Inc., New York, 1989; and Carruthers, Some Modern
Methods of Organic Synthesis, 3.sup.rd Edition, Cambridge
University Press, Cambridge, 1987.
[0026] Compounds described herein can comprise one or more
asymmetric centers, and thus can exist in various stereoisomeric
forms, e.g., enantiomers and/or diastereomers. For example, the
compounds described herein can be in the form of an individual
enantiomer, diastereomer or geometric isomer, or can be in the form
of a mixture of stereoisomers, including racemic mixtures and
mixtures enriched in one or more stereoisomer. "Racemic" refers to
a compound in which the percent by weight of one enantiomer is
equal to the percent by weight of the other enantiomer.
[0027] The terms "enantiomerically enriched," "enantiomerically
pure" and "non-racemic," as used interchangeably herein, refer to a
compound in which the percent by weight of one enantiomer is
greater than the amount of that one enantiomer compared to a
control mixture of the racemic composition (e.g., greater than 1:1
by weight). For example, an enantiomerically enriched enantiomer,
means a compound having greater than 50% by weight of one
enantiomer relative to the other enantiomer, e.g., at least 75% by
weight, or at least 80% by weight. In some embodiments, the
enrichment can be much greater than 80% by weight, providing a
"substantially enantiomerically enriched," "substantially
enantiomerically pure" or a "substantially non-racemic" compound,
which refers to a compound with at least 85% by weight of one
enantiomer relative to other enantiomer, e.g., at least 90% by
weight, or at least 95% by weight.
[0028] Enantiomers can be isolated from mixtures by methods known
to those skilled in the art, including chiral high pressure liquid
chromatography (HPLC) and the formation and crystallization of
chiral salts; or preferred enantiomers can be prepared by
asymmetric syntheses. See, for example, Jacques, et al.,
Enantiomers, Racemates and Resolutions (Wiley Interscience, New
York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977);
Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, N Y,
1962); and Wilen, S. H. Tables of Resolving Agents and Optical
Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press,
Notre Dame, Ind. 1972).
[0029] When a range of values is listed, it is intended to
encompass each value and sub-range within the range. For example
"C.sub.1-6 alkyl" is intended to encompass, C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-6, C.sub.1-5,
C.sub.1-4, C.sub.1-3, C.sub.1-2, C.sub.2-6, C.sub.2-5, C.sub.2-4,
C.sub.2-3, C.sub.3-6, C.sub.3-5, C.sub.3-4, C.sub.4-6, C.sub.4-5,
and C.sub.5-6 alkyl.
[0030] As used herein, "alkyl" refers to a radical of a
straight-chain or branched saturated hydrocarbon group having from
1 to 10 carbon atoms ("C.sub.1-10 alkyl"). In some embodiments, an
alkyl group has 1 to 9 carbon atoms ("C.sub.1-9 alkyl"). In some
embodiments, an alkyl group has 1 to 8 carbon atoms ("C.sub.1-8
alkyl"). In some embodiments, an alkyl group has 1 to 7 carbon
atoms ("C.sub.1-7 alkyl"). In some embodiments, an alkyl group has
1 to 6 carbon atoms ("C.sub.1-6 alkyl"). In some embodiments, an
alkyl group has 1 to 5 carbon atoms ("C.sub.1-5 alkyl"). In some
embodiments, an alkyl group has 1 to 4 carbon atoms ("C.sub.1-4
alkyl"). In some embodiments, an alkyl group has 1 to 3 carbon
atoms ("C.sub.1-3 alkyl"). In some embodiments, an alkyl group has
1 to 2 carbon atoms ("C.sub.1-2 alkyl"). In some embodiments, an
alkyl group has 1 carbon atom ("C.sub.1 alkyl"). In some
embodiments, an alkyl group has 2 to 6 carbon atoms ("C.sub.2-6
alkyl"). Examples of C.sub.1-6 alkyl groups include methyl
(C.sub.1), ethyl (C.sub.2), n-propyl (C.sub.3), isopropyl
(C.sub.3), n-butyl (C.sub.4), tert-butyl (C.sub.4), sec-butyl
(C.sub.4), iso-butyl (C.sub.4), n-pentyl (C.sub.5), 3-pentanyl (C),
amyl (C.sub.5), neopentyl (C.sub.5), 3-methyl-2-butanyl (C.sub.5),
tertiary amyl (C.sub.5), and n-hexyl (C.sub.6). Additional examples
of alkyl groups include n-heptyl (C.sub.7), n-octyl (C.sub.8) and
the like. Unless otherwise specified, each instance of an alkyl
group is independently unsubstituted (an "unsubstituted alkyl") or
substituted (a "substituted alkyl") with one or more substituents.
In certain embodiments, the alkyl group is an unsubstituted
C.sub.1-10 alkyl (e.g., --CH.sub.3). In certain embodiments, the
alkyl group is a substituted C.sub.1-10 alkyl.
[0031] As used herein, "haloalkyl" is a substituted alkyl group as
defined herein wherein one or more of the hydrogen atoms are
independently replaced by a halogen, e.g., fluoro, bromo, chloro,
or iodo. "Perhaloalkyl" is a subset of haloalkyl, and refers to an
alkyl group wherein all of the hydrogen atoms are independently
replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In
some embodiments, the haloalkyl moiety has 1 to 8 carbon atoms
("C.sub.1-8 haloalkyl"). In some embodiments, the haloalkyl moiety
has 1 to 6 carbon atoms ("C.sub.1-6 haloalkyl"). In some
embodiments, the haloalkyl moiety has 1 to 4 carbon atoms
("C.sub.1-4 haloalkyl"). In some embodiments, the haloalkyl moiety
has 1 to 3 carbon atoms ("C.sub.1-3 haloalkyl"). In some
embodiments, the haloalkyl moiety has 1 to 2 carbon atoms
("C.sub.1-2 haloalkyl"). In some embodiments, all of the haloalkyl
hydrogen atoms are replaced with fluoro to provide a perfluoroalkyl
group. In some embodiments, all of the haloalkyl hydrogen atoms are
replaced with chloro to provide a "perchloroalkyl" group. Examples
of haloalkyl groups include --CF.sub.3, --CF.sub.2CF.sub.3,
--CF.sub.2CF.sub.2CF.sub.3, --CCl.sub.3, --CFCl.sub.2,
--CF.sub.2Cl, and the like.
[0032] As used herein, "heteroalkyl" refers to an alkyl group as
defined herein which further includes at least one heteroatom
(e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen,
or sulfur within (i.e., inserted between adjacent carbon atoms of)
and/or placed at one or more terminal position(s) of the parent
chain. In certain embodiments, a heteroalkyl group refers to a
saturated group having from 1 to 10 carbon atoms and 1, 2, 3, or 4
heteroatoms within the parent chain ("heteroC.sub.1-10 alkyl"). In
some embodiments, a heteroalkyl group is a saturated group having 1
to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms within the parent
chain ("heteroC.sub.1-9 alkyl"). In some embodiments, a heteroalkyl
group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3,
or 4 heteroatoms within the parent chain ("heteroC.sub.1-8 alkyl").
In some embodiments, a heteroalkyl group is a saturated group
having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms within the
parent chain ("heteroC.sub.1-7 alkyl"). In some embodiments, a
heteroalkyl group is a saturated group having 1 to 6 carbon atoms
and 1, 2, or 3 heteroatoms within the parent chain
("heteroC.sub.1-6 alkyl"). In some embodiments, a heteroalkyl group
is a saturated group having 1 to 5 carbon atoms and 1 or 2
heteroatoms within the parent chain ("heteroC.sub.1-5 alkyl"). In
some embodiments, a heteroalkyl group is a saturated group having 1
to 4 carbon atoms and 1 or 2 heteroatoms within the parent chain
("heteroC.sub.1-4 alkyl"). In some embodiments, a heteroalkyl group
is a saturated group having 1 to 3 carbon atoms and 1 heteroatom
within the parent chain ("heteroC.sub.1-3 alkyl"). In some
embodiments, a heteroalkyl group is a saturated group having 1 to 2
carbon atoms and 1 heteroatom within the parent chain
("heteroC.sub.1-2 alkyl"). In some embodiments, a heteroalkyl group
is a saturated group having 1 carbon atom and 1 heteroatom
("heteroC.sub.1 alkyl"). In some embodiments, a heteroalkyl group
is a saturated group having 2 to 6 carbon atoms and 1 or 2
heteroatoms within the parent chain ("heteroC.sub.2-6 alkyl").
Unless otherwise specified, each instance of a heteroalkyl group is
independently unsubstituted (an "unsubstituted heteroalkyl") or
substituted (a "substituted heteroalkyl") with one or more
substituents. In certain embodiments, the heteroalkyl group is an
unsubstituted heteroC.sub.1-10 alkyl. In certain embodiments, the
heteroalkyl group is a substituted heteroC.sub.1-10 alkyl.
[0033] As used herein, "alkenyl" refers to a radical of a
straight-chain or branched hydrocarbon group having from 2 to 10
carbon atoms and one or more double bonds (e.g., 1, 2, 3, or 4
double bonds) and no triple bonds. In some embodiments, an alkenyl
group has 2 to 9 carbon atoms ("C.sub.2-9 alkenyl"). In some
embodiments, an alkenyl group has 2 to 8 carbon atoms ("C.sub.2-8
alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon
atoms ("C.sub.2-7 alkenyl"). In some embodiments, an alkenyl group
has 2 to 6 carbon atoms ("C.sub.2-6 alkenyl"). In some embodiments,
an alkenyl group has 2 to 5 carbon atoms ("C.sub.2-5 alkenyl"). In
some embodiments, an alkenyl group has 2 to 4 carbon atoms
("C.sub.2-4 alkenyl"). In some embodiments, an alkenyl group has 2
to 3 carbon atoms ("C.sub.2-3 alkenyl"). In some embodiments, an
alkenyl group has 2 carbon atoms ("C.sub.2 alkenyl"). The one or
more carbon-carbon double bonds can be internal (such as in
2-butenyl) or terminal (such as in 1-butenyl). Examples of
C.sub.2-4 alkenyl groups include ethenyl (C.sub.2), 1-propenyl
(C.sub.3), 2-propenyl (C.sub.3), 1-butenyl (C.sub.4), 2-butenyl
(C.sub.4), butadienyl (C.sub.4), and the like. Examples of
C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4
alkenyl groups as well as pentenyl (C.sub.5), pentadienyl
(C.sub.5), hexenyl (C.sub.6), and the like. Additional examples of
alkenyl include heptenyl (C.sub.7), octenyl (C.sub.8), octatrienyl
(C.sub.8), and the like. Unless otherwise specified, each instance
of an alkenyl group is independently unsubstituted (an
"unsubstituted alkenyl") or substituted (a "substituted alkenyl")
with one or more substituents. In certain embodiments, the alkenyl
group is an unsubstituted C.sub.2-10 alkenyl. In certain
embodiments, the alkenyl group is a substituted C.sub.2-10
alkenyl.
[0034] As used herein, "heteroalkenyl" refers to an alkenyl group
as defined herein which further includes at least one heteroatom
(e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen,
or sulfur within (i.e., inserted between adjacent carbon atoms of)
and/or placed at one or more terminal position(s) of the parent
chain. In certain embodiments, a heteroalkenyl group refers to a
group having from 2 to 10 carbon atoms, at least one double bond,
and 1, 2, 3, or 4 heteroatoms within the parent chain
("heteroC.sub.2-10 alkenyl"). In some embodiments, a heteroalkenyl
group has 2 to 9 carbon atoms at least one double bond, and 1, 2,
3, or 4 heteroatoms within the parent chain ("heteroC.sub.2-9
alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 8
carbon atoms, at least one double bond, and 1, 2, 3, or 4
heteroatoms within the parent chain ("heteroC.sub.2-8 alkenyl"). In
some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at
least one double bond, and 1, 2, 3, or 4 heteroatoms within the
parent chain ("heteroC.sub.2-7 alkenyl"). In some embodiments, a
heteroalkenyl group has 2 to 6 carbon atoms, at least one double
bond, and 1, 2, or 3 heteroatoms within the parent chain
("heteroC.sub.2-6 alkenyl"). In some embodiments, a heteroalkenyl
group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2
heteroatoms within the parent chain ("heteroC.sub.2-5 alkenyl"). In
some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at
least one double bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-4 alkenyl"). In some embodiments, a
heteroalkenyl group has 2 to 3 carbon atoms, at least one double
bond, and 1 heteroatom within the parent chain ("heteroC.sub.2-3
alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6
carbon atoms, at least one double bond, and 1 or 2 heteroatoms
within the parent chain ("heteroC.sub.2-6 alkenyl"). Unless
otherwise specified, each instance of a heteroalkenyl group is
independently unsubstituted (an "unsubstituted heteroalkenyl") or
substituted (a "substituted heteroalkenyl") with one or more
substituents. In certain embodiments, the heteroalkenyl group is an
unsubstituted heteroC.sub.2-10 alkenyl. In certain embodiments, the
heteroalkenyl group is a substituted heteroC.sub.2-10 alkenyl.
[0035] As used herein, "alkynyl" refers to a radical of a
straight-chain or branched hydrocarbon group having from 2 to 10
carbon atoms and one or more triple bonds (e.g., 1, 2, 3, or 4
triple bonds) and optionally one or more double bonds (e.g., 1, 2,
3, or 4 double bonds) ("C.sub.2-10 alkynyl"). An alkynyl group that
has one or more triple bonds and one or more double bonds is also
referred to as an "ene-yene" group. In some embodiments, an alkynyl
group has 2 to 9 carbon atoms ("C.sub.2-9 alkynyl"). In some
embodiments, an alkynyl group has 2 to 8 carbon atoms ("C.sub.2-8
alkynyl"). In some embodiments, an alkynyl group has 2 to 7 carbon
atoms ("C.sub.2-7 alkynyl"). In some embodiments, an alkynyl group
has 2 to 6 carbon atoms ("C.sub.2-6 alkynyl"). In some embodiments,
an alkynyl group has 2 to 5 carbon atoms ("C.sub.2-5 alkynyl"). In
some embodiments, an alkynyl group has 2 to 4 carbon atoms
("C.sub.2-4 alkynyl"). In some embodiments, an alkynyl group has 2
to 3 carbon atoms ("C.sub.2-3 alkynyl"). In some embodiments, an
alkynyl group has 2 carbon atoms ("C.sub.2 alkynyl"). The one or
more carbon-carbon triple bonds can be internal (such as in
2-butynyl) or terminal (such as in 1-butynyl). Examples of
C.sub.2-4 alkynyl groups include, without limitation, ethynyl
(C.sub.2), 1-propynyl (C.sub.3), 2-propynyl (C.sub.3), 1-butynyl
(C.sub.4), 2-butynyl (C.sub.4), and the like. Examples of C.sub.2-6
alkenyl groups include the aforementioned C.sub.2-4 alkynyl groups
as well as pentynyl (C.sub.5), hexynyl (C.sub.6), and the like.
Additional examples of alkynyl include heptynyl (C.sub.7), octynyl
(C.sub.8), and the like. Unless otherwise specified, each instance
of an alkynyl group is independently unsubstituted (an
"unsubstituted alkynyl") or substituted (a "substituted alkynyl")
with one or more substituents. In certain embodiments, the alkynyl
group is an unsubstituted C.sub.2-10 alkynyl. In certain
embodiments, the alkynyl group is a substituted C.sub.2-10
alkynyl.
[0036] As used herein, "heteroalkynyl" refers to an alkynyl group
as defined herein which further includes at least one heteroatom
(e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen,
or sulfur within (i.e., inserted between adjacent carbon atoms of)
and/or placed at one or more terminal position(s) of the parent
chain. In certain embodiments, a heteroalkynyl group refers to a
group having from 2 to 10 carbon atoms, at least one triple bond,
and 1, 2, 3, or 4 heteroatoms within the parent chain
("heteroC.sub.2-10 alkynyl"). In some embodiments, a heteroalkynyl
group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2,
3, or 4 heteroatoms within the parent chain ("heteroC.sub.2-9
alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 8
carbon atoms, at least one triple bond, and 1, 2, 3, or 4
heteroatoms within the parent chain ("heteroC.sub.2-8 alkynyl"). In
some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at
least one triple bond, and 1, 2, 3, or 4 heteroatoms within the
parent chain ("heteroC.sub.2-7 alkynyl"). In some embodiments, a
heteroalkynyl group has 2 to 6 carbon atoms, at least one triple
bond, and 1, 2, or 3 heteroatoms within the parent chain
("heteroC.sub.2-6 alkynyl"). In some embodiments, a heteroalkynyl
group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2
heteroatoms within the parent chain ("heteroC.sub.2-5 alkynyl"). In
some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at
least one triple bond, and 1 or 2 heteroatoms within the parent
chain ("heteroC.sub.2-4 alkynyl"). In some embodiments, a
heteroalkynyl group has 2 to 3 carbon atoms, at least one triple
bond, and 1 heteroatom within the parent chain ("heteroC.sub.2-3
alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6
carbon atoms, at least one triple bond, and 1 or 2 heteroatoms
within the parent chain ("heteroC.sub.2-6 alkynyl"). Unless
otherwise specified, each instance of a heteroalkynyl group is
independently unsubstituted (an "unsubstituted heteroalkynyl") or
substituted (a "substituted heteroalkynyl") with one or more
substituents. In certain embodiments, the heteroalkynyl group is an
unsubstituted heteroC.sub.2-10 alkynyl. In certain embodiments, the
heteroalkynyl group is a substituted heteroC.sub.2-10 alkynyl.
[0037] As used herein, "carbocyclyl" or "carbocyclic" refers to a
radical of a non-aromatic cyclic hydrocarbon group having from 3 to
14 ring carbon atoms ("C.sub.3-14 carbocyclyl") and zero
heteroatoms in the non-aromatic ring system. In some embodiments, a
carbocyclyl group has 3 to 10 ring carbon atoms ("C.sub.3-10
carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 9
ring carbon atoms ("C.sub.3-9 carbocyclyl"). In some embodiments, a
carbocyclyl group has 3 to 8 ring carbon atoms ("C.sub.3-8
carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 7
ring carbon atoms ("C.sub.3-7 carbocyclyl"). In some embodiments, a
carbocyclyl group has 3 to 6 ring carbon atoms ("C.sub.3-6
carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 10
ring carbon atoms ("C.sub.5-10 carbocyclyl"). Exemplary C.sub.3-6
carbocyclyl groups include, without limitation, cyclopropyl
(C.sub.3), cyclopropenyl (C.sub.3), cyclobutyl (C.sub.4),
cyclobutenyl (C.sub.4), cyclopentyl (C.sub.5), cyclopentenyl
(C.sub.5), cyclohexyl (C.sub.6), cyclohexenyl (C.sub.6),
cyclohexadienyl (C.sub.6), and the like. Exemplary C.sub.3-8
carbocyclyl groups include, without limitation, the aforementioned
C.sub.3-6 carbocyclyl groups as well as cycloheptyl (C.sub.7),
cycloheptenyl (C.sub.7), cycloheptadienyl (C.sub.7),
cycloheptatrienyl (C.sub.7), cyclooctyl (C.sub.8), cyclooctenyl
(C.sub.8), bicyclo[2.2.1]heptanyl (C.sub.7), bicyclo[2.2.2]octanyl
(C.sub.8), and the like. Exemplary C.sub.3-10 carbocyclyl groups
include, without limitation, the aforementioned C.sub.3-8
carbocyclyl groups as well as cyclononyl (C.sub.9), cyclononenyl
(C.sub.9), cyclodecyl (C.sub.10), cyclodecenyl (C.sub.10),
octahydro-1H-indenyl (C.sub.9), decahydronaphthalenyl (C.sub.10),
spiro[4.5]decanyl (C.sub.10), and the like. In certain embodiments,
the carbocyclyl group is either monocyclic ("monocyclic
carbocyclyl") or polycyclic (e.g., containing a fused, bridged or
spiro-fused ring system such as a bicyclic system ("bicyclic
carbocyclyl") or tricyclic system ("tricyclic carbocyclyl")) and
can be saturated or can contain one or more carbon-carbon double or
triple bonds. Exemplary fused bicyclic systems include, but are not
limited to, decalin (cis or trans decalin). Exemplary fused
tricyclic systems include, but are not limited to, fluorenyl.
Exemplary spiro-fused bicyclic systems include, but are not limited
to, spiropentane. Exemplary bridged bicyclic systems include, but
are not limited to, norbornane, norbornene, bicyclo[2.2.2]octane,
bicyclo[2.2.2]oct-2-ene, bicyclo[3.2.1]octane, and
bicyclo[2.2.1]heptan-2-one. Exemplary bridged tricyclic systems
include, but are not limited to adamantane. "Carbocyclyl" includes
ring systems wherein the carbocyclyl ring, as defined above, is
fused with one or more aryl or heteroaryl groups wherein the point
of attachment is on the carbocyclyl ring, and in such instances,
the number of carbons continue to designate the number of carbons
in the carbocyclic ring system. Unless otherwise specified, each
instance of a carbocyclyl group is independently unsubstituted (an
"unsubstituted carbocyclyl") or substituted (a "substituted
carbocyclyl") with one or more substituents. In certain
embodiments, the carbocyclyl group is an unsubstituted C.sub.3-14
carbocyclyl. In certain embodiments, the carbocyclyl group is a
substituted C.sub.3-14 carbocyclyl.
[0038] "Carbocyclylalkyl" is a subset of "alkyl" and refers to an
alkyl group, as defined herein, substituted by an carbocyclyl
group, as defined herein, wherein the point of attachment is on the
alkyl moiety.
[0039] As used herein, "heterocyclyl" or "heterocyclic" refers to a
radical of a 3- to 14-membered non-aromatic ring system having ring
carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom
is independently selected from nitrogen, oxygen, and sulfur ("3-14
membered heterocyclyl"). In heterocyclyl groups that contain one or
more nitrogen atoms, the point of attachment can be a carbon or
nitrogen atom, as valency permits. A heterocyclyl group can either
be monocyclic ("monocyclic heterocyclyl") or polycyclic (e.g., a
fused, bridged or spiro ring system such as a bicyclic system
("bicyclic heterocyclyl") or tricyclic system ("tricyclic
heterocyclyl")), and can be saturated or can contain one or more
carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring
systems can include one or more heteroatoms in one or both rings.
In certain embodiments, the heterocyclyl group is either monocyclic
("monocyclic heterocyclyl") or polycyclic (e.g., containing a
fused, bridged or spiro-fused ring system such as a bicyclic system
("bicyclic heterocyclyl") or tricyclic system ("tricyclic
heterocyclyl")) and can be saturated or can contain one or more
carbon-carbon double or triple bonds. "Heterocyclyl" also includes
ring systems wherein the heterocyclyl ring, as defined above, is
fused with one or more carbocyclyl groups wherein the point of
attachment is either on the carbocyclyl or heterocyclyl ring, or
ring systems wherein the heterocyclyl ring, as defined above, is
fused with one or more aryl or heteroaryl groups, wherein the point
of attachment is on the heterocyclyl ring, and in such instances,
the number of ring members continue to designate the number of ring
members in the heterocyclyl ring system. Unless otherwise
specified, each instance of heterocyclyl is independently
unsubstituted (an "unsubstituted heterocyclyl") or substituted (a
"substituted heterocyclyl") with one or more substituents. In
certain embodiments, the heterocyclyl group is an unsubstituted
3-14 membered heterocyclyl. In certain embodiments, the
heterocyclyl group is a substituted 3-14 membered heterocyclyl.
[0040] In some embodiments, a heterocyclyl group is a 5-10 membered
non-aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms, wherein each heteroatom is independently selected from
nitrogen, oxygen, and sulfur ("5-10 membered heterocyclyl"). In
some embodiments, a heterocyclyl group is a 5-8 membered
non-aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms, wherein each heteroatom is independently selected from
nitrogen, oxygen, and sulfur ("5-8 membered heterocyclyl"). In some
embodiments, a heterocyclyl group is a 5-6 membered non-aromatic
ring system having ring carbon atoms and 1-4 ring heteroatoms,
wherein each heteroatom is independently selected from nitrogen,
oxygen, and sulfur ("5-6 membered heterocyclyl"). In some
embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms
selected from nitrogen, oxygen, and sulfur. In some embodiments,
the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected
from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6
membered heterocyclyl has 1 ring heteroatom selected from nitrogen,
oxygen, and sulfur.
[0041] Exemplary 3-membered heterocyclyl groups containing 1
heteroatom include, without limitation, azirdinyl, oxiranyl,
thiorenyl. Exemplary 4-membered heterocyclyl groups containing 1
heteroatom include, without limitation, azetidinyl, oxetanyl and
thietanyl. Exemplary 5-membered heterocyclyl groups containing 1
heteroatom include, without limitation, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl,
pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary
5-membered heterocyclyl groups containing 2 heteroatoms include,
without limitation, dioxolanyl, oxathiolanyl, and dithiolanyl.
Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms
include, without limitation, triazolinyl, oxadiazolinyl, and
thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing
1 heteroatom include, without limitation, piperidinyl,
tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary
6-membered heterocyclyl groups containing 2 heteroatoms include,
without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl.
Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms
include, without limitation, triazinanyl. Exemplary 7-membered
heterocyclyl groups containing 1 heteroatom include, without
limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered
heterocyclyl groups containing 1 heteroatom include, without
limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic
heterocyclyl groups include, without limitation, indolinyl,
isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,
tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl,
decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl,
octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl,
naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepinyl,
1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl,
5,6-dihydro-4H-furo[3,2-b]pyrrolyl,
6,7-dihydro-5H-furo[3,2-b]pyranyl,
5,7-dihydro-4H-thieno[2,3-c]pyranyl,
2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl,
2,3-dihydrofuro[2,3-b]pyridinyl,
4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl,
4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl,
4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl,
1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like.
[0042] "Heterocyclylalkyl" is a subset of "alkyl" and refers to an
alkyl group, as defined herein, substituted by an heterocyclyl
group, as defined herein, wherein the point of attachment is on the
alkyl moiety.
[0043] As used herein, "aryl" refers to a radical of a monocyclic
or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring
system (e.g., having 6, 10, or 14 n electrons shared in a cyclic
array) having 6-14 ring carbon atoms and zero heteroatoms provided
in the aromatic ring system ("C.sub.6-14 aryl"). In some
embodiments, an aryl group has 6 ring carbon atoms ("C.sub.6 aryl";
e.g., phenyl). In some embodiments, an aryl group has 10 ring
carbon atoms ("C.sub.10 aryl"; e.g., naphthyl such as 1-naphthyl
and 2-naphthyl). In some embodiments, an aryl group has 14 ring
carbon atoms ("C.sub.14 aryl"; e.g., anthracenyl). "Aryl" also
includes ring systems wherein the aryl ring, as defined above, is
fused with one or more carbocyclyl or heterocyclyl groups wherein
the radical or point of attachment is on the aryl ring, and in such
instances, the number of carbon atoms continue to designate the
number of carbon atoms in the aryl ring system. Unless otherwise
specified, each instance of an aryl group is independently
unsubstituted (an "unsubstituted aryl") or substituted (a
"substituted aryl") with one or more substituents. In certain
embodiments, the aryl group is an unsubstituted C.sub.6-14 aryl. In
certain embodiments, the aryl group is a substituted C.sub.6-14
aryl.
[0044] "Aralkyl" is a subset of "alkyl" and refers to an alkyl
group, as defined herein, substituted by an aryl group, as defined
herein, wherein the point of attachment is on the alkyl moiety.
[0045] As used herein, "heteroaryl" refers to a radical of a 5-14
membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2
aromatic ring system (e.g., having 6, 10, or 14 .pi. electrons
shared in a cyclic array) having ring carbon atoms and 1-4 ring
heteroatoms provided in the aromatic ring system, wherein each
heteroatom is independently selected from nitrogen, oxygen and
sulfur ("5-14 membered heteroaryl"). In heteroaryl groups that
contain one or more nitrogen atoms, the point of attachment can be
a carbon or nitrogen atom, as valency permits. Heteroaryl
polycyclic ring systems can include one or more heteroatoms in one
or both rings. "Heteroaryl" includes ring systems wherein the
heteroaryl ring, as defined above, is fused with one or more
carbocyclyl or heterocyclyl groups wherein the point of attachment
is on the heteroaryl ring, and in such instances, the number of
ring members continue to designate the number of ring members in
the heteroaryl ring system. "Heteroaryl" also includes ring systems
wherein the heteroaryl ring, as defined above, is fused with one or
more aryl groups wherein the point of attachment is either on the
aryl or heteroaryl ring, and in such instances, the number of ring
members designates the number of ring members in the fused
polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl
groups wherein one ring does not contain a heteroatom (e.g.,
indolyl, quinolinyl, carbazolyl, and the like) the point of
attachment can be on either ring, i.e., either the ring bearing a
heteroatom (e.g., 2-indolyl) or the ring that does not contain a
heteroatom (e.g., 5-indolyl).
[0046] In some embodiments, a heteroaryl group is a 5-10 membered
aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms provided in the aromatic ring system, wherein each
heteroatom is independently selected from nitrogen, oxygen, and
sulfur ("5-10 membered heteroaryl"). In some embodiments, a
heteroaryl group is a 5-8 membered aromatic ring system having ring
carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring
system, wherein each heteroatom is independently selected from
nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some
embodiments, a heteroaryl group is a 5-6 membered aromatic ring
system having ring carbon atoms and 1-4 ring heteroatoms provided
in the aromatic ring system, wherein each heteroatom is
independently selected from nitrogen, oxygen, and sulfur ("5-6
membered heteroaryl"). In some embodiments, the 5-6 membered
heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen,
and sulfur. In some embodiments, the 5-6 membered heteroaryl has
1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In
some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom
selected from nitrogen, oxygen, and sulfur. Unless otherwise
specified, each instance of a heteroaryl group is independently
unsubstituted (an "unsubstituted heteroaryl") or substituted (a
"substituted heteroaryl") with one or more substituents. In certain
embodiments, the heteroaryl group is an unsubstituted 5-14 membered
heteroaryl. In certain embodiments, the heteroaryl group is a
substituted 5-14 membered heteroaryl.
[0047] Exemplary 5-membered heteroaryl groups containing 1
heteroatom include, without limitation, pyrrolyl, furanyl, and
thiophenyl. Exemplary 5-membered heteroaryl groups containing 2
heteroatoms include, without limitation, imidazolyl, pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary
5-membered heteroaryl groups containing 3 heteroatoms include,
without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
Exemplary 5-membered heteroaryl groups containing 4 heteroatoms
include, without limitation, tetrazolyl. Exemplary 6-membered
heteroaryl groups containing 1 heteroatom include, without
limitation, pyridinyl. Exemplary 6-membered heteroaryl groups
containing 2 heteroatoms include, without limitation, pyridazinyl,
pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups
containing 3 or 4 heteroatoms include, without limitation,
triazinyl and tetrazinyl, respectively. Exemplary 7-membered
heteroaryl groups containing 1 heteroatom include, without
limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary
5,6-bicyclic heteroaryl groups include, without limitation,
indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl,
isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl,
benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl,
benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
Exemplary 6,6-bicyclic heteroaryl groups include, without
limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl,
cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary
tricyclic heteroaryl groups include, without limitation,
phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl,
phenothiazinyl, phenoxazinyl and phenazinyl.
[0048] "Heteroaralkyl" is a subset of "alkyl" and refers to an
alkyl group, as defined herein, substituted by a heteroaryl group,
as defined herein, wherein the point of attachment is on the alkyl
moiety.
[0049] As used herein, the term "partially unsaturated" refers to a
ring moiety that includes at least one double or triple bond. The
term "partially unsaturated" is intended to encompass rings having
multiple sites of unsaturation, but is not intended to include
aromatic groups (e.g., aryl or heteroaryl moieties) as herein
defined.
[0050] As used herein, the term "saturated" refers to a ring moiety
that does not contain a double or triple bond, i.e., the ring
contains all single bonds.
[0051] Affixing the suffix "-ene" to a group indicates the group is
a divalent moiety, e.g., alkylene is the divalent moiety of alkyl,
alkenylene is the divalent moiety of alkenyl, alkynylene is the
divalent moiety of alkynyl, heteroalkylene is the divalent moiety
of heteroalkyl, heteroalkenylene is the divalent moiety of
heteroalkenyl, heteroalkynylene is the divalent moiety of
heteroalkynyl, carbocyclylene is the divalent moiety of
carbocyclyl, heterocyclylene is the divalent moiety of
heterocyclyl, arylene is the divalent moiety of aryl, and
heteroarylene is the divalent moiety of heteroaryl.
[0052] As understood from the above, alkyl, alkenyl, alkynyl,
heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl groups, as defined herein, are,
in certain embodiments, optionally substituted. Optionally
substituted refers to a group which may be substituted or
unsubstituted (e.g., "substituted" or "unsubstituted" alkyl,
"substituted" or "unsubstituted" alkenyl, "substituted" or
"unsubstituted" alkynyl, "substituted" or "unsubstituted"
heteroalkyl, "substituted" or "unsubstituted" heteroalkenyl,
"substituted" or "unsubstituted" heteroalkynyl, "substituted" or
"unsubstituted" carbocyclyl, "substituted" or "unsubstituted"
heterocyclyl, "substituted" or "unsubstituted" aryl or
"substituted" or "unsubstituted" heteroaryl group). In general, the
term "substituted", whether preceded by the term "optionally" or
not, means that at least one hydrogen present on a group (e.g., a
carbon or nitrogen atom) is replaced with a permissible
substituent, e.g., a substituent which upon substitution results in
a stable compound, e.g., a compound which does not spontaneously
undergo transformation such as by rearrangement, cyclization,
elimination, or other reaction. Unless otherwise indicated, a
"substituted" group has a substituent at one or more substitutable
positions of the group, and when more than one position in any
given structure is substituted, the substituent is either the same
or different at each position. The term "substituted" is
contemplated to include substitution with all permissible
substituents of organic compounds, any of the substituents
described herein that results in the formation of a stable
compound. The present invention contemplates any and all such
combinations in order to arrive at a stable compound. For purposes
of this invention, heteroatoms such as nitrogen may have hydrogen
substituents and/or any suitable substituent as described herein
which satisfy the valencies of the heteroatoms and results in the
formation of a stable moiety.
[0053] Exemplary carbon atom substituents include, but are not
limited to, halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H,
--SO.sub.3H, --OH, --OR.sup.aa, --ON(R.sup.bb).sub.2,
--N(R.sup.bb).sub.2, --N(R.sup.bb).sub.3.sup.+X.sup.-,
--N(OR.sup.cc)R.sup.bb, --SH, --SR.sup.aa, --SSR.sup.cc,
--C(.dbd.O)R.sup.aa, --CO.sub.2H, --CHO, --C(OR.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --OC(.dbd.O)R.sup.aa, --OCO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --OC(.dbd.O)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.O)R.sup.aa, --NR.sup.bbCO.sub.2R.sup.aa,
--NR.sup.bbC(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --OC(.dbd.NR.sup.bb)R.sup.aa,
--OC(.dbd.NR.sup.bb)OR.sup.aa,
--C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--OC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--C(.dbd.O)NR.sup.bbSO.sub.2R.sup.aa, --NR.sup.bbSO.sub.2R.sup.aa,
--SO.sub.2N(R.sup.bb).sub.2, --SO.sub.2R.sup.aa,
--SO.sub.2OR.sup.aa, --OSO.sub.2R.sup.aa, --S(.dbd.O)R.sup.aa,
--OS(.dbd.O)R.sup.aa, --Si(R.sup.aa).sub.3,
--OSi(R.sup.aa).sub.3--C(.dbd.S)N(R.sup.bb).sub.2,
--C(.dbd.O)SR.sup.aa, --C(.dbd.S)SR.sup.aa, --SC(.dbd.S)SR.sup.aa,
--SC(.dbd.O)SR.sup.aa, --OC(.dbd.O)SR.sup.aa,
--SC(.dbd.O)OR.sup.aa, --SC(.dbd.O)R.sup.aa,
--P(.dbd.O).sub.2R.sup.aa, --OP(.dbd.O).sub.2R.sup.aa,
--P(.dbd.O)(R.sup.aa).sub.2, --OP(.dbd.O)(R.sup.aa).sub.2,
--OP(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
--OP(.dbd.O).sub.2N(R.sup.bb).sub.2, --P(.dbd.O)(NR.sup.bb).sub.2,
--OP(.dbd.O)(NR.sup.bb).sub.2,
--NR.sup.bbP(.dbd.O)(OR.sup.cc).sub.2,
--NR.sup.bbP(.dbd.O)(NR.sup.bb).sub.2, --P(R.sup.cc).sub.2,
--P(R.sup.cc).sub.3, --OP(R.sup.cc).sub.2, --OP(R.sup.cc).sub.3,
--B(R.sup.aa).sub.2, --B(OR.sup.cc).sub.2, --BR.sup.aa(OR.sup.cc),
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.1-10 heteroalkyl, C.sub.2-10
heteroalkenyl, C.sub.2-10heteroalkynyl, C.sub.3-14 carbocyclyl,
3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered
heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl,
heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5
R.sup.dd groups;
[0054] or two geminal hydrogens on a carbon atom are replaced with
the group .dbd.O, .dbd.S, .dbd.NN(R.sup.bb).sub.2,
.dbd.NNR.sup.bbC(.dbd.O)R.sup.aa,
.dbd.NNR.sup.bbC(.dbd.O)OR.sup.aa,
.dbd.NNR.sup.bbS(.dbd.O).sub.2R.sup.aa, .dbd.NR.sup.bb, or
.dbd.NOR.sup.cc;
[0055] each instance of R.sup.aa is, independently, selected from
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.1-10 heteroalkyl, C.sub.2-10
heteroalkenyl, C.sub.2-10heteroalkynyl, C.sub.3-10 carbocyclyl,
3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered
heteroaryl, or two R.sup.aa groups are joined to form a 3-14
membered heterocyclyl or 5-14 membered heteroaryl ring, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0056] each instance of R.sup.bb is, independently, selected from
hydrogen, --OH, --OR.sup.aa, --N(R.sup.cc).sub.2, --CN,
--C(.dbd.O)R.sup.aa, --C(.dbd.O)N(R.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --SO.sub.2R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc, --P(.dbd.O).sub.2R,
--P(.dbd.O)(R.sup.aa).sub.2, --P(.dbd.O).sub.2N(R.sup.cc).sub.2,
--P(.dbd.O)(NR.sup.cc).sub.2, C.sub.1-10 alkyl, C.sub.1-10
perhaloalkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10
heteroalkyl, C.sub.2-10 heteroalkenyl, C.sub.2-10heteroalkynyl,
C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14
aryl, and 5-14 membered heteroaryl, or two R.sup.bb groups are
joined to form a 3-14 membered heterocyclyl or 5-14 membered
heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl,
heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5
R.sup.dd groups;
[0057] each instance of R.sup.cc is, independently, selected from
hydrogen, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10
alkenyl, C.sub.2-10 alkynyl, C.sub.1-10 heteroalkyl, C.sub.2-10
heteroalkenyl, C.sub.2-10heteroalkynyl, C.sub.3-10 carbocyclyl,
3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered
heteroaryl, or two R.sup.cc groups are joined to form a 3-14
membered heterocyclyl or 5-14 membered heteroaryl ring, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0058] each instance of R.sup.dd is, independently, selected from
halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H,
--OH, --OR.sup.ee, --ON(R.sup.ff).sub.2, --N(R.sup.ff).sub.2,
--N(R.sup.ff).sub.3.sup.+X.sup.-, --N(OR.sup.ee)R.sup.ff, --SH,
--SR.sup.ee, --SSR.sup.ee, --C(.dbd.O)R.sup.ee, --C, --CO.sub.2H,
--CO.sub.2R.sup.ee, --OC(.dbd.O)R.sup.ee, --OCO.sub.2R.sup.ee,
--C(.dbd.O)N(R.sup.ff).sub.2, --OC(.dbd.O)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.O)R.sup.ee, --NR.sup.ffCO.sub.2R.sup.ee,
--NR.sup.ffC(.dbd.O)N(R.sup.ff).sub.2,
--C(.dbd.NR.sup.ff)OR.sup.ee, --OC(.dbd.NR.sup.ff)R.sup.ee,
OC(.dbd.NR.sup.ff)OR.sup.ee, --C(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--OC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffSO.sub.2R.sup.ee, --SO.sub.2N(R.sup.ff).sub.2,
--SO.sub.2R.sup.ee, --SO.sub.2OR.sup.ee, --OSO.sub.2R.sup.ee,
--S(.dbd.O)R.sup.ee, --Si(R.sup.ee).sub.3, --OSi(R.sup.ee).sub.3,
--C(.dbd.S)N(R.sup.ff).sub.2, --C(.dbd.O)SR.sup.ee,
--C(.dbd.S)SR.sup.ee, --SC(.dbd.S)SR.sup.ee,
--P(.dbd.O).sub.2R.sup.ee, --P(.dbd.O)(R.sup.ee).sub.2,
--OP(.dbd.O)(R.sup.ee).sub.2, --OP(.dbd.O)(OR.sup.ee).sub.2,
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 heteroalkyl, C.sub.2-6 heteroalkenyl,
C.sub.2-6heteroalkynyl, C.sub.3-10 carbocyclyl, 3-10 membered
heterocyclyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups,
or two geminal R.sup.dd substituents can be joined to form .dbd.O
or .dbd.S;
[0059] each instance of R.sup.ee is, independently, selected from
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 heteroalkyl, C.sub.2-6 heteroalkenyl,
C.sub.2-6heteroalkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl,
3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg
groups;
[0060] each instance of R.sup.ff is, independently, selected from
hydrogen, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 heteroalkyl, C.sub.2-6
heteroalkenyl, C.sub.2-6heteroalkynyl, C.sub.3-10 carbocyclyl, 3-10
membered heterocyclyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, or two R.sup.ff groups are joined to form a 3-14
membered heterocyclyl or 5-14 membered heteroaryl ring, wherein
each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups;
and
[0061] each instance of R.sup.gg is, independently, halogen, --CN,
--NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H, --OH, --OC.sub.1-6
alkyl, --ON(C.sub.1-6 alkyl).sub.2, --N(C.sub.1-6 alkyl).sub.2,
--N(C.sub.1-6 alkyl).sub.3.sup.+X.sup.-, --NH(C.sub.1-6
alkyl).sub.2.sup.+X.sup.-, --NH.sub.2(C.sub.1-6
alkyl).sup.+X.sup.-, --NH.sub.3.sup.+X.sup.-, --N(OC.sub.1-6
alkyl)(C.sub.1-6 alkyl), --N(OH)(C.sub.1-6 alkyl), --NH(OH), --SH,
--SC.sub.1-6 alkyl, --SS(C.sub.1-6 alkyl), --C(.dbd.O)(C.sub.1-6
alkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6 alkyl),
--OC(.dbd.O)(C.sub.1-6 alkyl), --OCO.sub.2(C.sub.1-6 alkyl),
--C(.dbd.O)NH.sub.2, --C(.dbd.O)N(C.sub.1-6 alkyl).sub.2,
--OC(.dbd.O)NH(C.sub.1-6 alkyl), --NHC(.dbd.O)(C.sub.1-6 alkyl),
--N(C.sub.1-6 alkyl)C(.dbd.O)(C.sub.1-6 alkyl),
--NHCO.sub.2(C.sub.1-6 alkyl), --NHC(.dbd.O)N(C.sub.1-6
alkyl).sub.2, --NHC(.dbd.O)NH(C.sub.1-6 alkyl),
--NHC(.dbd.O)NH.sub.2, --C(.dbd.NH)O(C.sub.1-6 alkyl),
--OC(.dbd.NH)(C.sub.1-6 alkyl), --OC(.dbd.NH)OC.sub.1-6 alkyl,
--C(.dbd.NH)N(C.sub.1-6 alkyl).sub.2, --C(.dbd.NH)NH(C.sub.1-6
alkyl), --C(.dbd.NH)NH.sub.2, --OC(.dbd.NH)N(C.sub.1-6
alkyl).sub.2, --OC(NH)NH(C.sub.1-6 alkyl), --OC(NH)NH.sub.2,
--NHC(NH)N(C.sub.1-6 alkyl).sub.2, --NHC(.dbd.NH)NH.sub.2,
--NHSO.sub.2(C.sub.1-6 alkyl), --SO.sub.2N(C.sub.1-6 alkyl).sub.2,
--SO.sub.2NH(C.sub.1-6 alkyl), --SO.sub.2NH.sub.2,
--SO.sub.2C.sub.1-6 alkyl, --SO.sub.2OC.sub.1-6 alkyl,
--OSO.sub.2C.sub.1-6 alkyl, --SOC.sub.1-6 alkyl, --Si(C.sub.1-6
alkyl).sub.3, --OSi(C.sub.1-6 alkyl).sub.3-C(.dbd.S)N(C.sub.1-6
alkyl).sub.2, C(.dbd.S)NH(C.sub.1-6 alkyl), C(.dbd.S)NH.sub.2,
--C(.dbd.O)S(C.sub.1-6 alkyl), --C(.dbd.S)SC.sub.1-6 alkyl,
--SC(.dbd.S)SC.sub.1-6 alkyl, --P(.dbd.O).sub.2(C.sub.1-6 alkyl),
--P(.dbd.O)(C.sub.1-6 alkyl).sub.2, --OP(.dbd.O)(C.sub.1-6
alkyl).sub.2, --OP(.dbd.O)(OC.sub.1-6 alkyl).sub.2, C.sub.1-6
alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6heteroalkyl, C.sub.2-6 heteroalkenyl,
C.sub.2-6heteroalkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl,
3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two
geminal R.sup.gg substituents can be joined to form .dbd.O or
.dbd.S; wherein X is a counterion.
[0062] As used herein, the term "halo" or "halogen" refers to
fluorine (fluoro, --F), chlorine (chloro, --Cl), bromine (bromo,
--Br), or iodine (iodo, --I).
[0063] As used herein, a "counterion" is a negatively charged group
associated with a positively charged quarternary amine in order to
maintain electronic neutrality. Exemplary counterions include
halide ions (e.g., F.sup.-, Cl.sup.-, Br.sup.-, I.sup.-),
NO.sub.3.sup.-, ClO.sub.4.sup.-, OH.sup.-, H.sub.2PO.sub.4.sup.-,
HSO.sub.4.sup.-, sulfonate ions (e.g., methansulfonate,
trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate,
10-camphor sulfonate, naphthalene-2-sulfonate,
naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic
acid-2-sulfonate, and the like), and carboxylate ions (e.g.,
acetate, ethanoate, propanoate, benzoate, glycerate, lactate,
tartrate, glycolate, and the like).
[0064] As used herein, the term "hydroxyl" or "hydroxy" refers to
the group --OH. The term "substituted hydroxyl" or "substituted
hydroxyl," by extension, refers to a hydroxyl group wherein the
oxygen atom directly attached to the parent molecule is substituted
with a group other than hydrogen, and includes groups selected from
--OR.sup.aa, --ON(R.sup.bb).sub.2, --OC(.dbd.O)SR.sup.aa,
OC(.dbd.O)R.sup.aa, --OCO.sub.2R.sup.aa,
--OC(.dbd.O)N(R.sup.bb).sub.2, --OC(.dbd.NR.sup.bb)R.sup.aa,
--OC(.dbd.NR.sup.bb)OR.sup.aa,
--OC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2, --OS(.dbd.O)R.sup.aa,
--OSO.sub.2R.sup.aa, --OSi(R.sup.aa).sub.3, --OP(R.sup.cc).sub.2,
--OP(R.sup.cc).sub.3, --OP(.dbd.O).sub.2R.sup.aa,
--OP(.dbd.O)(R.sup.aa).sub.2, --OP(.dbd.O)(OR.sup.cc).sub.2,
--OP(.dbd.O).sub.2N(R.sup.bb).sub.2, and
--OP(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and
R.sup.cc are as defined herein.
[0065] As used herein, the term "thiol" or "thio" refers to the
group --SH. The term "substituted thiol" or "substituted thio," by
extension, refers to a thiol group wherein the sulfur atom directly
attached to the parent molecule is substituted with a group other
than hydrogen, and includes groups selected from --SR.sup.aa,
--S.dbd.SR.sup.cc, --SC(.dbd.S)SR.sup.aa, --SC(.dbd.O)SR.sup.aa,
--SC(.dbd.O)OR.sup.aa, and --SC(.dbd.O)R.sup.aa, wherein R.sup.aa
and R.sup.cc are as defined herein.
[0066] As used herein, the term, "amino" refers to the group
--NH.sub.2. The term "substituted amino," by extension, refers to a
monosubstituted amino, a disubstituted amino, or a trisubstituted
amino, as defined herein. In certain embodiments, the "substituted
amino" is a monosubstituted amino or a disubstituted amino
group.
[0067] As used herein, the term "monosubstituted amino" refers to
an amino group wherein the nitrogen atom directly attached to the
parent molecule is substituted with one hydrogen and one group
other than hydrogen, and includes groups selected from
--NH(R.sup.bb), --NHC(.dbd.O)R.sup.aa, NHCO.sub.2R.sup.aa,
--NHC(.dbd.O)N(R.sup.bb).sub.2,
--NHC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2, --NHSO.sub.2R.sup.aa,
--NHP(.dbd.O)(OR.sup.cc).sub.2, and --NHP(.dbd.O)(NR.sup.bb).sub.2,
wherein R.sup.aa, R.sup.bb and R.sup.cc are as defined herein, and
wherein R.sup.bb of the group --NH(R.sup.bb) is not hydrogen.
[0068] As used herein, the term "disubstituted amino" refers to an
amino group wherein the nitrogen atom directly attached to the
parent molecule is substituted with two groups other than hydrogen,
and includes groups selected from --N(R.sup.bb).sub.2, --NR.sup.bb
C(.dbd.O)R.sup.aa, --NR.sup.bbCO.sub.2R.sup.aa,
NR.sup.bbC(.dbd.O)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--NR.sup.bbSO.sub.2R.sup.aa, --NR.sup.bbP(.dbd.O)(OR.sup.cc).sub.2,
and --NR.sup.bbP(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa,
R.sup.bb, and R.sup.cc are as defined herein, with the proviso that
the nitrogen atom directly attached to the parent molecule is not
substituted with hydrogen.
[0069] As used herein, the term "trisubstituted amino" refers to an
amino group wherein the nitrogen atom directly attached to the
parent molecule is substituted with three groups, and includes
groups selected from --N(R.sup.bb).sub.3 and
--N(R.sup.bb).sub.3.sup.+X.sup.-, wherein R.sup.bb and X.sup.- are
as defined herein.
[0070] As used herein, the term "oxo" refers to the group .dbd.O,
and the term "thiooxo" refers to the group .dbd.S.
[0071] Nitrogen atoms can be substituted or unsubstituted as
valency permits, and include primary, secondary, tertiary, and
quarternary nitrogen atoms. Exemplary nitrogen atom substitutents
include, but are not limited to, hydrogen, --OH, --OR.sup.aa,
--N(R.sup.cc).sub.2, --CN, --C(.dbd.O)R.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --CO.sub.2R.sup.aa,
--SO.sub.2R.sup.aa, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O).sub.2N(R.sup.cc).sub.2, --P(.dbd.O)(NR.sup.cc).sub.2,
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.1-10 heteroalkyl, C.sub.2-10
heteroalkenyl, C.sub.2-10 heteroalkynyl, C.sub.3-10 carbocyclyl,
3-14 membered heterocyclyl, C.sub.6-14 aryl, and 5-14 membered
heteroaryl, or two R.sup.cc groups attached to an N atom are joined
to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl
ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl,
heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5
R.sup.dd groups, and wherein R.sup.aa, R.sup.bb, R.sup.cc and
R.sup.dd are as defined above.
[0072] In certain embodiments, the substituent present on the
nitrogen atom is an nitrogen protecting group (also referred to
herein as an "amino protecting group"). Nitrogen protecting groups
include, but are not limited to, --OH, --OR.sup.aa,
--N(R.sup.cc).sub.2, --C(.dbd.O)R.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --CO.sub.2R, --SO.sub.2R,
--C(.dbd.NR.sup.cc)R.sup.aa, --C(.dbd.NR.sup.cc)OR.sup.aa,
--C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2, --SO.sub.2N(R.sup.cc).sub.2,
--SO.sub.2R.sup.cc, --SO.sub.2OR.sup.cc, --SOR.sup.aa,
--C(.dbd.S)N(R.sup.cc).sub.2, --C(.dbd.O)SR.sup.cc,
--C(.dbd.S)SR.sup.cc, C.sub.1-10 alkyl (e.g., aralkyl,
heteroaralkyl), C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.1-10
heteroalkyl, C.sub.2-10 heteroalkenyl, C.sub.2-10 heteroalkynyl,
C.sub.3-10 carbocyclyl, 3-14 membered heterocyclyl, C.sub.6-14
aryl, and 5-14 membered heteroaryl groups, wherein each alkyl,
alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd groups,
and wherein R.sup.aa, R.sup.bb, R.sup.cc and R.sup.dd are as
defined herein. Nitrogen protecting groups are well known in the
art and include those described in detail in Protecting Groups in
Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3.sup.rd
edition, John Wiley & Sons, 1999, incorporated herein by
reference.
[0073] For example, nitrogen protecting groups such as amide groups
(e.g., --C(.dbd.O)R.sup.aa) include, but are not limited to,
formamide, acetamide, chloroacetamide, trichloroacetamide,
trifluoroacetamide, phenylacetamide, 3-phenylpropanamide,
picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl
derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide,
o-nitrophenoxyacetamide, acetoacetamide,
(N'-dithiobenzyloxyacylamino)acetamide,
3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide,
2-methyl-2-(o-nitrophenoxy)propanamide,
2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide,
3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine
derivative, o-nitrobenzamide and o-(benzoyloxymethyl)benzamide.
[0074] Nitrogen protecting groups such as carbamate groups (e.g.,
--C(.dbd.O)OR.sup.aa) include, but are not limited to, methyl
carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc),
9-(2-sulfo)fluorenylmethyl carbamate,
9-(2,7-dibromo)fluoroenylmethyl carbamate,
2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10,10-tetrahydrothioxanthyl)]meth-
yl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc),
2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl
carbamate (Teoc), 2-phenylethyl carbamate (hZ),
1-(1-adamantyl)-1-methylethyl carbamate (Adpoc),
1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl
carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate
(TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc),
1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'-
and 4'-pyridyl)ethyl carbamate (Pyoc),
2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate
(BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl
carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl
carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl
carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate,
benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz),
p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl
carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl
carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl
carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl
carbamate, 2-(p-toluenesulfonyl)ethyl carbamate,
[2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl
carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc),
2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl
carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate,
m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl
carbamate, 5-benzisoxazolylmethyl carbamate,
2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc),
m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate,
o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate,
phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl
thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate,
cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl
carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl
carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate,
1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate,
1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate,
2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobornyl
carbamate, isobutyl carbamate, isonicotinyl carbamate,
p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl
carbamate, 1-methylcyclohexyl carbamate,
1-methyl-1-cyclopropylmethyl carbamate,
1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate,
1-methyl-1-(p-phenylazophenyl)ethyl carbamate,
1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl
carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate,
2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl
carbamate, and 2,4,6-trimethylbenzyl carbamate.
[0075] Nitrogen protecting groups such as sulfonamide groups (e.g.,
--S(.dbd.O).sub.2R.sup.aa) include, but are not limited to,
p-toluenesulfonamide (Ts), benzenesulfonamide,
2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr),
2,4,6-trimethoxybenzenesulfonamide (Mtb),
2,6-dimethyl-4-methoxybenzenesulfonamide (Pme),
2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte),
4-methoxybenzenesulfonamide (Mbs),
2,4,6-trimethylbenzenesulfonamide (Mts),
2,6-dimethoxy-4-methylbenzenesulfonamide (iMds),
2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc),
methanesulfonamide (Ms), P-trimethylsilylethanesulfonamide (SES),
9-anthracenesulfonamide,
4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS),
benzylsulfonamide, trifluoromethylsulfonamide, and
phenacylsulfonamide.
[0076] Other nitrogen protecting groups include, but are not
limited to, phenothiazinyl-(10)-acyl derivative,
N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl
derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine
derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide,
N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide,
N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane
adduct (STABASE), 5-substituted
1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted
1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted
3,5-dinitro-4-pyridone, N-methylamine, N-allylamine,
N-[2-(trimethylsilyl)ethoxy]methylamine (SEM),
N-3-acetoxypropylamine,
N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary
ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine,
N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr),
N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr),
N-9-phenylfluorenylamine (PhF),
N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino
(Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethylthiomethyleneamine,
N-benzylideneamine, N-p-methoxybenzylideneamine,
N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine,
N--(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine,
N-p-nitrobenzylideneamine, N-salicylideneamine,
N-5-chlorosalicylideneamine,
N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine,
N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine,
N-borane derivative, N-diphenylborinic acid derivative,
N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper
chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine
N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide
(Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates,
dibenzyl phosphoramidate, diphenyl phosphoramidate,
benzenesulfenamide, o-nitrobenzenesulfenamide (Nps),
2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide,
2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide,
and 3-nitropyridinesulfenamide (Npys).
[0077] In certain embodiments, the substituent present on an oxygen
atom is an oxygen protecting group (also referred to herein as an
"hydroxyl protecting group"). Oxygen protecting groups include, but
are not limited to, --R, --N(R.sup.bb).sub.2, --C(.dbd.O)SR.sup.aa,
--C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
and --P(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and
R.sup.cc are as defined herein. Oxygen protecting groups are well
known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0078] Exemplary oxygen protecting groups include, but are not
limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM),
t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM),
benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM),
(4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM),
t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl,
2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl,
bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR),
tetrahydropyranyl (THP), 3-bromotetrahydropyranyl,
tetrahydrothiopyranyl, 1-methoxycyclohexyl,
4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl,
4-methoxytetrahydrothiopyranyl S,S-dioxide,
1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP),
1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl,
2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl,
1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,
1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,
2,2,2-trichloroethyl, 2-trimethylsilylethyl,
2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl,
p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl,
3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl,
2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl,
4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl,
p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl,
o-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl,
di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl,
4-(4'-bromophenacyloxyphenyl)diphenylmethyl,
4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl,
4,4',4''-tris(levulinoyloxyphenyl)methyl,
4,4',4''-tris(benzoyloxyphenyl)methyl,
3-(imidazol-1-yl)bis(4',4''-dimethoxyphenyl)methyl,
1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl,
9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,
1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido,
trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl
(TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl
(DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS),
t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl,
triphenylsilyl, diphenylmethylsilyl (DPMS),
t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate,
acetate, chloroacetate, dichloroacetate, trichloroacetate,
trifluoroacetate, methoxyacetate, triphenylmethoxyacetate,
phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate,
4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate
(levulinoyldithioacetal), pivaloate, adamantoate, crotonate,
4-methoxycrotonate, benzoate, p-phenylbenzoate,
2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate,
9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl
2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl
carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec),
2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl
carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl
p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl
p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate,
alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl
S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl
dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate,
4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate,
2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl,
4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate,
2,6-dichloro-4-methylphenoxyacetate,
2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,
2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,
isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate,
o-(methoxyacyl)benzoate, o-naphthoate, nitrate, alkyl
N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate,
borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate,
sulfate, methanesulfonate (mesylate, Ms), benzylsulfonate,
benzenesulfonate (besylate, Bs), and toluenesulfonate (tosylate,
Ts).
[0079] In certain embodiments, the substituent present on an sulfur
atom is a sulfur protecting group (also referred to as a "thiol
protecting group"). Sulfur protecting groups include, but are not
limited to, --R.sup.aa, --N(R.sup.bb).sub.2, --C(.dbd.O)SR.sup.aa,
--C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
and --P(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and
R.sup.cc are as defined herein. Sulfur protecting groups are well
known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0080] These and other exemplary substituents are described in more
detail in the Detailed Description, Examples, and claims. The
invention is not intended to be limited in any manner by the above
exemplary listing of substituents.
[0081] The term "pharmaceutically acceptable salt" refers to those
salts which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response, and
the like, and are commensurate with a reasonable benefit/risk
ratio. Pharmaceutically acceptable salts are well known in the art.
For example, Berge et al., describes pharmaceutically acceptable
salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19.
Pharmaceutically acceptable salts of the compounds of this
invention include those derived from suitable inorganic and organic
acids and bases. Examples of pharmaceutically acceptable, nontoxic
acid addition salts are salts of an amino group formed with
inorganic acids such as hydrochloric acid, hydrobromic acid,
phosphoric acid, sulfuric acid and perchloric acid or with organic
acids such as acetic acid, oxalic acid, maleic acid, tartaric acid,
citric acid, succinic acid or malonic acid or by using other
methods used in the art such as ion exchange. Other
pharmaceutically acceptable salts include adipate, alginate,
ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,
borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Pharmaceutically acceptable salts derived from appropriate bases
include alkali metal, alkaline earth metal, ammonium and
N.sup.+(C.sub.1-4alkyl).sub.4 salts. Representative alkali or
alkaline earth metal salts include sodium, lithium, potassium,
calcium, magnesium, and the like. Further pharmaceutically
acceptable salts include, when appropriate, nontoxic ammonium,
quaternary ammonium, and amine cations formed using counterions
such as halide, hydroxide, carboxylate, sulfate, phosphate,
nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0082] As used herein, a "leaving group" is an art-understood term
referring to a molecular fragment that departs with a pair of
electrons in heterolytic bond cleavage, wherein the molecular
fragment is an anion or neutral molecule. See, for example, Smith,
March Advanced Organic Chemistry 6th ed. (501-502). Exemplary
leaving groups include, but are not limited to, halo (e.g., chloro,
bromo, iodo) and sulfonyl substituted hydroxyl groups (e.g., tosyl,
mesyl, besyl).
Other Definitions
[0083] A "subject" to which administration is contemplated
includes, but is not limited to, humans (i.e., a male or female of
any age group, e.g., a pediatric subject (e.g, infant, child,
adolescent) or adult subject (e.g., young adult, middle-aged adult
or senior adult)) and/or other non-human animals, for example
mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys);
commercially relevant mammals such as cattle, pigs, horses, sheep,
goats, cats, and/or dogs), birds (e.g., commercially relevant birds
such as chickens, ducks, geese, and/or turkeys), reptiles,
amphibians, and fish. In certain embodiments, the non-human animal
is a mammal. The non-human animal may be a male or female and at
any stage of development. A non-human animal may be a transgenic
animal.
[0084] A "condition," "disease," and "disorder" are used
interchangeably herein.
[0085] As used herein, and unless otherwise specified, the terms
"treat," "treating" and "treatment" contemplate an action that
occurs while a subject is suffering from the specified disease,
disorder or condition, which reduces the severity of the disease,
disorder or condition, or retards or slows the progression of the
disease, disorder or condition ("therapeutic treatment"), and also
contemplates an action that occurs before a subject begins to
suffer from the specified disease, disorder or condition
("prophylactic treatment").
[0086] In general, the "effective amount" of a compound refers to
an amount sufficient to elicit the desired biological response. As
will be appreciated by those of ordinary skill in this art, the
effective amount of a compound of the invention may vary depending
on such factors as the desired biological endpoint, the
pharmacokinetics of the compound, the disease being treated, the
mode of administration, and the age, health, and condition of the
subject. An effective amount encompasses therapeutic and
prophylactic treatment.
[0087] As used herein, and unless otherwise specified, a
"therapeutically effective amount" of a compound is an amount
sufficient to provide a therapeutic benefit in the treatment of a
disease, disorder or condition, or to delay or minimize one or more
symptoms associated with the disease, disorder or condition. A
therapeutically effective amount of a compound means an amount of
therapeutic agent, alone or in combination with other therapies,
which provides a therapeutic benefit in the treatment of the
disease, disorder or condition. The term "therapeutically effective
amount" can encompass an amount that improves overall therapy,
reduces or avoids symptoms or causes of disease or condition, or
enhances the therapeutic efficacy of another therapeutic agent. In
the context of treatment of conditions associated with abherant
Her3 activity, in certain embodiments, a therapeutically effective
amount is an amount sufficient to reduce Her3 activity, reduce Her3
protein levels, and/or inhibit cell proliferation.
[0088] As used herein, and unless otherwise specified, a
"prophylactically effective amount" of a compound is an amount
sufficient to prevent a disease, disorder or condition, or one or
more symptoms associated with the disease, disorder or condition,
or prevent its recurrence. A prophylactically effective amount of a
compound means an amount of a therapeutic agent, alone or in
combination with other agents, which provides a prophylactic
benefit in the prevention of the disease, disorder or condition.
The term "prophylactically effective amount" can encompass an
amount that improves overall prophylaxis or enhances the
prophylactic efficacy of another prophylactic agent.
[0089] As used herein an "inhibitor" refers to the ability of a
compound to reduce (e.g., slow, halt) or prevent activity of a
particular biological process (kinase activity) in a cell relative
to vehicle.
[0090] As used herein, use of the phrase "at least one instance"
refers to 1, 2, 3, 4, or more instances, but also encompasses a
range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2,
from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.
[0091] "Kinase." A kinase is a type of enzyme that transfers
phosphate groups from high energy donor molecules, such as ATP, to
specific substrates, referred to as phosphorylation. Kinases are
part of the larger family of phosphotransferases. One of the
largest groups of kinases are protein kinases, which act on and
modify the activity of specific proteins. Kinases are used
extensively to transmit signals and control complex processes in
cells. Various other kinases act on small molecules such as lipids,
carbohydrates, amino acids, and nucleotides, either for signaling
or to prime them for metabolic pathways. Kinases are often named
after their substrates. More than 500 different protein kinases
have been identified in humans. These exemplary human protein
kinases include, but are not limited to, AAK1, ABL, ACK, ACTR2,
ACTR2B, AKT1, AKT2, AKT3, ALK, ALK1, ALK2, ALK4, ALK7, AMPKa1,
AMPKa2, ANKRD3, ANPa, ANPb, ARAF, ARAFps, ARG, AurA, AurAps1,
AurAps2, AurB, AurBps1, AurC, AXL, BARK1, BARK2, BIKE, BLK, BMPR1A,
BMPR1Aps1, BMPR1Aps2, BMPR1B, BMPR2, BMX, BRAF, BRAFps, BRK, BRSK1,
BRSK2, BTK, BUB1, BUBR1, CaMK1a, CaMK1b, CaMK1d, CaMK1g, CaMK2a,
CaMK2b, CaMK2d, CaMK2g, CaMK4, CaMKK1, CaMKK2, caMLCK, CASK, CCK4,
CCRK, CDC2, CDC7, CDK10, CDK11, CDK2, CDK3, CDK4, CDK4ps, CDK5,
CDK5ps, CDK6, CDK7, CDK7ps, CDK8, CDK8ps, CDK9, CDKL1, CDKL2,
CDKL3, CDKL4, CDKL5, CGDps, CHED, CHK1, CHK2, CHK2ps1, CHK2ps2,
CK1a, CK1a2, CK1aps1, CK1aps2, CK1aps3, CK1d, CK1e, CK1g1, CK1g2,
CK1g2ps, CK1g3, CK2a1, CK2a1-rs, CK2a2, CLIK1, CLIK1L, CLK1, CLK2,
CLK2ps, CLK3, CLK3ps, CLK4, COT, CRIK, CRK7, CSK, CTK, CYGD, CYGF,
DAPK1, DAPK2, DAPK3, DCAMKL1, DCAMKL2, DCAMKL3, DDR1, DDR2, DLK,
DMPK1, DMPK2, DRAK1, DRAK2, DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4,
EGFR, EphA1, EphA10, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7,
EphA8, EphB1, EphB2, EphB3, EphB4, EphB6, Erk1, Erk2, Erk3,
Erk3ps1, Erk3ps2, Erk3ps3, Erk3ps4, Erk4, Erk5, Erk7, FAK, FER,
FERps, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT1ps, FLT3,
FLT4, FMS, FRK, Fused, FYN, GAK, GCK, GCN2, GCN22, GPRK4, GPRK5,
GPRK6, GPRK6ps, GPRK7, GSK3A, GSK3B, Haspin, HCK, HER2/ErbB2,
HER3/ErbB3, HER4/ErbB4, HH498, HIPK1, HIPK2, HIPK3, HIPK4, HPK1,
HRI, HRIps, HSER, HUNK, ICK, IGF1R, IKKa, IKKb, IKKe, ILK, INSR,
IRAK1, IRAK2, IRAK3, IRAK4, IRE1, IRE2, IRR, ITK, JAK1, JAK12,
JAK2, JAK22, JAK3, JAK32, JNK1, JNK2, JNK3, KDR, KHS1, KHS2, KIS,
KIT, KSGCps, KSR1, KSR2, LATS1, LATS2, LCK, LIMK1, LIMK2, LIMK2ps,
LKB1, LMR1, LMR2, LMR3, LOK, LRRK1, LRRK2, LTK, LYN, LZK, MAK,
MAP2K1, MAP2K1ps, MAP2K2, MAP2K2ps, MAP2K3, MAP2K4, MAP2K5, MAP2K6,
MAP2K7, MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP3K6, MAP3K7,
MAP3K8, MAPKAPK2, MAPKAPK3, MAPKAPK5, MAPKAPKps1, MARK1, MARK2,
MARK3, MARK4, MARKps01, MARKps02, MARKps03, MARKps04, MARKps05,
MARKps07, MARKps08, MARKps09, MARKps10, MARKps11, MARKps12,
MARKps13, MARKps15, MARKps16, MARKps17, MARKps18, MARKps19,
MARKps20, MARKps21, MARKps22, MARKps23, MARKps24, MARKps25,
MARKps26, MARKps27, MARKps28, MARKps29, MARKps30, MAST1, MAST2,
MAST3, MAST4, MASTL, MELK, MER, MET, MISR2, MLK1, MLK2, MLK3, MLK4,
MLKL, MNK1, MNK1ps, MNK2, MOK, MOS, MPSK1, MPSK1ps, MRCKa, MRCKb,
MRCKps, MSK1, MSK12, MSK2, MSK22, MSSK1, MST1, MST2, MST3, MST3ps,
MST4, MUSK, MYO3A, MYO3B, MYT1, NDR1, NDR2, NEK1, NEK10, NEK11,
NEK2, NEK2ps1, NEK2ps2, NEK2ps3, NEK3, NEK4, NEK4ps, NEK5, NEK6,
NEK7, NEK8, NEK9, NIK, NIM1, NLK, NRBP1, NRBP2, NuaK1, NuaK2,
Obscn, Obscn2, OSR1, p38a, p38b, p38d, p38g, p70S6K, p70S6Kb,
p70S6Kps1, p70S6Kps2, PAK1, PAK2, PAK2ps, PAK3, PAK4, PAK5, PAK6,
PASK, PBK, PCTAIRE1, PCTAIRE2, PCTAIRE3, PDGFRa, PDGFRb, PDK1, PEK,
PFTAIRE1, PFTAIRE2, PHKg1, PHKg1ps1, PHKg1ps2, PHKg1ps3, PHKg2,
PIK3R4, PIM1, PIM2, PIM3, PINK1, PITSLRE, PKACa, PKACb, PKACg,
PKCa, PKCb, PKCd, PKCe, PKCg, PKCh, PKCi, PKCips, PKCt, PKCz, PKD1,
PKD2, PKD3, PKG1, PKG2, PKN1, PKN2, PKN3, PKR, PLK1, PLK1ps1,
PLK1ps2, PLK2, PLK3, PLK4, PRKX, PRKXps, PRKY, PRP4, PRP4ps, PRPK,
PSKH1, PSKH1ps, PSKH2, PYK2, QIK, QSK, RAF1, RAF1ps, RET, RHOK,
RIPK1, RIPK2, RIPK3, RNAseL, ROCK1, ROCK2, RON, ROR1, ROR2, ROS,
RSK1, RSK12, RSK2, RSK22, RSK3, RSK32, RSK4, RSK42, RSKL1, RSKL2,
RYK, RYKps, SAKps, SBK, SCYL1, SCYL2, SCYL2ps, SCYL3, SGK,
SgK050ps, SgK069, SgK071, SgK085, SgK110, SgK196, SGK2, SgK223,
SgK269, SgK288, SGK3, SgK307, SgK384ps, SgK396, SgK424, SgK493,
SgK494, SgK495, SgK496, SIK, skMLCK, SLK, Slob, smMLCK, SNRK, SPEG,
SPEG2, SRC, SRM, SRPK1, SRPK2, SRPK2ps, SSTK, STK33, STK33ps,
STLK3, STLK5, STLK6, STLK6ps1, STLK6-rs, SuRTK106, SYK, TAK1, TAO1,
TAO2, TAO3, TBCK, TBK1, TEC, TESK1, TESK2, TGFbR1, TGFbR2, TIE1,
TIE2, TLK1, TLK1ps, TLK2, TLK2ps1, TLK2ps2, TNK1, Trad, Trb1, Trb2,
Trb3, Trio, TRKA, TRKB, TRKC, TSSK1, TSSK2, TSSK3, TSSK4, TSSKps1,
TSSKps2, TTBK1, TTBK2, TTK, TTN, TXK, TYK2, TYK22, TYRO3, TYRO3ps,
ULK1, ULK2, ULK3, ULK4, VACAMKL, VRK1, VRK2, VRK3, VRK3ps, Wee1,
Wee1B, Wee1Bps, Wee1ps1, Wee1ps2, Wnk1, Wnk2, Wnk3, Wnk4, YANK1,
YANK2, YANK3, YES, YESps, YSK1, ZAK, ZAP70, ZC1/HGK, ZC2/TNIK,
ZC3/MINK, ZC4/NRK. In certain embodiments, the kinase is HER3/ErbB3
("Her3 kinase").
[0092] As used herein, "hydrophobic," in the context of a
"hydrophobic" group --R.sup.H, refers to a group --R.sup.H which
comprises zero hydrogen bond donors (e.g., zero --NH, --OH, and/or
--SH groups) and optionally zero hydrogen bond acceptors (e.g., O,
N, and/or S atoms). In certain embodiments, the hydrophobic group
--R.sup.H comprises zero hydrogen bond donors and zero hydrogen
bond acceptors. For example, in certain embodiments, the
hydrophobic group --R.sup.H is an unsubstituted hydrocarbon
(carbocyclylalkyl, carbocyclyl, aralkyl, or aryl) group, i.e.,
comprising only carbon and hydrogen. In certain embodiments, the
hydrophobic group --R.sup.H comprises at least 6 carbon atoms,
e.g., between 6 and 50 carbon atoms, between 6 and 40 carbon atoms,
between 6 and 30 carbon atoms, between 6 and 20 carbon atoms, or
between 6 and 15 carbon atoms. In certain embodiments, the
hydrophobic group --R.sup.H comprises 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, or 20 carbon atoms.
[0093] A "small organic molecule," (M) as used herein, refers to an
alkyl, alkenyl, alknyl, aryl, heteroaryl, carbocyclic, or
heterocyclic moiety, as defined herein, comprising carbon and
hydrogen, and optionally comprising one or more heteroatoms as a
part of the molecule (in the case of heteroaryl and heterocyclic
groups) and/or attached to the molecule selected from oxygen,
nitrogen, sulfur, phosphorus, boron, silicon, and selenium.
[0094] "Molecular weights." The molecular weight of said small
organic molecule (M), in the absence of the group -L.sup.1-R.sup.H
(such that the group -L.sup.1-R.sup.H is replaced with hydrogen to
provide M-H), is between about 100 g/mol and about 800 g/mol,
inclusive, e.g., between about 100 and about 750 g/mol, between
about 100 and about 700 g/mol, between about 100 and about 650
g/mol, between about 100 and about 600 g/mol, between about 100 and
about 550 g/mol, between about 100 and about 500 g/mol, between
about 100 and about 450 g/mol, between about 100 and about 400
g/mol, between about 100 and about 350 g/mol, between about 100 and
about 300 g/mol, between about 100 and about 250 g/mol, between
about 100 and about 200 g/mol, between about 100 and about 150
g/mol, between about 200 g/mol to about 800 g/mol, between about
200 g/mol to about 700 g/mol, between about 200 g/mol to about 600
g/mol, between about 200 g/mol to about 500 g/mol, between about
200 g/mol to about 400 g/mol, between about 200 g/mol to about 300
g/mol, between about 300 g/mol to about 800 g/mol, between about
300 g/mol to about 700 g/mol, between about 300 g/mol to about 600
g/mol, between about 300 g/mol to about 500 g/mol, between about
300 g/mol to about 400 g/mol, between about 400 g/mol to about 800
g/mol, between about 400 g/mol to about 700 g/mol, between about
400 g/mol to about 600 g/mol, between about 400 g/mol to about 500
g/mol, or between about 400 g/mol to about 400 g/mol,
inclusive.
[0095] The molecular weight of the group -L.sup.1-R.sup.H is, in
certain embodiments, between about 50 g/mol and about 600 g/mol,
inclusive, e.g., between about 50 g/mol and about 500 g/mol,
between about 100 g/mol and about 500 g/mol, between about 100
g/mol and about 400 g/mol, between about 100 g/mol and about 300
g/mol, between about 100 g/mol and about 200 g/mol, between about
200 g/mol and about 400 g/mol, or between about 200 g/mol and about
300 g/mol, inclusive.
[0096] The molecular weight of the hydrophobic group --R.sup.H is,
in certain embodiments, between about 100 g/mol and about 300
g/mol, inclusive, e.g., between about 100 g/mol and about 200
g/mol, between about 100 g/mol and about 180 g/mol, between about
110 g/mol and about 180 g/mol, between about 120 g/mol and about
180 g/mol, or between about 130 g/mol and about 180 g/mol,
inclusive.
[0097] The total molecular weight of the compound of Formula (I),
is the cumulative molecular weight of the small molecule (M) and
group -L.sup.1-R.sup.H. In certain embodiments, the total molecular
weight of the compound of Formula (I) is between about 200 g/mol to
about 1000 g/mol, inclusive, e.g., between about 200 g/mol to about
900 g/mol, between about 200 g/mol to about 800 g/mol, between
about 200 g/mol to about 700 g/mol, between about 200 g/mol to
about 600 g/mol, between about 200 g/mol to about 500 g/mol,
between about 200 g/mol to about 400 g/mol, between about 200 g/mol
to about 300 g/mol, between about 300 g/mol to about 800 g/mol,
between about 400 g/mol to about 1000 g/mol, between about 400
g/mol to about 900 g/mol, between about 400 g/mol to about 800
g/mol, between about 400 g/mol to about 700 g/mol, between about
400 g/mol to about 600 g/mol, between about 400 g/mol to about 500
g/mol, between about 500 g/mol to about 1000 g/mol, between about
500 g/mol to about 900 g/mol, between about 500 g/mol to about 800
g/mol, between about 500 g/mol to about 700 g/mol, or between about
500 g/mol to about 600 g/mol, inclusive.
[0098] For example, the molecular weight of the small molecule of
Formula (II'), which is the small molecule as defined in Formula
(II) in the absence of the group -L.sup.1-R.sup.H (wherein
-L.sup.1-R.sup.H is replaced with hydrogen to provide M-H):
##STR00011##
is between about 251 g/mol and about 800 g/mol, inclusive. 251
g/mol is the lowest molecular weight contemplated for this
particular formula, wherein a and b are each 0, both instances of
R.sup.B are hydrogen, and Ring A is unsubstituted cyclopropyl.
[0099] In certain embodiments, the molecular weight of the small
molecule (M-H) of Formula (II') is between about 251 g/mol to about
800 g/mol, between about 251 g/mol to about 700 g/mol, between
about 251 g/mol to about 600 g/mol, between about 251 g/mol to
about 500 g/mol, between about 251 g/mol to about 400 g/mol,
between about 300 g/mol to about 800 g/mol, between about 300 g/mol
to about 700 g/mol, between about 300 g/mol to about 600 g/mol,
between about 300 g/mol to about 500 g/mol, between about 300 g/mol
to about 400 g/mol, between about 400 g/mol to about 800 g/mol,
between about 400 g/mol to about 700 g/mol, between about 400 g/mol
to about 600 g/mol, or between about 400 g/mol to about 500 g/mol,
inclusive.
[0100] Furthermore, in the instance of the total molecular weight
of a compound of Formula (II), which is the cumulative molecular
weight of the small molecule (M) and the group -L.sup.1-R.sup.H,
is, in certain embodiments, between about 351 g/mol and about 1000
g/mol, inclusive, e.g., between about 400 g/mol to about 1000
g/mol, between about 400 g/mol to about 900 g/mol, between about
400 g/mol to about 800 g/mol, between about 400 g/mol to about 700
g/mol, between about 400 g/mol to about 600 g/mol, between about
400 g/mol to about 500 g/mol, between about 500 g/mol to about 1000
g/mol, between about 500 g/mol to about 900 g/mol, between about
500 g/mol to about 800 g/mol, between about 500 g/mol to about 700
g/mol, or between about 500 g/mol to about 600 g/mol,
inclusive.
[0101] Furthermore, in the instance of a compound of Formula (II),
in certain embodiments, the molecular weight of the group
-L.sup.1-R.sup.H provided in Formula (II) is between about 50 g/mol
and about 400 g/mol, e.g., between about 100 g/mol and about 400
g/mol, between about 100 g/mol and about 300 g/mol, between about
100 g/mol and about 200 g/mol, between about 200 g/mol and about
400 g/mol, or between about 200 g/mol and about 300 g/mol,
inclusive.
[0102] In certain embodiments, the total molecular weight of the
compound of Formula (II) is between about 500 g/mol to about 1000
g/mol, inclusive, and the molecular weight of the group
-L.sup.1-R.sup.H provided in Formula (II) is between about 100
g/mol and about 400 g/mol, inclusive.
[0103] In certain embodiments, the total molecular weight of the
compound of Formula (II) is between about 500 g/mol to about 1000
g/mol, inclusive, and the molecular weight of the small molecule
(M-H) of Formula (II') is between about 400 g/mol to about 600
g/mol, inclusive.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
[0104] As generally described herein, the present invention is
based on the development of bifunctional compounds (i.e., a kinase
binding small molecule tagged with a hydrophobic moiety) that can
induce the degradation of a kinase, e.g., a protein kinase, of
interest. These bifunctional compounds possess a kinase recognition
element that can bind either covalently or non-covalently and a
`hydrophobic` tag element that signals to the intracellular protein
homeostasis machinery to induce degradation of the targeted
kinase.
[0105] Bifunctional compounds contemplated herein may be generally
represented by Formula (I):
##STR00012##
or a pharmaceutically acceptable salt thereof; wherein:
[0106] M represents a small organic molecule which binds to a
kinase;
[0107] L.sup.1 represents a linker selected from the group
consisting of substituted and unsubstituted alkylene, substituted
and unsubstituted alkenylene, substituted and unsubstituted
alkynylene, substituted and unsubstituted heteroalkylene,
substituted and unsubstituted heteroalkenylene, substituted and
unsubstituted heteroalkynylene, substituted and unsubstituted
heterocyclylene, substituted and unsubstituted carbocyclylene,
substituted and unsubstituted arylene, substituted and
unsubstituted heteroarylene, and combinations thereof; and
[0108] R.sup.H represents a hydrophobic group selected from the
group consisting of substituted and unsubstituted aryl, substituted
and unsubstituted heteroaryl, substituted and unsubstituted
carbocyclyl, substituted and unsubstituted heterocyclyl,
substituted and unsubstituted aralkyl, substituted and
unsubstituted heteroarylalkyl, substituted and unsubstituted
carbocycylalkyl, and substituted and unsubstituted
heterocyclylalkyl.
[0109] As described herein, M represents a small organic molecule
which binds, covalently or non-covalently, to a particular kinase
even when the group -L.sup.1-R.sup.H is absent, i.e., wherein the
group -L.sup.1-R.sup.H is replaced, for example, with hydrogen
(M-H). In certain embodiments, the small organic molecule (M or
M-H) covalently binds the kinase. In certain embodiments, the small
organic molecule (M or M-H) non-covalently binds the kinase. In
certain embodiments, the non-covalent binding affinity of the small
organic molecule (M or M-H) to the kinase is between about 0.1
nanomolar and 1000 nanomolar, inclusive, e.g., between about 1
nanomolar and 1000 nanomolar, between about 10 nanomolar and 1000
nanomolar, between about 100 nanomolar and 1000 nanomolar, between
about 500 nanomolar and 1000 nanomolar, between about 0.1 nanomolar
and 500 nanomolar, between about 0.1 nanomolar and 100 nanomolar,
between about 0.1 nanomolar and 50 nanomolar, inclusive.
[0110] In certain embodiments the kinase is a protein kinase. In
certain embodiments the kinase is a human protein kinase. In
certain embodiments, the human protein kinase is HER3/ErbB3 ("Her3
kinase").
Linker L.sup.1
[0111] As described herein, L.sup.1 represents a linker selected
from the group consisting of substituted and unsubstituted
alkylene; substituted and unsubstituted alkenylene; substituted and
unsubstituted alkynylene; substituted and unsubstituted
heteroalkylene; substituted and unsubstituted heteroalkenylene;
substituted and unsubstituted heteroalkynylene; substituted and
unsubstituted heterocyclylene; substituted and unsubstituted
carbocyclylene; substituted and unsubstituted arylene; substituted
and unsubstituted heteroarylene; and combinations thereof.
[0112] As used herein, reference to a linker consisting of a
combination refers to a linker comparing 1, 2, 3, 4 or more of the
recited moieties. For example, the linker may consist of an
alkylene attached to a heteroalkylene, which may be further
optionally attached to another alkylene. As used herein "at least
one instance" refers to 1, 2, 3, 4, or more instances of the
recited moiety.
[0113] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted alkylene, e.g.,
substituted or unsubstituted C.sub.1-6alkylene, substituted or
unsubstituted C.sub.1-2alkylene, substituted or unsubstituted
C.sub.2-3alkylene, substituted or unsubstituted C.sub.3-4alkylene,
substituted or unsubstituted C.sub.4-5alkylene, substituted or
unsubstituted C.sub.5-6alkylene, substituted or unsubstituted
C.sub.3-6alkylene, or substituted or unsubstituted
C.sub.4-6alkylene. Exemplary alkylene groups include unsubstituted
alkylene groups such as methylene --CH.sub.2--, ethylene
--(CH.sub.2).sub.2--, n-propylene --(CH.sub.2).sub.3--, n-butylene
--(CH.sub.2).sub.4--, n-pentylene --(CH.sub.2).sub.5--, and
n-hexylene --(CH.sub.2).sub.6--.
[0114] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted alkenylene, e.g.,
substituted or unsubstituted C.sub.2-6alkenylene, substituted or
unsubstituted C.sub.2-3alkenylene, substituted or unsubstituted
C.sub.3-4alkenylene, substituted or unsubstituted
C.sub.4-5alkenylene, or substituted or unsubstituted
C.sub.5-6alkenylene.
[0115] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted alkynylene, e.g.,
substituted or unsubstituted C.sub.2-6alkynylene, substituted or
unsubstituted C.sub.2-3alkynylene, substituted or unsubstituted
C.sub.3-4alkynylene, substituted or unsubstituted
C.sub.4-5alkynylene, or substituted or unsubstituted
C.sub.5-6alkynylene.
[0116] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted heteroalkylene, e.g.,
substituted or unsubstituted heteroC.sub.1-6alkylene, substituted
or unsubstituted heteroC.sub.1-2alkylene, substituted or
unsubstituted heteroC.sub.2-3alkylene, substituted or unsubstituted
heteroC.sub.3-4alkylene, substituted or unsubstituted
heteroC.sub.4-5alkylene, or substituted or unsubstituted
heteroC.sub.5-6alkylene. Exemplary heteroalkylene groups include
unsubstituted alkylene groups such as
--(CH.sub.2).sub.2--O(CH.sub.2).sub.2--, --OCH.sub.2--,
--CH.sub.2O--, --O(CH.sub.2).sub.2--, --(CH.sub.2).sub.2O--,
--O(CH.sub.2).sub.3--, --(CH.sub.2).sub.3O--,
--O(CH.sub.2).sub.4--, --(CH.sub.2).sub.4O--,
--O(CH.sub.2).sub.5--, --(CH.sub.2).sub.5O--,
--O(CH.sub.2).sub.6--, and --O(CH.sub.2).sub.6O--.
[0117] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted heteroalkenylene, e.g.,
substituted or unsubstituted heteroC.sub.2-6alkenylene, substituted
or unsubstituted heteroC.sub.2-3alkenylene, substituted or
unsubstituted heteroC.sub.3-4alkenylene, substituted or
unsubstituted heteroC.sub.4-5alkenylene, or substituted or
unsubstituted heteroC.sub.5-6alkenylene.
[0118] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted heteroalkynylene, e.g.,
substituted or unsubstituted heteroC.sub.2-6alkynylene, substituted
or unsubstituted heteroC.sub.2-3alkynylene, substituted or
unsubstituted heteroC.sub.3-4alkynylene, substituted or
unsubstituted heteroC.sub.4-5alkynylene, or substituted or
unsubstituted heteroC.sub.5-6alkynylene.
[0119] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted carbocyclylene, e.g.,
substituted or unsubstituted C.sub.3-6carbocyclylene, substituted
or unsubstituted C.sub.3-4carbocyclylene, substituted or
unsubstituted C.sub.4-5 carbocyclylene, or substituted or
unsubstituted C.sub.5-6 carbocyclylene.
[0120] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted heterocyclylene, e.g.,
substituted or unsubstituted C.sub.3-6 heterocyclylene, substituted
or unsubstituted C.sub.3-4 heterocyclylene, substituted or
unsubstituted C.sub.4-5 heterocyclylene, or substituted or
unsubstituted C.sub.5-6 heterocyclylene.
[0121] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted arylene, e.g., substituted
or unsubstituted phenylene.
[0122] In certain embodiments, L.sup.1 comprises at least one
instance of substituted or unsubstituted heteroarylene, e.g.,
substituted or unsubstituted 5- to 6-membered heteroarylene.
[0123] In certain embodiments, L.sup.1 is a linker that contains an
asymmetric carbon/stereocenter, i.e., an sp.sup.3 hybridized carbon
atom bearing 4 different groups attached thereto. In certain
embodiments, the compound comprising such an L.sup.1 group is
enantiomerically enriched or substantially enantiomerically
enriched, as defined herein. However, in certain embodiments, the
compound comprising such an L.sup.1 group is racemic.
[0124] In certain embodiments, L.sup.1 represents a linker
consisting of a combination of one or more consecutive covalently
bonded groups of the formulae:
##STR00013## ##STR00014##
wherein: [0125] each instance of n is independently an integer
between 1 to 10, inclusive; [0126] each instance of m is
independently 0, 1, or 2; [0127] each instance of Q is
independently --NR.sup.W1--; --NR.sup.W1--NR.sup.W1--;
--O--NR.sup.W1--; --NR.sup.W1--O--; --S--; or --O--; [0128] each
instance of W is independently O, S, or NR.sup.W1;
[0129] each instance of G.sub.1 and G.sub.2 are independently N or
CH;
[0130] each instance of R.sup.W1 is independently hydrogen;
substituted or unsubstituted alkyl; substituted or unsubstituted
alkenyl; substituted or unsubstituted alkynyl; substituted or
unsubstituted carbocyclyl; substituted or unsubstituted
heterocyclyl; substituted or unsubstituted aryl; substituted or
unsubstituted heteroaryl; a nitrogen protecting group if attached
to a nitrogen atom, or an oxygen protecting group if attached to an
oxygen atom; [0131] each instance of R.sup.W2 is independently
hydrogen; substituted or unsubstituted alkyl; substituted or
unsubstituted alkenyl; substituted or unsubstituted alkynyl;
substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or two R.sup.W2 groups are
joined to form a 5-6 membered ring; and
[0132] each instance of R.sup.W3 is independently hydrogen;
halogen; substituted or unsubstituted alkyl; substituted or
unsubstituted alkenyl; substituted or unsubstituted alkynyl;
substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl; or
substituted or unsubstituted heteroaryl, or two R.sup.W3 groups are
joined to form a 3-6 membered ring;
[0133] or R.sup.W1 and R.sup.W3 are joined to form a 5-6 membered
heterocyclic ring.
[0134] As described herein, n of any of the below formulae is
independently an integer between 1 to 10, inclusive, e.g., 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10:
##STR00015##
In certain embodiments, n is 1, 2, or 3. In certain embodiments,
each instance of R.sup.W3 is independently hydrogen; halogen; or
substituted or unsubstituted alkyl (e.g., methyl).
[0135] As described herein, m of any of the below formulae is
independently 0, 1, or 2, and G.sub.1 and G.sub.2 are independently
N or CH:
##STR00016##
In certain embodiments, m is 0, and R.sup.W3 is absent. In certain
embodiments, m is 1. In certain embodiments, m is 2. In certain
embodiments, G.sub.1 is N. In certain embodiments, G.sub.1 is CH.
In certain embodiments, G.sub.2 is N. In certain embodiments,
G.sub.2 is CH. In certain embodiments, G.sub.1 is N and G.sub.2 is
CH. In certain embodiments, G.sub.1 is CH and G.sub.2 is CH. In
certain embodiments, G.sub.1 is N and G.sub.2 is N. In certain
embodiments, G.sub.1 is CH and G.sub.2 is N. In certain
embodiments, each instance of R.sup.W3 is independently hydrogen;
halogen; or substituted or unsubstituted alkyl (e.g., methyl).
[0136] As described herein, each instance of Q of any of the below
formulae is independently --NR.sup.W1--; --NR.sup.W1--NR.sup.W1--;
--O--NR.sup.W1--; --NR.sup.W1--O--; --S--; or --O--, and each
instance of W of any of the below formulae is independently O, S,
or NR.sup.W1:
##STR00017##
In certain embodiments, Q is --NR.sup.W1--. In certain embodiments,
Q is --NR.sup.W1--NR.sup.W1--. In certain embodiments, Q is
--O--NR.sup.W1--. In certain embodiments, Q is --NR.sup.W1--O--. In
certain embodiments, Q is --S--. In certain embodiments, Q is
--O--. In certain embodiments, W is O. In certain embodiments, W is
S. In certain embodiments, W is NR.sup.W1. In certain embodiments,
W is O and Q is independently --S--, --NR.sup.W1--, or --O--. In
certain embodiments, R.sup.W1 is not hydrogen. In certain
embodiments, R.sup.W2 is hydrogen or substituted or unsubstituted
alkyl (e.g., methyl).
[0137] As described herein, each instance of R.sup.W1 is
independently hydrogen; substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; a nitrogen protecting
group if attached to a nitrogen atom, or an oxygen protecting group
if attached to an oxygen atom. In any of the above formulae, as
described herein, each instance of R.sup.W1 is independently
hydrogen; substituted or unsubstituted alkyl (e.g., methyl); a
nitrogen protecting group if attached to a nitrogen atom, or an
oxygen protecting group if attached to an oxygen atom.
[0138] As described herein, each instance of R.sup.W2 is
independently hydrogen; substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or two R.sup.W2 groups are
joined to form a 5-6 membered ring. In any of the above formulae,
as described herein, each instance of R.sup.W2 is independently
hydrogen or substituted or unsubstituted alkyl (e.g., methyl).
[0139] As described herein, each instance of R.sup.W3 is
independently hydrogen; halogen; substituted or unsubstituted
alkyl; substituted or unsubstituted alkenyl; substituted or
unsubstituted alkynyl; substituted or unsubstituted carbocyclyl;
substituted or unsubstituted heterocyclyl; substituted or
unsubstituted aryl; or substituted or unsubstituted heteroaryl, or
two R.sup.W3 groups are joined to form a 3-6 membered ring. In any
of the above formulae, as described herein, each instance of
R.sup.W3 is independently hydrogen; halogen; substituted or
unsubstituted alkyl (e.g., methyl).
[0140] In certain embodiments, L.sup.1 represents a linker
consisting of a combination of one or more consecutively covalently
bonded groups of the formula:
##STR00018##
[0141] In certain embodiments, L.sup.1 represents a linker
consisting of a combination of 1 to 20 consecutive covalently
bonded groups of the above described formulae, e.g., 2 to 20, 3 to
20, 4 to 20, 5 to 20, 6 to 20, 8 to 20, 9 to 20, 10 to 20, 2 to 10,
2 to 9, 2 to 8, 2 to 7, 2 to 6, or 2 to 5 groups, inclusive. In
certain embodiments, L.sup.1 represents a linker consisting of a
combination of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, or 20 consecutive covalently bonded groups of the
above described formulae.
[0142] In certain embodiments, L.sup.1 represents a linker 4 to 20
consecutive covalently bonded atoms in length, inclusive, e.g., 4
to 19, 4 to 18, 4 to 17, 4 to 16, 4 to 15, 4 to 14, 4 to 13, 4 to
12, 4 to 11, 4 to 10, 4 to 9, 4 to 8, 4 to 7, 4 to 6, or 5 to 11
consecutive covalently bonded atoms in length, inclusive. In
certain embodiments, L.sup.1 represents a linker 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive
covalently bonded atoms in length. In certain embodiments, L.sup.1
represents a linker 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15
consecutive covalently bonded atoms in length.
[0143] It should be generally understood that multiple instances of
a given variable or group present in a linker may optionally
differ. Thus, in further defining the linker L.sup.1, it is
generally helpful to further distinguish multiple instances of a
given variable with different numbers.
[0144] For example, in certain embodiments, -L.sup.1-R.sup.H
represents a group of the formula:
##STR00019##
which may also be depicted as:
##STR00020##
wherein n3 and n4 are as defined for variable n, and are each
independently an integer between 1 to 10, inclusive, and wherein Q,
R.sup.W3 and R.sup.H are as defined herein. In certain embodiments,
n3 is 2 or 3 and n4 is 1, 2, or 3.
[0145] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00021##
which may also be depicted as:
##STR00022##
wherein n1, n2, n3, and n4 are as defined for variable n, and are
each independently an integer between 1 to 10, inclusive, and
wherein Q, R.sup.W3 and R.sup.H are as defined herein. In certain
embodiments, n1 is 1, n2 is 1 or 2, n3 is 1, and n4 is 1, 2, or
3.
[0146] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00023##
which may also be depicted as:
##STR00024##
wherein n3 and n4 are as defined for variable n, and are each
independently an integer between 1 to 10, inclusive, and wherein
G.sub.1, G.sub.2, Q, R.sup.W3, and R.sup.H are as defined herein.
In certain embodiments, n3 is 2 or 3 and n4 is 1, 2, or 3.
[0147] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00025##
which may also be depicted as:
##STR00026##
wherein n1, n2, n3, and n4 are as defined for variable n, and are
each independently an integer between 1 to 10, inclusive, and
wherein G.sub.1, G.sub.2, Q, R.sup.W3 and R.sup.H are as defined
herein. In certain embodiments, n1 is 1, n2 is 1 or 2, n3 is 1, and
n4 is 1, 2, or 3.
[0148] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00027##
wherein n is an integer between 1 to 10, inclusive, and wherein
R.sup.W3 and R.sup.H are as defined herein. In certain embodiments,
n is 1, 2, or 3.
[0149] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00028##
wherein R.sup.H is as defined herein.
[0150] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00029##
wherein n is an integer between 1 to 10, inclusive, and wherein
G.sub.1, G.sub.2, Q, R.sup.W3 and R.sup.H are as defined herein. In
certain embodiments, n is 1, 2, or 3.
[0151] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00030##
wherein G.sub.1, G.sub.2, and R.sup.H are as defined herein.
[0152] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00031##
wherein R.sup.H is as defined herein.
[0153] In certain embodiments, -L.sup.1-R.sup.H represents a group
of the formula:
##STR00032##
wherein R.sup.H is as defined herein.
Hydrophobic Group R.sup.H
[0154] As described herein, R.sup.H represents a hydrophobic group
selected from the group consisting of substituted and unsubstituted
aryl, substituted and unsubstituted heteroaryl, substituted and
unsubstituted carbocyclyl, substituted and unsubstituted
heterocyclyl, substituted and unsubstituted aralkyl, substituted
and unsubstituted heteroarylalkyl, substituted and unsubstituted
carbocycylalkyl, and substituted and unsubstituted
heterocyclylalkyl.
[0155] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted aryl or substituted or unsubstituted aralkyl
moiety. In certain embodiments, R.sup.H is a hydrophobic
substituted or unsubstituted aryl moiety, e.g., substituted or
unsubstituted phenyl, substituted or unsubstituted biphenyl,
substituted or unsubstituted naphthyl, or substituted or
unsubstituted anthracenyl. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted aralkyl moiety, e.g.,
substituted or unsubstituted benzyl (--CH.sub.2-phenyl),
substituted or unsubstituted diphenylmethyl, substituted or
unsubstituted trityl, substituted or unsubstituted biphenylmethyl,
substituted or unsubstituted naphthylmethyl, or substituted or
unsubstituted anthracenylmethyl.
[0156] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted aryl moiety, e.g., of the formula:
##STR00033##
wherein each occurrence of R.sup.H1 and R.sup.H2 is independently
halogen (e.g., fluoro, bromo, iodo, or chloro), alkyl (e.g.,
methyl, ethyl, propyl, isopropyl, tertbutyl), haloalkyl (e.g.,
difluoromethyl, perfluoromethyl), alkoxy (e.g., methoxy, ethoxy,
isopropoxy), or dialkylamino (e.g., dimethylamino, diethylamino);
and p and q are independently 0, 1, 2, or 3. In certain
embodiments, each occurrence of R.sup.H1 and R.sup.H2 is
independently fluoro, bromo, iodo, chloro, methyl, ethyl, propyl,
isopropyl, tertbutyl, difluoromethyl, perfluoromethyl, methoxy,
ethoxy, isopropoxy, dimethylamino, or diethylamino. In certain
embodiments, p is 0 or 1. In certain embodiments, q is 0 or 1. In
certain embodiments, p is 0. In certain embodiments, q is 0. In
certain embodiments, p is 0, and q is 0.
[0157] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted aralkyl moiety, e.g., of the formula:
##STR00034##
wherein each occurrence of R.sup.H1, R.sup.H2, and R.sup.H3 is
independently halogen (e.g., fluoro, bromo, iodo, or chloro), alkyl
(e.g., methyl, ethyl, propyl, isopropyl, tertbutyl), haloalkyl
(e.g., difluoromethyl, perfluoromethyl), alkoxy (e.g., methoxy,
ethoxy, isopropoxy), or dialkylamino (e.g., dimethylamino,
diethylamino); and p, q, and r are independently 0, 1, 2, or 3. In
certain embodiments, each occurrence of R.sup.H1, R.sup.H2, and
R.sup.H3 is independently fluoro, bromo, iodo, chloro, methyl,
ethyl, propyl, isopropyl, tertbutyl, difluoromethyl,
perfluoromethyl, methoxy, ethoxy, isopropoxy, dimethylamino, or
diethylamino. In certain embodiments, p is 0 or 1. In certain
embodiments, q is 0 or 1. In certain embodiments, r is 0 or 1. In
certain embodiments, p is 0. In certain embodiments, q is 0. In
certain embodiments, r is 0. In certain embodiments, p is 0, q is
0, and r is 0.
[0158] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted heteroaryl or substituted or unsubstituted
heteroarylalkyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted heteroaryl moiety, e.g.,
substituted or unsubstituted 5-membered heteroaryl or substituted
or unsubstituted 6-membered heteroaryl. In certain embodiments,
R.sup.H is a hydrophobic substituted or unsubstituted
heteroarylaralkyl moiety, e.g., substituted or unsubstituted
5-membered heteroarylmethyl or substituted or unsubstituted
6-membered heteroarylmethyl.
[0159] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted carbocyclyl or substituted or unsubstituted
carbocycylalkyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted carbocyclyl moiety, e.g.,
a C.sub.5-14carbocyclyl moiety which may be monocyclic, bicyclic,
or tricyclic and/or fused, bridged, or spiro-fused, e.g.,
substituted or unsubstituted C.sub.5-13carbocyclyl, substituted or
unsubstituted C.sub.5-12carbocyclyl, substituted or unsubstituted
C.sub.5-11carbocyclyl, substituted or unsubstituted
C.sub.5-10carbocyclyl, substituted or unsubstituted
C.sub.5-9carbocyclyl, substituted or unsubstituted
C.sub.5-8carbocyclyl, substituted or unsubstituted
C.sub.5-7carbocyclyl, substituted or unsubstituted
C.sub.3-6carbocyclyl, substituted or unsubstituted
C.sub.3-4carbocyclyl, substituted or unsubstituted C.sub.4-5
carbocyclyl, or substituted or unsubstituted C.sub.5-6 carbocyclyl.
In certain embodiments, R.sup.H is a hydrophobic substituted or
unsubstituted fused bicyclic carbocyclyl, e.g., substituted or
unsubstituted cis- or trans-decalin. In certain embodiments,
R.sup.H is a hydrophobic substituted or unsubstituted fused
tricyclic carbocyclyl, e.g., substituted or unsubstituted
fluorenyl. In certain embodiments, R.sup.H is a hydrophobic
substituted or unsubstituted spiro-fused bicyclic carbocyclyl,
e.g., substituted or unsubstituted spiropentane. In certain
embodiments, R.sup.H is a hydrophobic substituted or unsubstituted
bridged bicyclic carbocyclyl, e.g., substituted or unsubstituted
norbornane, norbornene, bicyclo[2.2.2]octane,
bicyclo[2.2.2]oct-2-ene, bicyclo[3.2.1]octane, or
bicyclo[2.2.1]heptan-2-one. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted bridged tricyclic
carbocyclyl moiety, e.g., substituted or unsubstituted adamantane.
In certain embodiments, R.sup.H is a hydrophobic substituted or
unsubstituted carbocycylalkyl moiety, e.g., hydrophobic substituted
or unsubstituted carbocycylmethyl.
[0160] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted carbocyclyl moiety, e.g., of the formula:
##STR00035##
wherein each occurrence of R.sup.H1 and R.sup.H2 is independently
halogen (e.g., fluoro, bromo, iodo, or chloro), alkyl (e.g.,
methyl, ethyl, propyl, isopropyl, tertbutyl), haloalkyl (e.g.,
difluoromethyl, perfluoromethyl), alkoxy (e.g., methoxy, ethoxy,
isopropoxy), or dialkylamino (e.g., dimethylamino, diethylamino);
and p and q are independently 0, 1, 2, or 3. In certain
embodiments, each occurrence of R.sup.H1 and R.sup.H2 is
independently fluoro, bromo, iodo, chloro, methyl, ethyl, propyl,
isopropyl, tertbutyl, difluoromethyl, perfluoromethyl, methoxy,
ethoxy, isopropoxy, dimethylamino, or diethylamino. In certain
embodiments, p is 0 or 1. In certain embodiments, q is 0 or 1. In
certain embodiments, p is 0. In certain embodiments, q is 0. In
certain embodiments, p is 0, and q is 0.
[0161] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted carbocyclylalkyl moiety, e.g., of the formula:
##STR00036##
wherein each occurrence of R.sup.H1 and R.sup.H2 is independently
halogen (e.g., fluoro, bromo, iodo, or chloro), alkyl (e.g.,
methyl, ethyl, propyl, isopropyl, tertbutyl), haloalkyl (e.g.,
difluoromethyl, perfluoromethyl), alkoxy (e.g., methoxy, ethoxy,
isopropoxy), or dialkylamino (e.g., dimethylamino, diethylamino);
and p and q are independently 0, 1, 2, or 3. In certain
embodiments, each occurrence of R.sup.H1 and R.sup.H2 is
independently fluoro, bromo, iodo, chloro, methyl, ethyl, propyl,
isopropyl, tertbutyl, difluoromethyl, perfluoromethyl, methoxy,
ethoxy, isopropoxy, dimethylamino, or diethylamino. In certain
embodiments, p is 0 or 1. In certain embodiments, q is 0 or 1. In
certain embodiments, p is 0. In certain embodiments, q is 0. In
certain embodiments, p is 0, and q is 0.
[0162] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted heterocyclyl or substituted or unsubstituted
heterocyclylalkyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted heterocyclyl moiety, e.g.,
a 5-14-membered heterocyclyl which may be monocyclic, bicyclic, or
tricyclic and/or a fused, bridged, or spiro-fused moiety, e.g.,
substituted or unsubstituted 5-13-membered heterocyclyl,
substituted or unsubstituted 5-12-membered heterocyclyl,
substituted or unsubstituted 5-11-membered heterocyclyl,
substituted or unsubstituted 5-10-membered heterocyclyl,
substituted or unsubstituted 5-9-membered heterocyclyl, substituted
or unsubstituted 5-8-membered heterocyclyl, substituted or
unsubstituted 5-7-membered heterocyclyl, substituted or
unsubstituted 3-6-membered heterocyclyl, substituted or
unsubstituted 3-4-membered heterocyclyl, substituted or
unsubstituted 4-5-membered heterocyclyl, or substituted or
unsubstituted 5-6-membered heterocyclyl. In certain embodiments,
R.sup.H is a hydrophobic substituted or unsubstituted fused
bicyclic heterocyclyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted fused tricyclic
heterocyclyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted spiro-fused bicyclic
heterocyclyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted bridged bicyclic
heterocyclyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted bridged tricyclic
heterocyclyl moiety. In certain embodiments, R.sup.H is a
hydrophobic substituted or unsubstituted heterocyclyl alkyl moiety,
e.g., hydrophobic substituted or unsubstituted heterocyclylmethyl.
Exemplary heterocylyl groups include, but are not limited to,
piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl,
piperazinyl, morpholinyl, dithianyl, dioxanyl, and triazinanyl
moieties, which may comprise one or more heterocycyl, carbocyclyl,
aryl or heteroaryl rings fused thereto.
[0163] In certain embodiments, R.sup.H is a hydrophobic substituted
or unsubstituted heterocyclyl moiety, e.g., of the formula:
##STR00037##
wherein each occurrence of R.sup.H1 and R.sup.H2 is independently
halogen (e.g., fluoro, bromo, iodo, or chloro), alkyl (e.g.,
methyl, ethyl, propyl, isopropyl, tertbutyl), haloalkyl (e.g.,
difluoromethyl, perfluoromethyl), alkoxy (e.g., methoxy, ethoxy,
isopropoxy), or dialkylamino (e.g., dimethylamino, diethylamino);
and p and q are independently 0, 1, 2, or 3. In certain
embodiments, each occurrence of R.sup.H1 and R.sup.H2 is
independently fluoro, bromo, iodo, chloro, methyl, ethyl, propyl,
isopropyl, tertbutyl, difluoromethyl, perfluoromethyl, methoxy,
ethoxy, isopropoxy, dimethylamino, or diethylamino. In certain
embodiments, p is 0 or 1. In certain embodiments, q is 0 or 1. In
certain embodiments, p is 0. In certain embodiments, q is 0. In
certain embodiments, p is 0, and q is 0.
[0164] In certain embodiments, R.sup.H is a hydrophobic group of
the formula:
##STR00038##
[0165] In certain embodiments, R.sup.H is a hydrophobic group of
the formula:
##STR00039##
Optional Warhead -L.sup.2-R.sup.D
[0166] As generally understood herein, M of Formula (I) represents
a small organic molecule which covalently or non-covalently binds a
kinase, e.g., a protein kinase.
##STR00040##
[0167] In certain embodiments, the small organic molecule M
includes and is substituted with a group -L.sup.2-R.sup.D, wherein
L.sup.2 is a bond or a linker, and R.sup.D is a group that
covalently or non-covalently binds to the kinase.
[0168] In certain embodiments, L.sup.2 is a bond or a linker
selected from the group consisting of substituted and unsubstituted
alkylene; substituted and unsubstituted alkenylene; substituted and
unsubstituted alkynylene; substituted and unsubstituted
heteroalkylene; substituted and unsubstituted heteroalkenylene;
substituted and unsubstituted heteroalkynylene; substituted and
unsubstituted heterocyclylene; substituted and unsubstituted
carbocyclylene; substituted and unsubstituted arylene; substituted
and unsubstituted heteroarylene; and combinations thereof.
[0169] In certain embodiments, L.sup.2 is a bond.
[0170] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted alkylene, e.g.,
substituted or unsubstituted C.sub.1-6alkylene, substituted or
unsubstituted C.sub.2-6alkylene, substituted or unsubstituted
C.sub.3-6alkylene, substituted or unsubstituted C.sub.4-6alkylene,
substituted or unsubstituted C.sub.5-6alkylene, substituted or
unsubstituted C.sub.2-5alkylene, substituted or unsubstituted
C.sub.2-4alkylene, substituted or unsubstituted C.sub.2-3alkylene,
substituted or unsubstituted C.sub.1alkylene, substituted or
unsubstituted C.sub.2alkylene, substituted or unsubstituted
C.sub.3alkylene, substituted or unsubstituted C.sub.4alkylene,
substituted or unsubstituted C.sub.5alkylene, or substituted or
unsubstituted C.sub.6alkylene. In certain embodiments, L.sup.2 is
substituted or unsubstituted alkylene.
[0171] In certain embodiments, L.sup.2 is linker comprising at
least one instance of substituted or unsubstituted alkenylene,
e.g., substituted or unsubstituted C.sub.2-6alkenylene, substituted
or unsubstituted C.sub.3-6alkenylene, substituted or unsubstituted
C.sub.4-6alkenylene, substituted or unsubstituted
C.sub.5-6alkenylene, substituted or unsubstituted
C.sub.2-5alkenylene, substituted or unsubstituted
C.sub.2-4alkenylene, substituted or unsubstituted
C.sub.2-3alkenylene, substituted or unsubstituted
C.sub.2alkenylene, substituted or unsubstituted C.sub.3alkenylene,
substituted or unsubstituted C.sub.4alkenylene, substituted or
unsubstituted C.sub.5alkenylene, or substituted or unsubstituted
C.sub.6alkenylene. In certain embodiments, L.sup.2 is substituted
or unsubstituted alkenylene.
[0172] In certain embodiments, L.sup.2 is linker comprising at
least one instance of substituted or unsubstituted alkynylene,
e.g., substituted or unsubstituted C.sub.2-6alkynylene, substituted
or unsubstituted C.sub.3-6alkynylene, substituted or unsubstituted
C.sub.4-6alkynylene, substituted or unsubstituted
C.sub.5-6alkynylene, substituted or unsubstituted
C.sub.2-5alkynylene, substituted or unsubstituted
C.sub.2-4alkynylene, substituted or unsubstituted
C.sub.2-3alkynylene, substituted or unsubstituted
C.sub.2alkynylene, substituted or unsubstituted C.sub.3alkynylene,
substituted or unsubstituted C.sub.4alkynylene, substituted or
unsubstituted C.sub.5alkynylene, or substituted or unsubstituted
C.sub.6alkynylene. In certain embodiments, L.sup.2 is substituted
or unsubstituted alkynylene.
[0173] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted heteroalkylene,
e.g., substituted or unsubstituted heteroC.sub.1-6alkylene,
substituted or unsubstituted heteroC.sub.2-6alkylene, substituted
or unsubstituted heteroC.sub.3-6alkylene, substituted or
unsubstituted heteroC.sub.4-6alkylene, substituted or unsubstituted
heteroC.sub.5-6alkylene, substituted or unsubstituted
heteroC.sub.2-5alkylene, substituted or unsubstituted
heteroC.sub.2-4alkylene, substituted or unsubstituted
heteroC.sub.2-3alkylene, substituted or unsubstituted
heteroC.sub.1alkylene, substituted or unsubstituted
heteroC.sub.2alkylene, substituted or unsubstituted
heteroC.sub.3alkylene, substituted or unsubstituted
heteroC.sub.4alkylene, substituted or unsubstituted
heteroC.sub.5alkylene, or substituted or unsubstituted
heteroC.sub.6alkylene. In certain embodiments, L.sup.2 is
substituted or unsubstituted heteroalkylene.
[0174] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted
heteroalkenylene, e.g., substituted or unsubstituted
heteroC.sub.2-6alkenylene, substituted or unsubstituted
heteroC.sub.3-6alkenylene, substituted or unsubstituted
heteroC.sub.4-6 alkenylene, substituted or unsubstituted
heteroC.sub.5-6alkenylene, substituted or unsubstituted
heteroC.sub.2-5alkenylene, substituted or unsubstituted
heteroC.sub.2-4alkenylene, substituted or unsubstituted
heteroC.sub.2-3alkenylene, substituted or unsubstituted
heteroC.sub.2alkenylene, substituted or unsubstituted
heteroC.sub.3alkenylene, substituted or unsubstituted
heteroC.sub.4alkenylene, substituted or unsubstituted
heteroC.sub.5alkenylene, or substituted or unsubstituted
heteroC.sub.6alkenylene. In certain embodiments, L.sup.2 is
substituted or unsubstituted heteroalkenylene.
[0175] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted
heteroalkynylene, e.g., substituted or unsubstituted
heteroC.sub.2-6alkynylene, substituted or unsubstituted
heteroC.sub.3-6alkynylene, substituted or unsubstituted
heteroC.sub.4-6alkynylene, substituted or unsubstituted
heteroC.sub.5-6alkynylene, substituted or unsubstituted
heteroC.sub.2-5alkynylene, substituted or unsubstituted
heteroC.sub.2-4alkynylene, substituted or unsubstituted
heteroC.sub.2-3alkynylene, substituted or unsubstituted
heteroC.sub.2alkynylene, substituted or unsubstituted
heteroC.sub.3alkynylene, substituted or unsubstituted
heteroC.sub.4alkynylene, substituted or unsubstituted
heteroC.sub.5alkynylene, or substituted or unsubstituted
heteroC.sub.6alkynylene. In certain embodiments, L.sup.2 is
substituted or unsubstituted heteroalkynylene.
[0176] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted heterocyclylene,
e.g., substituted or unsubstituted 5- to 8-membered
heterocyclylene, substituted or unsubstituted 5- to 7-membered
heterocyclylene, substituted or unsubstituted 5- to 6-membered
heterocyclylene, substituted or unsubstituted 5-membered
heterocyclylene, substituted or unsubstituted 6-membered
heterocyclylene, substituted or unsubstituted 7-membered
heterocyclylene, or substituted or unsubstituted 8-membered
heterocyclylene. In certain embodiments, L.sup.2 is substituted or
unsubstituted heterocyclylene.
[0177] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted carbocyclylene,
e.g., substituted or unsubstituted C.sub.3-6 carbocyclylene,
substituted or unsubstituted C.sub.3-5 carbocyclylene, substituted
or unsubstituted C.sub.3-4 carbocyclylene, substituted or
unsubstituted C.sub.3 carbocyclylene, substituted or unsubstituted
C.sub.4 carbocyclylene, substituted or unsubstituted C.sub.5
carbocyclylene, or substituted or unsubstituted C.sub.6
carbocyclylene. In certain embodiments, L.sup.2 is substituted or
unsubstituted carbocyclylene.
[0178] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted arylene, e.g.,
substituted or unsubstituted C.sub.6 arylene (phenylene) or
substituted or unsubstituted C.sub.10 arylene (naphthylene). In
certain embodiments, L.sup.2 is substituted or unsubstituted
arylene.
[0179] In certain embodiments, L.sup.2 is a linker comprising at
least one instance of substituted or unsubstituted heteroarylene,
e.g., substituted or unsubstituted 5-membered heteroarylene or
substituted or unsubstituted 6-membered heteroarylene. In certain
embodiments, L.sup.2 is substituted or unsubstituted
heteroarylene.
[0180] In certain embodiments, R.sup.D is an electrophilic group
that covalently binds a kinase, e.g., a protein kinase, by reaction
with a nucleophilic moiety, e.g., such as a cysteine in the ATP
binding pocket of the kinase. In this instance, in certain
embodiments, R.sup.D is a group of formula:
##STR00041## ##STR00042## ##STR00043##
wherein:
[0181] R.sup.D1 is hydrogen, halogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--CN, --NO.sub.2, --OR.sup.D1a, --N(R.sup.D1a).sub.2, --SR.sup.D1a,
--CH.sub.2OR.sup.D1a, --CH.sub.2N(R.sup.D1a).sub.2,
--CH.sub.2SR.sup.D1a, --C(.dbd.O)R.sup.D1a, --C(.dbd.O)OR.sup.D1a,
--C(.dbd.O)SR.sup.D1a, --C(.dbd.O)N(R.sup.D1a).sub.2,
--C(.dbd.S)R.sup.D1a, --C(.dbd.S)OR.sup.D1a, --C(.dbd.S)SR.sup.D1a,
--C(.dbd.S)N(R.sup.D1a).sub.2, --C(.dbd.NR.sup.D1a)R.sup.D1a,
--C(.dbd.NR.sup.D1a)OR.sup.D1a, C(.dbd.NR.sup.D1a)SR.sup.D1a, or
--C(.dbd.NR.sup.D1a)N(R.sup.D1a).sub.2, wherein each occurrence of
R.sup.D1a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
or two R.sup.D1a groups are joined to form an substituted or
unsubstituted heterocyclic ring;
[0182] R.sup.D2 is hydrogen, halogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--CN, --NO.sub.2, --OR.sup.D2a, --N(R.sup.D2a).sub.2, --SR.sup.D2a,
--CH.sub.2OR.sup.D2a, --CH.sub.2N(R.sup.D2a).sub.2,
--CH.sub.2SR.sup.D2a, --C(.dbd.O)R.sup.D2a, --C(.dbd.O)OR.sup.D2a,
--C(.dbd.O)SR.sup.D2a, --C(.dbd.O)N(R.sup.D2a).sub.2,
--C(.dbd.S)R.sup.D2a, --C(.dbd.S)OR.sup.D2a, --C(.dbd.S)SR.sup.D2a,
--C(.dbd.S)N(R.sup.D2a).sub.2, --C(.dbd.NR.sup.D2a)R.sup.D2a,
--C(.dbd.NR.sup.D2a)OR.sup.D2a, --C(.dbd.NR.sup.D2a)SR.sup.D2a, and
--C(.dbd.NR.sup.D2a)N(R.sup.D2a).sub.2, wherein each occurrence of
R.sup.D2a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
or two R.sup.D2a groups are joined to form an substituted or
unsubstituted heterocyclic ring;
[0183] R.sup.D3 is hydrogen, halogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.D3a, --N(R.sup.D3a).sub.2, --SR.sup.D3a,
--CH.sub.2OR.sup.D3a, --CH.sub.2N(R.sup.D3a).sub.2,
--CH.sub.2SR.sup.D3a, --C(.dbd.O)R.sup.D3a, --C(.dbd.O)OR.sup.D3a,
--C(.dbd.O)SR.sup.D3a, --C(.dbd.O)N(R.sup.D3a).sub.2,
--C(.dbd.S)R.sup.D3a, --C(.dbd.S)OR.sup.D3a, --C(.dbd.S)SR.sup.D3a,
--C(.dbd.S)N(R.sup.D3a).sub.2, --C(.dbd.NR.sup.D3a)R.sup.D3a,
--C(.dbd.NR.sup.D3a)OR.sup.D3a, --C(.dbd.NR.sup.D3a)SR.sup.D3a, or
--C(.dbd.NR.sup.D3a)N(R.sup.D3a).sub.2 wherein each occurrence of
R.sup.D3a is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
or two R.sup.D3a groups are joined to form an substituted or
unsubstituted heterocyclic ring;
[0184] optionally R.sup.D1 and R.sup.D3, or R.sup.D2 and R.sup.D3,
or R.sup.D1 and R.sup.D2 are joined to form an substituted or
unsubstituted carbocyclic or substituted or unsubstituted
heterocyclic ring;
[0185] R.sup.D4 is a leaving group selected from the group
consisting of --Br, --Cl, --I, and --OS(.dbd.O).sub.wR.sup.D4a,
wherein w is 1 or 2, and R.sup.D4a is substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl;
[0186] X.sup.1 is a bond or NR.sup.D5, wherein R.sup.D5 is
hydrogen, C.sub.1-6 alkyl, or a nitrogen protecting group;
[0187] each instance of Y is independently O, S, or NR.sup.D6,
wherein R.sup.D6 is hydrogen, C.sub.1-6 alkyl, or a nitrogen
protecting group; and
[0188] z is 0, 1, 2, 3, 4, 5, or 6.
[0189] In certain embodiments, R.sup.D is a group of Formula (i-1),
(i-3), or (i-20):
##STR00044##
wherein each instance of X.sup.1 is bond or NR.sup.D5, Y is
independently O, S, or NR.sup.D6, and R.sup.D1, R.sup.D2 and
R.sup.D3 are as defined herein. In certain embodiments, X.sup.1 is
a bond. In certain embodiments, X.sup.1 is NR.sup.D5. In certain
embodiments, Y is O. In certain embodiments, R.sup.D1 is hydrogen.
In certain embodiments, R.sup.D1 is --CN. In certain embodiments,
R.sup.D2 is hydrogen. In certain embodiments, R.sup.D3 is hydrogen.
In certain embodiments, R.sup.D2 is --CH.sub.2N(R.sup.D2a).sub.2,
and R.sup.D3 is hydrogen. In certain embodiments, R.sup.D2 is
--CH.sub.2N(R.sup.D3a).sub.2, and R.sup.D3 is hydrogen. In certain
embodiments, R.sup.D2 and R.sup.D3 are hydrogen. In certain
embodiments, R.sup.D1, R.sup.D2 and R.sup.D3 are hydrogen.
[0190] In certain embodiments, R.sup.D is a group of Formula
(i-19), (i-17), or (i-18):
##STR00045##
wherein Y is independently O, S, or NR.sup.D6; and R.sup.D1,
R.sup.D2, and R.sup.D3 are as defined herein. In certain
embodiments, Y is O. In certain embodiments, R.sup.D1 is hydrogen.
In certain embodiments, R.sup.D2 is hydrogen. In certain
embodiments, R.sup.D2 is --CN. In certain embodiments, R.sup.D3 is
substituted or unsubstituted alkyl.
[0191] In certain embodiments, R.sup.D is a group of Formula (i-7)
or (i-8):
##STR00046##
wherein Y is independently O, S, or NR.sup.D6; and R.sup.D1,
R.sup.D2, and R.sup.D3 are as defined herein. In certain
embodiments, Y is O. In certain embodiments, R.sup.D1 is hydrogen.
In certain embodiments, R.sup.D2 is hydrogen. In certain
embodiments, R.sup.D3 is hydrogen.
[0192] In certain embodiments, R.sup.D is a group of Formula (i-13)
or (i-14):
##STR00047##
wherein each instance of X.sup.1 is bond or NR.sup.D5; Y is
independently O, S, or NR.sup.D6; and R.sup.D1 and R.sup.D2 are as
defined herein. In certain embodiments, X.sup.1 is a bond. In
certain embodiments, X.sup.1 is NR.sup.D5. In certain embodiments,
Y is O. In certain embodiments, R.sup.D1 is hydrogen. In certain
embodiments, R.sup.D1 is halogen, e.g., --F or --Cl. In certain
embodiments, R.sup.D2 is hydrogen. In certain embodiments, R.sup.D2
is halogen, e.g., --F or --Cl.
[0193] In certain embodiments, R.sup.D is a group of Formula (i-11)
or (i-12):
##STR00048##
wherein each instance of X.sup.1 is bond or NR.sup.D5; Y is
independently O, S, or NR.sup.D6; z is 0, 1, 2, 3, 4, 5, or 6; and
R.sup.D1 is as defined herein. In certain embodiments, X.sup.1 is a
bond. In certain embodiments, X.sup.1 is NR.sup.D5. In certain
embodiments, Y is O. In certain embodiments z is 0 or 1. In certain
embodiments, R.sup.D1 is substituted or unsubstituted alkyl.
[0194] In certain embodiments, R.sup.D is a group of Formula
(i-10), (i-16), or (i-9):
##STR00049##
wherein each instance of X.sup.1 is bond or NR.sup.D5; Y is
independently O, S, or NR.sup.D6; z is 0, 1, 2, 3, 4, 5, or 6; and
R.sup.D4 is a leaving group selected from the group consisting of
--Br, --Cl, --I, and --OS(.dbd.O).sub.wR.sup.D4a, wherein w is 1 or
2. In certain embodiments, X.sup.1 is a bond. In certain
embodiments, X.sup.1 is NR.sup.D5. In certain embodiments, Y is O.
In certain embodiments, z is 0. In certain embodiments, z is 1.
[0195] In certain embodiments, R.sup.D is a group of Formula (i-4)
or (i-5):
##STR00050##
wherein each instance of X.sup.1 is bond or NR.sup.D5; and R.sup.D1
is as defined herein. In certain embodiments, X.sup.1 is a bond. In
certain embodiments, X.sup.1 is NR.sup.D5. In certain embodiments,
R.sup.D1 is hydrogen.
[0196] In certain embodiments, R.sup.D is a group of Formula
(i-6):
##STR00051##
wherein each instance of X.sup.1 is bond or NR.sup.D5; Y is
independently O, S, or NR.sup.D6; and R.sup.D1 is as defined
herein. In certain embodiments, X.sup.1 is a bond. In certain
embodiments, X.sup.1 is NR.sup.D5. In certain embodiments, Y is O.
In certain embodiments, R.sup.D1 is hydrogen.
Her3 Protein Kinase
[0197] In certain embodiments, the small organic molecule, even in
the absence of the hydrophobic moiety -L.sup.1-R.sup.H, covalently
or non-covalently binds Her3 protein kinase.
[0198] Her3 (ErbB3) is a transmembrane receptor tyrosine protein
kinase which is overexpressed and deregulated in many cancers such
as breast, ovarian, and non-small cell lung cancers, and
specifically Her2 driven breast cancer, 22% of gefitinib-resistant
non-small cell lung cancer, and as much as 53% of ovarian cancer.
See, e.g., Baselga et al., Nat. Rev. Cancer (2009) 9:463;
Lee-Hoeflich et al., Cancer Res. (2008) 68:5878; Hammerman et al.,
Clin. Cancer Res. (2009) 15:7502; Tanner et al., J. Clin. Oncol.
(2006) 24:4317. It is a member of the HER family which also
includes: EGFR (ErbB1/Her1), Her2 (ErbB2), and Her4 (ErbB4). Among
them, HER3 is unique because it has extremely low protein kinase
activity and is considered to be a so-called "pseudo-kinase." See,
e.g., Shi et al., Proc. Natl. Acad. Sci. USA (2010) 107:7692.
Despite the lack of protein kinase activity, Her3 is often an
essential heterodimerization partner with EGFR and Her2, resulting
in recruitment and activation of PI3K to the plasma membrane. Her3
has been extensively validated as a promising oncology kinase
target using genetic approaches and currently several antibodies
directed against the extracellular ligand-binding domain of Her3
are under clinical evaluation. See, e.g., Sergina et al., Nature
(2007) 445:437. Due to the weak kinase activity of Her3, there are
currently no small molecules reported that can inhibit Her3
function, and the kinase is considered to be an "undruggable
target." For example, many small molecules which covalently or
non-covalently bind to the ATP site of Her3, due to the low kinase
activity of Her3, neither inhibit Her3-dependent proliferation nor
inhibit Her3 signaling. To overcome this problem, the inventors
envisioned linking such small molecules to a hydrophobic tag such
that the bi-functional molecule may, upon selectively binding Her3,
then selectively induce Her3 protein degradation, e.g., by
unfolding and subsequent degradation by the proteasome.
[0199] To discover chemical starting points for developing Her3
inhibitors, the inventors screened a library of 1,500
kinase-directed compounds using the LanthaScreen.TM. Eu methodology
for compounds that could bind to the ATP-site of Her3. The most
potent Her3 binder from this screen was KIN001-111, which evolved
to TX-1-85-1 using structure-based drug design and iterative rounds
of synthesis and evaluation. See, e.g., Stachlewitz et al., J
Pharmacol Exp Ther. (2005) 315:36-41. TX1-85-1 possesses an
acrylamide which forms a covalent bond with Cys721 in the Her3 ATP
binding site (as shown by mass spectrometry). TX1-85-1 is a potent
binder of Her3, and it can covalently label Her3 in cells.
##STR00052##
[0200] To evaluate the ability of covalent Her3 inhibitors to
inhibit Her3-dependent growth, two established cells lines, PC9 GR4
and Ocvar8, were utilized that have been shown to be Her3-dependent
using siRNA mediated depletion of Her3. At 5 .mu.M of TX1-85-1, a
concentration sufficient to fully label Her3 in cells, there was no
observed growth inhibition of PC9 GR4 or Ovcar8 cells and no
observed inhibition of the phosphorylation of downstream effectors
of Her3, such as Erk and Akt. To overcome this problem, the
inventors appended an adamantane hydrophobic tag via a linker to
TX1-85-1 to yield TX2-62-1, which maintained potent and covalent
Her3 binding ability. However, TX2-62-1 still did not inhibit
Her3-dependent growth. Without wishing to be bound by any
particular theory, the inventors hypothesize that this lack of
inhibition is the result of poor cell penetration of TX2-62-1 due
to its high molecular weight (MW=828.5). The inventors tested this
hypothesis by designing a strategy whereby the two halves of
TX2-62-1 (TX2-49-1 and TX2-57-1) were brought together inside of a
cell via oxime formation. See Scheme 1 below. The inventors
discovered that formation of TX2-62-1 via intracellular oxime
formation resulted in efficient degradation of Her3, inhibition of
Her3-dependent signaling, and loss of viability of Her3-addicted
cells. As expected, when TX2-62-1 was washed out, Her3 protein was
resynthesized and cell proliferation resumed.
##STR00053##
[0201] Based in part on the work with TX1-85-1 and TX2-62-1, the
inventors envisioned certain desirable, but non-limiting,
characteristics in a hydrophobically tagged compound of Formula
(I), and specifically in a compound of Formula (II):
[0202] (1) In certain embodiments, the linker L.sup.1, joining the
small molecule (M) to the hydrophobic tag R.sup.H, is long enough
in order for the hydrophobic tag R.sup.H to be exposed for ligase
recognition but short enough that the compound of Formula (I) or
(II) will have a low enough molecular weight to be cell permeable,
e.g., for example, in certain embodiments, the linker L.sup.1 is 4
to 20 consecutive covalently bonded atoms in length, inclusive. In
certain embodiments, the linker L.sup.1 is 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, or 15 consecutive covalently bonded atoms in
length.
[0203] (2) In certain embodiments, the compound of Formula (I) or
(II) has a low enough molecular weight, e.g., between about 400 and
about 800 g/mol, between about 500 and about 800 g/mol, between
about 600 and about 800 g/mol, or between about 700 and about 800
g/mol, in order to ensure sufficient cell penetration.
[0204] (3) In certain embodiments, the compound of Formula (I) or
(II) has a high enough polarity, e.g., as measured by a c log P of
less than 5, in order to ensure cell penetration, e.g., between
about -8 and about 4.9, between about -8 and about 4, between about
-8 and about 3, between about -8 and about 2, between about -8 and
about 1, or between about -8 and about 0, inclusive. The c log P
value of a molecule, which is the logarithm of its partition
coefficient between n-octanol and water log(.sub.coctanol/cwater),
is a well-established measure of the molecule's hydrophilicity. Low
hydrophilicities and therefore high log P values cause poor
absorption or permeation.
[0205] (4) In certain embodiments, the terminal hydrophobic tag
R.sup.H has enough hydrophobic character in order to induce the
desired protein degradation of the target. Hydrophobic character of
a particular group may be optimized by first limiting the number of
hydrogen bond donors, e.g., to zero donors, and optionally by also
limiting the number of hydrogen bond acceptors, e.g., optionally to
zero acceptors.
[0206] (5) Of course, in its entirety, the compound of Formula (I)
or (II) may comprise a number of hydrogen bond donors and
acceptors, but in certain embodiments, the overall number of
hydrogen bond donors and acceptors present is also limited, for
example, to 5 or less hydrogen bond donors, and/or to 10 or less
hydrogen bond acceptors. In certain embodiments, the compound of
Formula (I) or (II) has 0, 1, 2, 3, 4, or 5 hydrogen bond donors;
e.g., for example, 0, 1, 2, 3, 4, or 5 --OH, --SH, or --NH groups.
In certain embodiments, the compound of Formula (I) or (II) has 0,
1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hydrogen bond acceptors, e.g., for
example, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 O, S, or N atoms which
do not comprise a hydrogen attached thereto.
[0207] (6) Furthermore, in certain embodiments, the compound of
Formula (I) or (II) comprises an additional functionality which
covalently or non-covalently binds the kinase, e.g., a protein
kinase such as a Her3 protein kinase. This additional
functionality, also referred to as a "warhead," is not attached to
the linker or hydrophobic tag, but is appended to another area on
the molecule such that the warhead does not interfere with the
linker-tag's interaction with the protein kinase. In certain
embodiments, the warhead non-covalently binds to the ATP binding
site of kinase, e.g., the Her3 protein kinase. In certain
embodiments, the warhead covalently binds to the ATP binding site
of the kinase, e.g., the Her3 protein kinase. In certain
embodiments, the warhead covalently binds to a cysteine residue in
the ATP binding site of kinase, e.g., the Her3 protein kinase,
e.g., Cys721 of the Her3 protein kinase.
[0208] Compounds of the present invention may comprise one or more
of the above characteristics.
[0209] In certain embodiments, the compound of Formula (I) is a
compound of Formula (II):
##STR00054##
or a pharmaceutically acceptable salt thereof; wherein:
[0210] L.sup.1, L.sup.2, R.sup.H, and R.sup.D are as defined
herein;
[0211] Ring A is substituted or unsubstituted carbocyclylene,
substituted or unsubstituted heterocyclylene, substituted or
unsubstituted arylene, or substituted or unsubstituted
heteroarylene;
[0212] each occurrence of R.sup.B is independently selected from
the group consisting of hydrogen, acyl, substituted and
unsubstituted alkyl, substituted and unsubstituted alkenyl,
substituted and unsubstituted alkynyl, substituted and
unsubstituted carbocyclyl, substituted and unsubstituted
heterocyclyl, substituted and unsubstituted aryl, substituted and
unsubstituted heteroaryl, a nitrogen protecting group, or two
R.sup.B groups are joined to form an substituted or unsubstituted
heterocyclic or substituted or unsubstituted heteroaryl ring;
[0213] each instance of R.sup.C is independently hydrogen, halogen,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted carbocyclyl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aryl, substituted or
unsubstituted heteroaryl, --OR.sup.C1, --N(R.sup.C1).sub.2,
--SR.sup.C1, --C(.dbd.O)R.sup.C1, --C(.dbd.O)OR.sup.C1,
--C(.dbd.O)SR.sup.C1, --C(.dbd.O)N(R.sup.C1).sub.2,
--NR.sup.C1(.dbd.O)R.sup.C1, --NR.sup.C1C(.dbd.O)OR.sup.C1,
--NR.sup.C1C(.dbd.O)SR.sup.C1, or
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2, wherein each occurrence of
R.sup.C1 is independently hydrogen, acyl, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl, a
nitrogen protecting group when attached to a nitrogen atom, an
oxygen protecting group when attached to an oxygen atom, and a
sulfur protecting group when attached to a sulfur atom, or two
R.sup.C1 groups are joined to form an substituted or unsubstituted
heterocyclic or substituted or unsubstituted heteroaryl ring;
[0214] a is 0, 1, 2, 3, or 4; and
[0215] b is 0 or 1.
[0216] As generally defined above, each occurrence of R.sup.B is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group, or two R.sup.B groups are joined to form an substituted or
unsubstituted heterocyclic or substituted or unsubstituted
heteroaryl ring.
[0217] In certain embodiments, each instance of R.sup.B is
hydrogen. In certain embodiments, at least one instance of R.sup.B
is hydrogen, and at least one instance of R.sup.B is a non-hydrogen
group, i.e., acyl, substituted or unsubstituted alkyl, substituted
or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or a nitrogen protecting
group. In certain embodiments, two R.sup.B groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring.
[0218] As generally defined above, each instance of R.sup.C is
independently hydrogen, halogen, substituted or unsubstituted
alkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl,
--OR.sup.C1, --N(R.sup.C1).sub.2, --SR.sup.C1, --C(.dbd.O)R.sup.C1,
--C(.dbd.O)OR.sup.C1, --C(.dbd.O)SR.sup.C1,
--C(.dbd.O)N(R.sup.C1).sub.2, --NR.sup.C1C(.dbd.O)R.sup.C1,
--NR.sup.C1C(.dbd.O)OR.sup.C1, --NR.sup.C1C(.dbd.O)SR.sup.C1, or
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2; and a is 0, 1, 2, 3, or
4.
[0219] In certain embodiments, a is 0, and R.sup.C is absent. In
certain embodiments, a is 1, 2, 3, or 4.
[0220] In certain embodiments, wherein a is 1, 2, 3, or 4, at least
one instance of R.sup.C is --OR.sup.C1, --N(R.sup.C1).sub.2,
--SR.sup.C1, --C(.dbd.O)R.sup.C1, --C(.dbd.O)OR.sup.C1,
--C(.dbd.O)SR.sup.C1, --C(.dbd.O)N(R.sup.C1).sub.2,
--NR.sup.C1C(.dbd.O)R.sup.C1, --NR.sup.C1C(.dbd.O)OR.sup.C1,
--NR.sup.C1C(.dbd.O)SR.sup.C1, or
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2. In certain embodiments, at
least one instance of R.sup.C is --OR.sup.C1. In certain
embodiments, at least one instance of R.sup.C is
--N(R.sup.C1).sub.2. In certain embodiments, at least one instance
of R.sup.C is --SR.sup.C1. In certain embodiments, at least one
instance of R.sup.C is --C(.dbd.O)R.sup.C1. In certain embodiments,
at least one instance of R.sup.C is --C(.dbd.O)OR.sup.C1. In
certain embodiments, at least one instance of R.sup.C is
--C(.dbd.O)SR.sup.C1. In certain embodiments, at least one instance
of R.sup.C is --C(.dbd.O)N(R.sup.C1).sub.2. In certain embodiments,
at least one instance of R.sup.C is --NR.sup.C1C(.dbd.O)R.sup.C1.
In certain embodiments, at least one instance of R.sup.C is
--NR.sup.C1C(.dbd.O)OR.sup.C1. In certain embodiments, at least one
instance of R.sup.C is --NR.sup.C1C(.dbd.O)SR.sup.C1. In certain
embodiments, at least one instance of R.sup.C is
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2.
[0221] In certain embodiments, a is 1. In certain embodiments, a is
2.
[0222] In certain embodiments, a is 1, and b is 1. In this
instance, in certain embodiments, the groups R.sup.C and
-L.sup.2-R.sup.D are ortho to each other. In certain embodiments,
the groups R.sup.C and -L.sup.2-R.sup.D are meta to each other. In
certain embodiments, the groups R.sup.C and -L.sup.2-R.sup.D are
para to each other.
[0223] In certain embodiments, a is 2, and b is 0. In this
instance, in certain embodiments, the two groups R.sup.C are ortho
to each other. In certain embodiments, the two groups R.sup.C are
meta to each other. In certain embodiments, the two groups R.sup.C
are para to each other.
[0224] In certain embodiments, the compound of Formula (II) reduces
protein kinase activity by targeted degradation of Her3. In certain
embodiments, the compound of Formula (II) reduces protein kinase
activity by inducing unfolding of the protein. In certain
embodiments, the compound of Formula (II) reduces protein kinase
activity by covalently binding to Her3. In certain embodiments, the
compound of Formula (II) reduces protein kinase activity by
non-covalently binding to Her3. In certain embodiments, wherein b
is 1, and group -L.sup.2-R.sup.D is present, the compound of
Formula (II) covalently binds to Her3 protein kinase. In certain
embodiments, wherein b is 0, and group -L.sup.2-R.sup.D is absent,
the compound of Formula (II) non-covalently binds to Her3 protein
kinase. In certain embodiments, the reduction of protein kinase
activity results in the inhibition of Her3-dependent signaling
and/or loss of viability of Her3-addicted cells.
[0225] For example, in certain embodiments of Formula (II), wherein
a is 1, and b is 1 (and thus the group -L.sup.2-R.sup.D is
present), provided is a compound of Formula (II-a):
##STR00055##
or a pharmaceutically acceptable salt thereof; wherein R.sup.C is
as defined herein. In certain embodiments, R.sup.C is hydrogen,
--OR.sup.C1, --N(R.sup.C1).sub.2, or --SR.sup.C1. In certain
embodiments, R.sup.C is --OR.sup.C1, wherein R.sup.C1 is
substituted or unsubstituted alkyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In certain embodiments, R.sup.C is --OR.sup.C1, wherein R.sup.C1 is
substituted or unsubstituted aryl, e.g., substituted or
unsubstituted phenyl.
[0226] In certain embodiments of Formula (II-a), provided is a
compound of Formula (II-a1):
##STR00056##
or a pharmaceutically acceptable salt thereof. In certain
embodiments, R.sup.C1 is substituted or unsubstituted alkyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl.
[0227] In certain embodiments of Formula (II), wherein a is 2, and
b is 0 (and thus the group -L.sup.2-R.sup.D is absent), provided is
a compound of Formula (II-b):
##STR00057##
or a pharmaceutically acceptable salt thereof; wherein each
instance of R.sup.C is as defined herein. In certain embodiments,
one instance of R.sup.C is hydrogen, --OR.sup.C1,
--N(R.sup.C1).sub.2, or --SR.sup.C1. In certain embodiments, one
instance of R.sup.C is --OR.sup.C1, wherein R.sup.C1 is substituted
or unsubstituted alkyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl. In
certain embodiments, R.sup.C is --OR.sup.C1, wherein R.sup.C1 is
substituted or unsubstituted alkyl, e.g., methyl. In certain
embodiments, one R.sup.C is --C(.dbd.O)R.sup.C1,
--C(.dbd.O)OR.sup.C1, --C(.dbd.O)SR.sup.C1,
--C(.dbd.O)N(R.sup.C1).sub.2, --NR.sup.C1C(.dbd.O)R.sup.C1,
--NR.sup.C1C(.dbd.O)OR.sup.C1, --NR.sup.C1C(.dbd.O)SR.sup.C1, or
--NR.sup.C1C(.dbd.O)N(R.sup.C1).sub.2. In certain embodiments, one
R.sup.C is --C(.dbd.O)R.sup.C1, --C(.dbd.O)OR.sup.C1,
--C(.dbd.O)SR.sup.C1, --C(.dbd.O)N(R.sup.C1).sub.2,
--NHC(.dbd.O)R.sup.C1, --NHC(.dbd.O)OR.sup.C1,
--NHC(.dbd.O)SR.sup.C1, or --NHC(.dbd.O)N(R.sup.C1).sub.2. In
certain embodiments, one R.sup.C is --C(.dbd.O)R.sup.C1,
--C(.dbd.O)OR.sup.C1, --C(.dbd.O)SR.sup.C1,
--C(.dbd.O)N(R.sup.C1).sub.2, --NHC(.dbd.O)R.sup.C1,
--NHC(.dbd.O)OR.sup.C1, --NHC(.dbd.O)SR.sup.C1, or
--NHC(.dbd.O)N(R.sup.C1).sub.2, wherein one R.sup.C1 is substituted
or unsubstituted alkyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl. In
certain embodiments, one R.sup.C is --C(.dbd.O)R.sup.C1,
--C(.dbd.O)OR.sup.C1, --C(.dbd.O)SR.sup.C1,
--C(.dbd.O)N(R.sup.C1).sub.2, --NHC(.dbd.O)R.sup.C1,
--NHC(.dbd.O)OR.sup.C1, --NHC(.dbd.O)SR, or
--NHC(.dbd.O)N(R.sup.C1).sub.2, wherein one R.sup.C1 is substituted
or unsubstituted heteroaryl, e.g., a substituted or unsubstituted
bicyclic heteroaryl moiety, such as indolyl.
[0228] In certain embodiments of Formula (II-b), provided is a
compound of Formula (II-b1):
##STR00058##
or a pharmaceutically acceptable salt thereof. In certain
embodiments, R.sup.C1 is substituted or unsubstituted alkyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl. In certain embodiments,
R.sup.C is --C(.dbd.O)R.sup.C1, --C(.dbd.O)OR.sup.C1,
--C(.dbd.O)SR.sup.C1, --C(.dbd.O)N(R.sup.C1).sub.2,
--NHC(.dbd.O)R.sup.C1, --NHC(.dbd.O)OR.sup.C1,
--NHC(.dbd.O)SR.sup.C1, or --NHC(.dbd.O)N(R.sup.C1).sub.2.
[0229] In certain embodiments of Formula (II-b), provided is a
compound of Formula (II-b2):
##STR00059##
or a pharmaceutically acceptable salt thereof. In certain
embodiments, R.sup.C is --OR.sup.C1, wherein R.sup.C1 is
substituted or unsubstituted alkyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
In certain embodiments, R.sup.C1 of the amide moiety is a
substituted or unsubstituted heteroaryl moiety, e.g., a substituted
or unsubstituted bicyclic heteroaryl moiety, such as indolyl.
[0230] In certain embodiments of Formula (II-b), provided is a
compound of Formula (II-b3):
##STR00060##
or a pharmaceutically acceptable salt thereof. In certain
embodiments, R.sup.C1 of the --OR.sup.C1 group is substituted or
unsubstituted alkyl, substituted or unsubstituted carbocyclyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aryl, or substituted or unsubstituted heteroaryl. In
certain embodiments, R.sup.C1 of the amide moiety is a substituted
or unsubstituted heteroaryl moiety, e.g., a substituted or
unsubstituted bicyclic heteroaryl moiety, such as indolyl.
[0231] As generally defined above, Ring A is substituted or
unsubstituted carbocyclylene, substituted or unsubstituted
heterocyclylene, substituted or unsubstituted arylene, or
substituted or unsubstituted heteroarylene. It is understood that
Ring A is already substituted with the group -L.sup.1-R.sup.H.
Thus, "substituted" in the context of Ring A refers to additional
substitution(s) on the ring. In certain embodiments, Ring A is not
further substituted (unsubstituted Ring A). In certain embodiments,
Ring A is additionally substituted (substituted Ring A).
[0232] In certain embodiments, Ring A is substituted or
unsubstituted arylene, e.g., substituted or unsubstituted phenylene
or substituted or unsubstituted naphthylene.
[0233] In certain embodiments, wherein Ring A is substituted or
unsubstituted phenylene, the compound of Formula (II) is of Formula
(II-c):
##STR00061##
or a pharmaceutically acceptable salt thereof, wherein:
[0234] each occurrence of R.sup.A is, independently, hydrogen,
halogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.A1,
--N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1, or
--C(.dbd.O)OR.sup.A1 wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and
[0235] c is 0 or 1.
[0236] In certain embodiments of Formula (II-c), c is 0, and
R.sup.A is absent. In certain embodiments, c is 1, and R.sup.A is
present, either ortho, meta, or para to the point of attachment of
the phenylene group to the pyrazolyl ring. In certain embodiments,
the group L.sup.1-R.sup.H is present either ortho, meta, or para to
the point of attachment of the phenylene group to the pyrazolyl
ring. In certain embodiments, b is 0. In certain embodiments, b is
1, L.sup.2 is a bond, and R.sup.D is a group of Formula (i-1). In
certain embodiments, each instance of R.sup.B is hydrogen. In
certain embodiments, L.sup.1 is 5 to 15 consecutive covalently
bonded atoms in length. In certain embodiments, R.sup.H is a group
of formula:
##STR00062##
[0237] For example, in certain embodiments of Formula (II-c),
wherein the group L.sup.1-R.sup.H is para to the point of
attachment of the phenylene group to the pyrazolyl ring, provided
is a compound of Formula (II-c1):
##STR00063##
or a pharmaceutically acceptable salt thereof. In certain
embodiments of Formula (II-c1), c is 0, and R.sup.A is absent. In
certain embodiments, c is 1, and R.sup.A is present, either ortho,
meta, or para to the point of attachment of the phenylene group to
the pyrazolyl ring. In certain embodiments, the group
L.sup.1-R.sup.H is present either ortho, meta, or para to the point
of attachment of the phenylene group to the pyrazolyl ring. In
certain embodiments, b is 0. In certain embodiments, b is 1,
L.sup.2 is a bond, and R.sup.D is a group of Formula (i-1). In
certain embodiments, each instance of R.sup.B is hydrogen. In
certain embodiments, L.sup.1 is 5 to 15 consecutive covalently
bonded atoms in length. In certain embodiments, R.sup.H is a group
of formula:
##STR00064##
[0238] In certain embodiments, Ring A is substituted or
unsubstituted heteroarylene, e.g., a substituted or unsubstituted
5- to 6-membered heteroarylene. In certain embodiments, Ring A is a
6-membered heteroarylene, e.g., pyridinylene.
[0239] For example, in certain embodiments, wherein Ring A is
substituted or unsubstituted pyridinylene, provided is a compound
of Formula (II-d):
##STR00065##
or a pharmaceutically acceptable salt thereof, wherein:
[0240] each occurrence of R.sup.A is, independently, hydrogen,
halogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.A1,
--N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1, or
--C(.dbd.O)OR.sup.A1, wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and
[0241] c is 0 or 1.
[0242] In certain embodiments of Formula (II-d), c is 0, and
R.sup.A is absent. In certain embodiments, c is 1, and R.sup.A is
present, either ortho, meta, or para to the point of attachment of
the pyridinylene group to the pyrazolyl ring. In certain
embodiments, the group L.sup.1-R.sup.H is present either ortho,
meta, or para to the point of attachment of the pyridinylene group
to the pyrazolyl ring. In certain embodiments, b is 0. In certain
embodiments, b is 1, L.sup.2 is a bond, and R.sup.D is a group of
Formula (i-1). In certain embodiments, each instance of R.sup.B is
hydrogen. In certain embodiments, L.sup.1 is 5 to 15 consecutive
covalently bonded atoms in length. In certain embodiments, R.sup.H
is a group of formula:
##STR00066##
[0243] In certain embodiments, Ring A is substituted or
unsubstituted carbocyclylene, e.g., a substituted or unsubstituted
C.sub.3-8 carbocyclylene. In certain embodiments, Ring A is a
substituted or unsubstituted cyclopropylene, substituted or
unsubstituted cyclobutylene, substituted or unsubstituted
cyclopentylene, substituted or unsubstituted cyclohexylene,
substituted or unsubstituted cycloheptylene, or substituted or
unsubstituted cyclooctylene.
[0244] For example, in certain embodiments, wherein Ring A is
substituted or unsubstituted C.sub.3-8 carbocyclylene, provided is
a compound of Formula (II-e):
##STR00067##
or a pharmaceutically acceptable salt thereof, wherein:
[0245] each occurrence of R.sup.A is, independently, hydrogen,
halogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.A1,
--N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1, or
--C(.dbd.O)OR.sup.A1, wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring;
[0246] c is 0 or 1; and
[0247] d is 0, 1, 2, 3, 4, or 5.
[0248] In certain embodiments of Formula (II-e), c is 0 and R.sup.A
is absent. In certain embodiments, c is 1. In certain embodiments,
b is 0. In certain embodiments, b is 1, L.sup.2 is a bond, and
R.sup.D is a group of Formula (i-1). In certain embodiments, each
instance of R.sup.B is hydrogen. In certain embodiments, L.sup.1 is
5 to 15 consecutive covalently bonded atoms in length. In certain
embodiments, R.sup.H is a group of formula:
##STR00068##
[0249] For example, in certain embodiments, wherein Ring A is
substituted or unsubstituted C.sub.3-8 carbocyclylene, provided is
a compound of Formula (II-e1), (II-e2), (II-e3), (II-e4), (II-e5),
or (II-e6):
##STR00069## ##STR00070##
or a pharmaceutically acceptable salt thereof.
[0250] In certain embodiments of Formula (II-e1), (II-e2), (II-e3),
(II-e4), (II-e5), or (II-e6), c is 0, and R.sup.A is absent. In
certain embodiments, c is 1. In certain embodiments, b is 0. In
certain embodiments, b is 1, L.sup.2 is a bond, and R.sub.D is a
group of Formula (i-1). In certain embodiments, each instance of
R.sup.B is hydrogen. In certain embodiments, L.sup.1 is 5 to 15
consecutive covalently bonded atoms in length. In certain
embodiments, R.sup.H is a group of formula:
##STR00071##
[0251] For example, in certain embodiments of Formula (II-e3)
provided is a compound of Formula (II-e3a):
##STR00072##
or a pharmaceutically acceptable salt thereof. In certain
embodiments of Formula (II-e3) or (II-e3a), c is 0, and R.sup.A is
absent. In certain embodiments, c is 1, and R.sup.A is present
either at the 2 or 3 position from the point of attachment of the
cyclopentylene group to the pyrazolyl ring. In certain embodiments,
the group L.sup.1-R.sup.H is present either at the 2 or 3 position
from the point of attachment of the cyclopentylene group to the
pyrazolyl ring. In certain embodiments, b is 0. In certain
embodiments, b is 1, L.sup.2 is a bond, and R.sup.D is a group of
Formula (i-1). In certain embodiments, each instance of R.sup.B is
hydrogen. In certain embodiments, L.sup.1 is 5 to 15 consecutive
covalently bonded atoms in length. In certain embodiments, R.sup.H
is a group of formula:
##STR00073##
[0252] For example, in certain embodiments of Formula (II-e4)
provided is a compound of Formula (II-e4a):
##STR00074##
or a pharmaceutically acceptable salt thereof. In certain
embodiments of Formula (II-e4) or (II-e4a), c is 0, and R.sup.A is
absent. In certain embodiments, c is 1, and R.sup.A is present,
either at the 2, 3, or 4 position from the point of attachment of
the cyclohexylene group to the pyrazolyl ring. In certain
embodiments, the group L.sup.1-R.sup.H is present either at the 2,
3, or 4 position from the point of attachment of the cyclohexylene
group to the pyrazolyl ring. In certain embodiments, b is 0. In
certain embodiments, b is 1, L.sup.2 is a bond, and R.sup.D is a
group of Formula (i-1). In certain embodiments, each instance of
R.sup.B is hydrogen. In certain embodiments, L.sup.1 is 5 to 15
consecutive covalently bonded atoms in length. In certain
embodiments, R.sup.H is a group of formula:
##STR00075##
[0253] In certain embodiments, Ring A is substituted or
unsubstituted heterocyclylene, e.g., substituted or unsubstituted
3- to 8-membered heterocyclylene, e.g., substituted or
unsubstituted 3-membered heterocyclylene, substituted or
unsubstituted 4-membered heterocyclylene, substituted or
unsubstituted 5-membered heterocyclylene, substituted or
unsubstituted 6-membered heterocyclylene, substituted or
unsubstituted 7-membered heterocyclylene, or substituted or
unsubstituted 8-membered heterocyclylene. In certain embodiments,
Ring A is substituted or unsubstituted 5-membered heterocyclylene,
e.g., substituted or unsubstituted pyrrolidinylene. In certain
embodiments, Ring A is substituted or unsubstituted 6-membered
heterocyclylene, e.g., substituted or unsubstituted morpholinylene,
substituted or unsubstituted piperidinylene, or substituted or
unsubstituted piperazinylene.
[0254] For example, in certain embodiments, wherein Ring A is
substituted or unsubstituted pyrrolidinylene, provided is a
compound of Formula (II-f):
##STR00076##
or a pharmaceutically acceptable salt thereof, wherein:
[0255] each occurrence of R.sup.A is, independently, hydrogen,
halogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.A1,
--N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1 or
--C(.dbd.O)OR.sup.A1, wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and
[0256] c is 0 or 1.
[0257] In certain embodiments of Formula (II-f), c is 0 and R.sup.A
is absent. In certain embodiments, c is 1, and R.sup.A is present,
either at the 2 or 3 position from the point of attachment of the
pyrrolidinyl group to the pyrazolyl ring. In certain embodiments,
the group L.sup.1-R.sup.H is present either at the 2 or 3 position
from the point of attachment of the pyrrolidinyl group to the
pyrazolyl ring. In certain embodiments, b is 0. In certain
embodiments, b is 1, L.sup.2 is a bond, and R.sup.D is a group of
Formula (i-1). In certain embodiments, each instance of R.sup.B is
hydrogen. In certain embodiments, L.sup.1 is 5 to 15 consecutive
covalently bonded atoms in length. In certain embodiments, R.sup.H
is a group of formula:
##STR00077##
[0258] In certain embodiments of Formula (II-f) provided is a
compound of Formula (II-f1):
##STR00078##
or a pharmaceutically acceptable salt thereof. In certain
embodiments of Formula (II-f1), c is 0 and R.sup.A is absent. In
certain embodiments, c is 1, and R.sup.A is present, either at the
2 or 3 position from the point of attachment of the pyrrolidinyl
group to the pyrazolyl ring. In certain embodiments, the group
L.sup.1-R.sup.H is present either at the 2 or 3 position from the
point of attachment of the pyrrolidinyl group to the pyrazolyl
ring. In certain embodiments, b is 0. In certain embodiments, b is
1, L.sup.2 is a bond, and R.sup.D is a group of Formula (i-1). In
certain embodiments, each instance of R.sup.B is hydrogen. In
certain embodiments, L.sup.1 is 5 to 15 consecutive covalently
bonded atoms in length. In certain embodiments, R.sup.H is a group
of formula:
##STR00079##
[0259] In certain embodiments, wherein Ring A is substituted or
unsubstituted piperidinylene, provided is a compound of Formula
(II-g):
##STR00080##
or a pharmaceutically acceptable salt thereof, wherein:
[0260] each occurrence of R.sup.A is, independently, hydrogen,
halogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, --OR.sup.A1,
--N(R.sup.A1).sub.2, --SR.sup.A1, --C(.dbd.O)R.sup.A1, or
--C(.dbd.O)OR.sup.A1, wherein each occurrence of R.sup.A1 is
independently hydrogen, acyl, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, a nitrogen protecting
group when attached to a nitrogen atom, an oxygen protecting group
when attached to an oxygen atom, or a sulfur protecting group when
attached to a sulfur atom, or two R.sup.A1 groups are joined to
form an substituted or unsubstituted heterocyclic or substituted or
unsubstituted heteroaryl ring; and
[0261] c is 0 or 1.
[0262] In certain embodiments of Formula (II-g), c is 0, and
R.sup.A is absent. In certain embodiments, c is 1 and R.sup.A is
present, either at the 2, 3, or 4 position from the point of
attachment of the piperidinylene group to the pyrazolyl ring. In
certain embodiments, the group L.sup.1-R.sup.H is present either at
the 2, 3, or 4 position from the point of attachment of the
piperidinylene group to the pyrazolyl ring. In certain embodiments,
b is 0. In certain embodiments, b is 1, L.sup.2 is a bond, and
R.sup.D is a group of Formula (i-1). In certain embodiments, each
instance of R.sup.B is hydrogen. In certain embodiments, L.sup.1 is
5 to 15 consecutive covalently bonded atoms in length. In certain
embodiments, R.sup.H is a group of formula:
##STR00081##
[0263] For example, in certain embodiments of Formula (II-g)
provided is a compound of Formula (II-g1):
##STR00082##
or a pharmaceutically acceptable salt thereof. In certain
embodiments of Formula (II-g1), c is 0, and R.sup.A is absent. In
certain embodiments, c is 1, and R.sup.A is present, either at the
2 or 3 position from the point of attachment of the piperidinylene
group to the pyrazolyl ring. In certain embodiments, the group
L.sup.1-R.sup.H is present either at the 2 or 3 position from the
point of attachment of the piperidinylene group to the pyrazolyl
ring. In certain embodiments, b is 0. In certain embodiments, b is
1, L.sup.2 is a bond, and R.sup.D is a group of Formula (i-1). In
certain embodiments, each instance of R.sup.B is hydrogen. In
certain embodiments, L.sup.1 is 5 to 15 consecutive covalently
bonded atoms in length. In certain embodiments, R.sup.H is a group
of formula:
##STR00083##
[0264] Non-limiting examples of compounds of Formula (I) and (II),
and pharmaceutically acceptable salts, thereof are provided below
in Table 1.
TABLE-US-00001 TABLE 1 Structure ##STR00084## TX2-120-1
##STR00085## TX2-112-1 MW.sub.total = 674 g/mol
MW(-L.sup.1-R.sup.H) = 220 g/mol MW(M - H) = 455 g/mol L.sup.1 = 5
atoms long ##STR00086## TX2-126-1 MW.sub.total = 757 g/mol
MW(-L.sup.1-R.sup.H) = 262 g/mol MW(M - H) = 496 g/mol L.sup.1 = 7
atoms ##STR00087## (R)-TX2-126-1 ##STR00088## (S)-TX2-126-1
##STR00089## TX2-113-1 MW.sub.total = 688 g/mol
MW(-L.sup.1-R.sup.H) = 234 g/mol MW(M - H) = 455 g/mol L.sup.1 = 6
atoms long ##STR00090## TX2-121-1 MW.sub.total = 716 g/mol
MW(-L.sup.1-R.sup.H) = 262 g/mol MW(M - H) = 455 g/mol L.sup.1 = 7
atoms long ##STR00091## (R)-TX2-121-1 ##STR00092## (S)-TX2-121-1
##STR00093## TX2-121-3 MW.sub.total = 718 g/mol
MW(-L.sup.1-R.sup.H) = 262 g/mol MW(M - H) = 457 g/mol L.sup.1 = 7
atoms long ##STR00094## (R)-TX2-121-3 ##STR00095## (S)-TX2-121-3
##STR00096## TX2-114-1 MW.sub.total = 718 g/mol
MW(-L.sup.1-R.sup.H) = 264 g/mol MW(M - H) = 455 g/mol L.sup.1 = 8
atoms long ##STR00097## SML-11-124-1 MW.sub.total = 841 g/mol
MW(-L.sup.1-R.sup.H) = 346 g/mol MW(M -H) = 495 g/mol L.sup.1 = 11
atoms long ##STR00098## (R)-SML-11-124-1 ##STR00099##
(S)-SML-11-124-1
Pharmaceutical Compositions
[0265] In certain embodiments, the present invention provides a
pharmaceutical composition comprising a compound of Formula (I) or
(II) or a pharmaceutically acceptable salt thereof and, optionally,
a pharmaceutically acceptable excipient. In certain embodiments,
the compound is present in an effective amount, e.g., a
therapeutically effective amount or a prophylactically effective
amount.
[0266] Pharmaceutically acceptable excipients include any and all
solvents, diluents or other liquid vehicles, dispersion or
suspension aids, surface active agents, isotonic agents, thickening
or emulsifying agents, preservatives, solid binders, lubricants and
the like, as suited to the particular dosage form desired. General
considerations in the formulation and/or manufacture of
pharmaceutical compositions agents can be found, for example, in
Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W.
Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The
Science and Practice of Pharmacy, 21.sup.st Edition (Lippincott
Williams & Wilkins, 2005).
[0267] Pharmaceutical compositions described herein can be prepared
by any method known in the art of pharmacology. In general, such
preparatory methods include the steps of bringing the compound of
Formula (I) or (II) or a pharmaceutically acceptable salt thereof
(the "active ingredient") into association with the excipient
and/or one or more other accessory ingredients, and then, if
necessary and/or desirable, shaping and/or packaging the product
into a desired single- or multi-dose unit.
[0268] Pharmaceutical compositions can be prepared, packaged,
and/or sold in bulk, as a single unit dose, and/or as a plurality
of single unit doses. As used herein, a "unit dose" is discrete
amount of the pharmaceutical composition comprising a predetermined
amount of the active ingredient. The amount of the active
ingredient is generally equal to the dosage of the active
ingredient which would be administered to a subject and/or a
convenient fraction of such a dosage such as, for example, one-half
or one-third of such a dosage.
[0269] Relative amounts of the active ingredient, the
pharmaceutically acceptable carrier, and/or any additional
ingredients in a pharmaceutical composition of the invention will
vary, depending upon the identity, size, and/or condition of the
subject treated and further depending upon the route by which the
composition is to be administered. By way of example, the
composition may comprise between 0.1% and 100% (w/w) active
ingredient.
[0270] Pharmaceutically acceptable excipients used in the
manufacture of provided pharmaceutical compositions include inert
diluents, dispersing and/or granulating agents, surface active
agents and/or emulsifiers, disintegrating agents, binding agents,
preservatives, buffering agents, lubricating agents, and/or oils.
Excipients such as cocoa butter and suppository waxes, coloring
agents, coating agents, sweetening, flavoring, and perfuming agents
may also be present in the composition.
[0271] Exemplary diluents include calcium carbonate, sodium
carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate,
calcium hydrogen phosphate, sodium phosphate lactose, sucrose,
cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol,
inositol, sodium chloride, dry starch, cornstarch, powdered sugar,
etc., and combinations thereof.
[0272] Exemplary granulating and/or dispersing agents include
potato starch, corn starch, tapioca starch, sodium starch
glycolate, clays, alginic acid, guar gum, citrus pulp, agar,
bentonite, cellulose and wood products, natural sponge,
cation-exchange resins, calcium carbonate, silicates, sodium
carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone),
sodium carboxymethyl starch (sodium starch glycolate),
carboxymethyl cellulose, cross-linked sodium carboxymethyl
cellulose (croscarmellose), methylcellulose, pregelatinized starch
(starch 1500), microcrystalline starch, water insoluble starch,
calcium carboxymethyl cellulose, magnesium aluminum silicate
(Veegum), sodium lauryl sulfate, quaternary ammonium compounds,
etc., and combinations thereof.
[0273] Exemplary surface active agents and/or emulsifiers include
natural emulsifiers (e.g. acacia, agar, alginic acid, sodium
alginate, tragacanth, chondrux, cholesterol, xanthan, pectin,
gelatin, egg yolk, casein, wool fat, cholesterol, wax, and
lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and
Veegum [magnesium aluminum silicate]), long chain amino acid
derivatives, high molecular weight alcohols (e.g. stearyl alcohol,
cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene
glycol distearate, glyceryl monostearate, and propylene glycol
monostearate, polyvinyl alcohol), carbomers (e.g. carboxy
polymethylene, polyacrylic acid, acrylic acid polymer, and
carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.
carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl
cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,
methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene
sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween
60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan
monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan
tristearate [Span 65], glyceryl monooleate, sorbitan monooleate
[Span 80]), polyoxyethylene esters (e.g. polyoxyethylene
monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil,
polyethoxylated castor oil, polyoxymethylene stearate, and
Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid
esters (e.g., Cremophor), polyoxyethylene ethers, (e.g.
polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone),
diethylene glycol monolaurate, triethanolamine oleate, sodium
oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate,
sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium
bromide, cetylpyridinium chloride, benzalkonium chloride, docusate
sodium, etc. and/or combinations thereof.
[0274] Exemplary binding agents include starch (e.g. cornstarch and
starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose,
dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and
synthetic gums (e.g. acacia, sodium alginate, extract of Irish
moss, panwar gum, ghatti gum, mucilage of isapol husks,
carboxymethylcellulose, methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, microcrystalline cellulose, cellulose acetate,
poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and
larch arabogalactan), alginates, polyethylene oxide, polyethylene
glycol, inorganic calcium salts, silicic acid, polymethacrylates,
waxes, water, alcohol, etc., and/or combinations thereof.
[0275] Exemplary preservatives include antioxidants, chelating
agents, antimicrobial preservatives, antifungal preservatives,
alcohol preservatives, acidic preservatives, and other
preservatives.
[0276] Exemplary antioxidants include alpha tocopherol, ascorbic
acid, acorbyl palmitate, butylated hydroxyanisole, butylated
hydroxytoluene, monothioglycerol, potassium metabisulfite,
propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite,
sodium metabisulfite, and sodium sulfite.
[0277] Exemplary chelating agents include
ethylenediaminetetraacetic acid (EDTA) and salts and hydrates
thereof (e.g., sodium edetate, disodium edetate, trisodium edetate,
calcium disodium edetate, dipotassium edetate, and the like),
citric acid and salts and hydrates thereof (e.g., citric acid
monohydrate), fumaric acid and salts and hydrates thereof, malic
acid and salts and hydrates thereof, phosphoric acid and salts and
hydrates thereof, and tartaric acid and salts and hydrates thereof.
Exemplary antimicrobial preservatives include benzalkonium
chloride, benzethonium chloride, benzyl alcohol, bronopol,
cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol,
chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin,
hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol,
phenylmercuric nitrate, propylene glycol, and thimerosal.
[0278] Exemplary antifungal preservatives include butyl paraben,
methyl paraben, ethyl paraben, propyl paraben, benzoic acid,
hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium
benzoate, sodium propionate, and sorbic acid.
[0279] Exemplary alcohol preservatives include ethanol,
polyethylene glycol, phenol, phenolic compounds, bisphenol,
chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0280] Exemplary acidic preservatives include vitamin A, vitamin C,
vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic
acid, ascorbic acid, sorbic acid, and phytic acid.
[0281] Other preservatives include tocopherol, tocopherol acetate,
deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA),
butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl
sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium
bisulfite, sodium metabisulfite, potassium sulfite, potassium
metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115,
Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments,
the preservative is an anti-oxidant. In other embodiments, the
preservative is a chelating agent.
[0282] Exemplary buffering agents include citrate buffer solutions,
acetate buffer solutions, phosphate buffer solutions, ammonium
chloride, calcium carbonate, calcium chloride, calcium citrate,
calcium glubionate, calcium gluceptate, calcium gluconate,
D-gluconic acid, calcium glycerophosphate, calcium lactate,
propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium
phosphate, phosphoric acid, tribasic calcium phosphate, calcium
hydroxide phosphate, potassium acetate, potassium chloride,
potassium gluconate, potassium mixtures, dibasic potassium
phosphate, monobasic potassium phosphate, potassium phosphate
mixtures, sodium acetate, sodium bicarbonate, sodium chloride,
sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic
sodium phosphate, sodium phosphate mixtures, tromethamine,
magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free
water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and
combinations thereof.
[0283] Exemplary lubricating agents include magnesium stearate,
calcium stearate, stearic acid, silica, talc, malt, glyceryl
behanate, hydrogenated vegetable oils, polyethylene glycol, sodium
benzoate, sodium acetate, sodium chloride, leucine, magnesium
lauryl sulfate, sodium lauryl sulfate, etc., and combinations
thereof.
[0284] Exemplary natural oils include almond, apricot kernel,
avocado, babassu, bergamot, black current seed, borage, cade,
camomile, canola, caraway, carnauba, castor, cinnamon, cocoa
butter, coconut, cod liver, coffee, corn, cotton seed, emu,
eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd,
grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui
nut, lavandin, lavender, lemon, litsea cubeba, macademia nut,
mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange,
orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed,
pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood,
sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,
soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut,
and wheat germ oils. Exemplary synthetic oils include, but are not
limited to, butyl stearate, caprylic triglyceride, capric
triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360,
isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol,
silicone oil, and combinations thereof.
[0285] Liquid dosage forms for oral and parenteral administration
include pharmaceutically acceptable emulsions, microemulsions,
solutions, suspensions, syrups and elixirs. In addition to the
active ingredients, the liquid dosage forms may comprise inert
diluents commonly used in the art such as, for example, water or
other solvents, solubilizing agents and emulsifiers such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
dimethylformamide, oils (e.g., cottonseed, groundnut, corn, germ,
olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl
alcohol, polyethylene glycols and fatty acid esters of sorbitan,
and mixtures thereof. Besides inert diluents, the oral compositions
can include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring, and perfuming agents. In
certain embodiments for parenteral administration, the conjugates
of the invention are mixed with solubilizing agents such as
Cremophor, alcohols, oils, modified oils, glycols, polysorbates,
cyclodextrins, polymers, and combinations thereof.
[0286] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions can be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation can be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that can be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0287] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0288] In order to prolong the effect of a drug, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This can be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution which, in turn, may depend upon
crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0289] Compositions for rectal or vaginal administration are
typically suppositories which can be prepared by mixing the
conjugates of this invention with suitable non-irritating
excipients or carriers such as cocoa butter, polyethylene glycol or
a suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active ingredient.
[0290] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active ingredient is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar, calcium
carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may comprise buffering agents.
[0291] Solid compositions of a similar type can be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally comprise opacifying agents and can be of a composition
that they release the active ingredient(s) only, or preferentially,
in a certain part of the intestinal tract, optionally, in a delayed
manner. Examples of embedding compositions which can be used
include polymeric substances and waxes. Solid compositions of a
similar type can be employed as fillers in soft and hard-filled
gelatin capsules using such excipients as lactose or milk sugar as
well as high molecular weight polethylene glycols and the like.
[0292] The active ingredients can be in micro-encapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active ingredient can be admixed with at least one inert diluent
such as sucrose, lactose or starch. Such dosage forms may comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may comprise
buffering agents. They may optionally comprise opacifying agents
and can be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions which can be used include polymeric
substances and waxes.
[0293] Dosage forms for topical and/or transdermal administration
of a compound of this invention may include ointments, pastes,
creams, lotions, gels, powders, solutions, sprays, inhalants and/or
patches. Generally, the active ingredient is admixed under sterile
conditions with a pharmaceutically acceptable carrier and/or any
needed preservatives and/or buffers as can be required.
Additionally, the present invention contemplates the use of
transdermal patches, which often have the added advantage of
providing controlled delivery of an active ingredient to the body.
Such dosage forms can be prepared, for example, by dissolving
and/or dispensing the active ingredient in the proper medium.
Alternatively or additionally, the rate can be controlled by either
providing a rate controlling membrane and/or by dispersing the
active ingredient in a polymer matrix and/or gel.
[0294] Suitable devices for use in delivering intradermal
pharmaceutical compositions described herein include short needle
devices such as those described in U.S. Pat. Nos. 4,886,499;
5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496;
and 5,417,662. Intradermal compositions can be administered by
devices which limit the effective penetration length of a needle
into the skin, such as those described in PCT publication WO
99/34850 and functional equivalents thereof. Jet injection devices
which deliver liquid vaccines to the dermis via a liquid jet
injector and/or via a needle which pierces the stratum corneum and
produces a jet which reaches the dermis are suitable. Jet injection
devices are described, for example, in U.S. Pat. Nos. 5,480,381;
5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911;
5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627;
5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460;
and PCT publications WO 97/37705 and WO 97/13537. Ballistic
powder/particle delivery devices which use compressed gas to
accelerate vaccine in powder form through the outer layers of the
skin to the dermis are suitable. Alternatively or additionally,
conventional syringes can be used in the classical mantoux method
of intradermal administration.
[0295] Formulations suitable for topical administration include,
but are not limited to, liquid and/or semi liquid preparations such
as liniments, lotions, oil in water and/or water in oil emulsions
such as creams, ointments and/or pastes, and/or solutions and/or
suspensions. Topically-administrable formulations may, for example,
comprise from about 1% to about 10% (w/w) active ingredient,
although the concentration of the active ingredient can be as high
as the solubility limit of the active ingredient in the solvent.
Formulations for topical administration may further comprise one or
more of the additional ingredients described herein.
[0296] A pharmaceutical composition of the invention can be
prepared, packaged, and/or sold in a formulation suitable for
pulmonary administration via the buccal cavity. Such a formulation
may comprise dry particles which comprise the active ingredient and
which have a diameter in the range from about 0.5 to about 7
nanometers or from about 1 to about 6 nanometers. Such compositions
are conveniently in the form of dry powders for administration
using a device comprising a dry powder reservoir to which a stream
of propellant can be directed to disperse the powder and/or using a
self propelling solvent/powder dispensing container such as a
device comprising the active ingredient dissolved and/or suspended
in a low-boiling propellant in a sealed container. Such powders
comprise particles wherein at least 98% of the particles by weight
have a diameter greater than 0.5 nanometers and at least 95% of the
particles by number have a diameter less than 7 nanometers.
Alternatively, at least 95% of the particles by weight have a
diameter greater than 1 nanometer and at least 90% of the particles
by number have a diameter less than 6 nanometers. Dry powder
compositions may include a solid fine powder diluent such as sugar
and are conveniently provided in a unit dose form.
[0297] Low boiling propellants generally include liquid propellants
having a boiling point of below 65.degree. F. at atmospheric
pressure. Generally the propellant may constitute 50 to 99.9% (w/w)
of the composition, and the active ingredient may constitute 0.1 to
20% (w/w) of the composition. The propellant may further comprise
additional ingredients such as a liquid non-ionic and/or solid
anionic surfactant and/or a solid diluent (which may have a
particle size of the same order as particles comprising the active
ingredient).
[0298] Pharmaceutical compositions of the invention formulated for
pulmonary delivery may provide the active ingredient in the form of
droplets of a solution and/or suspension. Such formulations can be
prepared, packaged, and/or sold as aqueous and/or dilute alcoholic
solutions and/or suspensions, optionally sterile, comprising the
active ingredient, and may conveniently be administered using any
nebulization and/or atomization device. Such formulations may
further comprise one or more additional ingredients including, but
not limited to, a flavoring agent such as saccharin sodium, a
volatile oil, a buffering agent, a surface active agent, and/or a
preservative such as methylhydroxybenzoate. The droplets provided
by this route of administration may have an average diameter in the
range from about 0.1 to about 200 nanometers.
[0299] The formulations described herein as being useful for
pulmonary delivery are useful for intranasal delivery of a
pharmaceutical composition of the invention. Another formulation
suitable for intranasal administration is a coarse powder
comprising the active ingredient and having an average particle
from about 0.2 to 500 micrometers. Such a formulation is
administered, by rapid inhalation through the nasal passage from a
container of the powder held close to the nares.
[0300] Formulations for nasal administration may, for example,
comprise from about as little as 0.1% (w/w) and as much as 100%
(w/w) of the active ingredient, and may comprise one or more of the
additional ingredients described herein. A pharmaceutical
composition of the invention can be prepared, packaged, and/or sold
in a formulation for buccal administration. Such formulations may,
for example, be in the form of tablets and/or lozenges made using
conventional methods, and may contain, for example, 0.1 to 20%
(w/w) active ingredient, the balance comprising an orally
dissolvable and/or degradable composition and, optionally, one or
more of the additional ingredients described herein. Alternately,
formulations for buccal administration may comprise a powder and/or
an aerosolized and/or atomized solution and/or suspension
comprising the active ingredient. Such powdered, aerosolized,
and/or aerosolized formulations, when dispersed, may have an
average particle and/or droplet size in the range from about 0.1 to
about 200 nanometers, and may further comprise one or more of the
additional ingredients described herein.
[0301] A pharmaceutical composition of the invention can be
prepared, packaged, and/or sold in a formulation for ophthalmic
administration. Such formulations may, for example, be in the form
of eye drops including, for example, a 0.1/1.0% (w/w) solution
and/or suspension of the active ingredient in an aqueous or oily
liquid carrier. Such drops may further comprise buffering agents,
salts, and/or one or more other of the additional ingredients
described herein. Other opthalmically administrable formulations
which are useful include those which comprise the active ingredient
in microcrystalline form and/or in a liposomal preparation. Ear
drops and/or eye drops are contemplated as being within the scope
of this invention.
[0302] Although the descriptions of pharmaceutical compositions
provided herein are principally directed to pharmaceutical
compositions which are suitable for administration to humans, it
will be understood by the skilled artisan that such compositions
are generally suitable for administration to animals of all sorts.
Modification of pharmaceutical compositions suitable for
administration to humans in order to render the compositions
suitable for administration to various animals is well understood,
and the ordinarily skilled veterinary pharmacologist can design
and/or perform such modification with ordinary experimentation.
General considerations in the formulation and/or manufacture of
pharmaceutical compositions can be found, for example, in
Remington: The Science and Practice of Pharmacy 21.sup.st ed.,
Lippincott Williams & Wilkins, 2005.
[0303] Still further encompassed by the invention are
pharmaceutical packs and/or kits. Pharmaceutical packs and/or kits
provided may comprise a provided composition and a container (e.g.,
a vial, ampoule, bottle, syringe, and/or dispenser package, or
other suitable container). In some embodiments, provided kits may
optionally further include a second container comprising a suitable
aqueous carrier for dilution or suspension of the provided
composition for preparation of administration to a subject. In some
embodiments, contents of provided formulation container and solvent
container combine to form at least one unit dosage form.
[0304] Optionally, a single container may comprise one or more
compartments for containing a provided composition, and/or
appropriate aqueous carrier for suspension or dilution. In some
embodiments, a single container can be appropriate for modification
such that the container may receive a physical modification so as
to allow combination of compartments and/or components of
individual compartments. For example, a foil or plastic bag may
comprise two or more compartments separated by a perforated seal
which can be broken so as to allow combination of contents of two
individual compartments once the signal to break the seal is
generated. A pharmaceutical pack or kit may thus comprise such
multi-compartment containers including a provided composition and
appropriate solvent and/or appropriate aqueous carrier for
suspension.
[0305] Optionally, instructions for use are additionally provided
in such kits of the invention. Such instructions may provide,
generally, for example, instructions for dosage and administration.
In other embodiments, instructions may further provide additional
detail relating to specialized instructions for particular
containers and/or systems for administration. Still further,
instructions may provide specialized instructions for use in
conjunction and/or in combination with additional therapy.
Methods of Treatment
[0306] The present invention also provides methods of using the
compounds of Formula (I) or (II) as described herein for treating a
condition associated with aberrant activity of a kinase. "Aberrant
activity" of a kinase refers to any undesired activity, and
includes, but is not limited to, over-activity and/or
over-expression of the kinase compared to a normal cell. Such
methods include therapeutic as well as prophylactic (preventative)
methods.
[0307] For example, in one aspect, provided is a method of treating
a condition associated with aberrant activity of a kinase, the
method comprising administering an effective amount of a compound
of Formula (I) or (II), or pharmaceutical composition thereof, to a
subject in need thereof in an amount sufficient to reduce kinase
activity.
[0308] In certain embodiments, the compound reduces or prevents
kinase activity by targeted degradation of the kinase. In certain
embodiments, the compound reduces kinase activity by inducing
unfolding of the kinase. In certain embodiments, the compound
reduces kinase activity by inducing degradation of the kinase. In
certain embodiments, the compound reduces kinase activity by
covalently binding to the kinase. In certain embodiments, compound
reduces kinase activity by non-covalently binding to the
kinase.
[0309] Exemplary conditions associated with aberrant activity of a
kinase includes, but are not limited to, proliferative disorders,
inflammatory disorders, autoimmune disorders, painful conditions,
metabolic disorders, CNS disorders, and viral infections.
[0310] In certain embodiments, the condition associated with
aberrant activity of a kinase is a proliferative disorder.
Exemplary proliferative diseases include, but are not limited to,
tumors, begnin neoplasms, pre-malignant neoplasms (carcinoma in
situ), and malignant neoplasms (cancers).
[0311] Exemplary cancers include, but are not limited to, acoustic
neuroma, adenocarcinoma, adrenal gland cancer, anal cancer,
angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma,
hemangiosarcoma), appendix cancer, benign monoclonal gammopathy,
biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast
cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of
the breast, mammary cancer, medullary carcinoma of the breast),
brain cancer (e.g., meningioma; glioma, e.g., astrocytoma,
oligodendroglioma; medulloblastoma), bronchus cancer, carcinoid
tumor, cervical cancer (e.g., cervical adenocarcinoma),
choriocarcinoma, chordoma, craniopharyngioma, colorectal cancer
(e.g., colon cancer, rectal cancer, colorectal adenocarcinoma),
epithelial carcinoma, ependymoma, endotheliosarcoma (e.g., Kaposi's
sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial
cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer
(e.g., adenocarcinoma of the esophagus, Barrett's adenocarinoma),
Ewing's sarcoma, eye cancer (e.g., intraocular melanoma,
retinoblastoma), familiar hypereosinophilia, gall bladder cancer,
gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal
stromal tumor (GIST), head and neck cancer (e.g., head and neck
squamous cell carcinoma, oral cancer (e.g., oral squamous cell
carcinoma (OSCC), throat cancer (e.g., laryngeal cancer, pharyngeal
cancer, nasopharyngeal cancer, oropharyngeal cancer)),
hematopoietic cancers (e.g., leukemia such as acute lymphocytic
leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic
leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic
leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic
lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL); lymphoma
such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and
non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large
cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL)),
follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone
B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT)
lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal
zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt
lymphoma, lymphoplasmacytic lymphoma (i.e., "Waldenstrom's
macroglobulinemia"), hairy cell leukemia (HCL), immunoblastic large
cell lymphoma, precursor B-lymphoblastic lymphoma and primary
central nervous system (CNS) lymphoma; and T-cell NHL such as
precursor T-lymphoblastic lymphomalleukemia, peripheral T-cell
lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g.,
mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell
lymphoma, extranodal natural killer T-cell lymphoma, enteropathy
type T-cell lymphoma, subcutaneous panniculitis-like T-cell
lymphoma, anaplastic large cell lymphoma); a mixture of one or more
leukemia/lymphoma as described above; and multiple myeloma (MM)),
heavy chain disease (e.g., alpha chain disease, gamma chain
disease, mu chain disease), hemangioblastoma, inflammatory
myofibroblastic tumors, immunocytic amyloidosis, kidney cancer
(e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell carcinoma),
liver cancer (e.g., hepatocellular cancer (HCC), malignant
hepatoma), lung cancer (e.g., bronchogenic carcinoma, small cell
lung cancer (SCLC), non-small cell lung cancer (NSCLC),
adenocarcinoma of the lung), leiomyosarcoma (LMS), mastocytosis
(e.g., systemic mastocytosis), myelodysplastic syndrome (MDS),
mesothelioma, myeloproliferative disorder (MPD) (e.g., polycythemia
Vera (PV), essential thrombocytosis (ET), agnogenic myeloid
metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic
myelofibrosis, chronic myelocytic leukemia (CML), chronic
neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)),
neuroblastoma, neurofibroma (e.g., neurofibromatosis (NF) type 1 or
type 2, schwannomatosis), neuroendocrine cancer (e.g.,
gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid
tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma,
ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary
adenocarcinoma, pancreatic cancer (e.g., pancreatic
andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN),
Islet cell tumors), penile cancer (e.g., Paget's disease of the
penis and scrotum), pinealoma, primitive neuroectodermal tumor
(PNT), prostate cancer (e.g., prostate adenocarcinoma), rectal
cancer, rhabdomyosarcoma, salivary gland cancer, skin cancer (e.g.,
squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma,
basal cell carcinoma (BCC)), small bowel cancer (e.g., appendix
cancer), soft tissue sarcoma (e.g., malignant fibrous histiocytoma
(MFH), liposarcoma, malignant peripheral nerve sheath tumor
(MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous
gland carcinoma, sweat gland carcinoma, synovioma, testicular
cancer (e.g., seminoma, testicular embryonal carcinoma), thyroid
cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid
carcinoma (PTC), medullary thyroid cancer), urethral cancer,
vaginal cancer and vulvar cancer (e.g., Paget's disease of the
vulva).
[0312] In certain embodiments, the condition associated with
aberrant activity of a kinase is an inflammatory disorder. The term
"inflammatory disorder" refers to those diseases, disorders or
conditions that are characterized by signs of pain (dolor, from the
generation of noxious substances and the stimulation of nerves),
heat (calor, from vasodilatation), redness (rubor, from
vasodilatation and increased blood flow), swelling (tumor, from
excessive inflow or restricted outflow of fluid), and/or loss of
function (functio laesa, which can be partial or complete,
temporary or permanent. Inflammation takes on many forms and
includes, but is not limited to, acute, adhesive, atrophic,
catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative,
fibrinous, fibrosing, focal, granulomatous, hyperplastic,
hypertrophic, interstitial, metastatic, necrotic, obliterative,
parenchymatous, plastic, productive, proliferous, pseudomembranous,
purulent, sclerosing, seroplastic, serous, simple, specific,
subacute, suppurative, toxic, traumatic, and/or ulcerative
inflammation.
[0313] Exemplary inflammatory disorders include, but are not
limited to, inflammation associated with acne, anemia (e.g.,
aplastic anemia, haemolytic autoimmune anaemia), asthma, arteritis
(e.g., polyarteritis, temporal arteritis, periarteritis nodosa,
Takayasu's arteritis), arthritis (e.g., crystalline arthritis,
osteoarthritis, psoriatic arthritis, gouty arthritis, reactive
arthritis, rheumatoid arthritis and Reiter's arthritis), ankylosing
spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune
diseases, allergies or allergic reactions, atherosclerosis,
bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas
disease, chronic obstructive pulmonary disease, cermatomyositis,
diverticulitis, diabetes (e.g., type I diabetes mellitus, type 2
diabetes mellitus), a skin condition (e.g., psoriasis, eczema,
burns, dermatitis, pruritus (itch)), endometriosis, Guillain-Barre
syndrome, infection, ischaemic heart disease, Kawasaki disease,
glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g.,
migraine headaches, tension headaches), ileus (e.g., postoperative
ileus and ileus during sepsis), idiopathic thrombocytopenic
purpura, interstitial cystitis (painful bladder syndrome),
gastrointestinal disorder (e.g., selected from peptic ulcers,
regional enteritis, diverticulitis, gastrointestinal bleeding,
eosinophilic gastrointestinal disorders (e.g., eosinophilic
esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis,
eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux
disease (GORD, or its synonym GERD), inflammatory bowel disease
(IBD) (e.g., Crohn's disease, ulcerative colitis, collagenous
colitis, lymphocytic colitis, ischaemic colitis, diversion colitis,
Behcet's syndrome, indeterminate colitis) and inflammatory bowel
syndrome (IBS)), lupus, multiple sclerosis, morphea, myeasthenia
gravis, myocardial ischemia, nephrotic syndrome, pemphigus
vulgaris, pernicious aneaemia, peptic ulcers, polymyositis, primary
biliary cirrhosis, neuroinflammation associated with brain
disorders (e.g., Parkinson's disease, Huntington's disease, and
Alzheimer's disease), prostatitis, chronic inflammation associated
with cranial radiation injury, pelvic inflammatory disease,
reperfusion injury, regional enteritis, rheumatic fever, systemic
lupus erythematosus, schleroderma, scierodoma, sarcoidosis,
spondyloarthopathies, Sjogren's syndrome, thyroiditis,
transplantation rejection, tendonitis, trauma or injury (e.g.,
frostbite, chemical irritants, toxins, scarring, burns, physical
injury), vasculitis, vitiligo and Wegener's granulomatosis.
[0314] In certain embodiments, the inflammatory disorder is
inflammation associated with a proliferative disorder, e.g.,
inflammation associated with cancer.
[0315] In certain embodiments, the condition associated with
aberrant activity of a kinase is an autoimmune disorder. Exemplary
autoimmune disorders include, but are not limited to, arthritis
(including rheumatoid arthritis, spondyloarthopathies, gouty
arthritis, degenerative joint diseases such as osteoarthritis,
systemic lupus erythematosus, Sjogren's syndrome, ankylosing
spondylitis, undifferentiated spondylitis, Behcet's disease,
haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic
lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and
juvenile arthritis), asthma, atherosclerosis, osteoporosis,
bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis,
eczema, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic
disease, gastrointestinal disorder (e.g., selected from peptic
ulcers, regional enteritis, diverticulitis, gastrointestinal
bleeding, eosinophilic gastrointestinal disorders (e.g.,
eosinophilic esophagitis, eosinophilic gastritis, eosinophilic
gastroenteritis, eosinophilic colitis), gastritis, diarrhea,
gastroesophageal reflux disease (GORD, or its synonym GERD),
inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative
colitis, collagenous colitis, lymphocytic colitis, ischaemic
colitis, diversion colitis, Behcet's syndrome, indeterminate
colitis) and inflammatory bowel syndrome (IBS)), and disorders
ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative
ileus and ileus during sepsis; gastroesophageal reflux disease
(GORD, or its synonym GERD); eosinophilic esophagitis,
gastroparesis such as diabetic gastroparesis; food intolerances and
food allergies and other functional bowel disorders, such as
non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP,
including costo-chondritis)).
[0316] In certain embodiments, the condition associated with
aberrant activity of a kinase is a painful condition. A "painful
condition" includes, but is not limited to, neuropathic pain (e.g.,
peripheral neuropathic pain), central pain, deafferentiation pain,
chronic pain (e.g., chronic nociceptive pain, and other forms of
chronic pain such as post-operative pain, e.g., pain arising after
hip, knee, or other replacement surgery), pre-operative pain,
stimulus of nociceptive receptors (nociceptive pain), acute pain
(e.g., phantom and transient acute pain), noninflammatory pain,
inflammatory pain, pain associated with cancer, wound pain, burn
pain, postoperative pain, pain associated with medical procedures,
pain resulting from pruritus, painful bladder syndrome, pain
associated with premenstrual dysphoric disorder and/or premenstrual
syndrome, pain associated with chronic fatigue syndrome, pain
associated with pre-term labor, pain associated with withdrawl
symptoms from drug addiction, joint pain, arthritic pain (e.g.,
pain associated with crystalline arthritis, osteoarthritis,
psoriatic arthritis, gouty arthritis, reactive arthritis,
rheumatoid arthritis or Reiter's arthritis), lumbosacral pain,
musculo-skeletal pain, headache, migraine, muscle ache, lower back
pain, neck pain, toothache, dental/maxillofacial pain, visceral
pain and the like. One or more of the painful conditions
contemplated herein can comprise mixtures of various types of pain
provided above and herein (e.g. nociceptive pain, inflammatory
pain, neuropathic pain, etc.). In some embodiments, a particular
pain can dominate. In other embodiments, the painful condition
comprises two or more types of pains without one dominating. A
skilled clinician can determine the dosage to achieve a
therapeutically effective amount for a particular subject based on
the painful condition.
[0317] In certain embodiments, the painful condition is
inflammatory pain. In certain embodiments, the painful condition
(e.g., inflammatory pain) is associated with an inflammatory
disorder and/or an autoimmune disorder.
[0318] In certain embodiments, the condition associated with
aberrant activity of a kinase is a metabolic disorder (e.g., a
wasting condition, an obesity-related condition or complication
thereof).
[0319] In certain embodiments, the metabolic disorder is a wasting
condition. A "wasting condition," as used herein, includes but is
not limited to, anorexia and cachexias of various natures (e.g.,
weight loss associated with cancer, weight loss associated with
other general medical conditions, weight loss associated with
failure to thrive, and the like). In certain embodiments, the
metabolic disorder is an obesity-related condition or a
complication thereof. An "obesity-related condition" as used
herein, includes, but is not limited to, obesity, undesired weight
gain (e.g., from medication-induced weight gain, from cessation of
smoking) and an over-eating disorder (e.g., binge eating, bulimia,
compulsive eating, or a lack of appetite control each of which can
optionally lead to undesired weight gain or obesity). "Obesity" and
"obese" as used herein, refers to class I obesity, class II
obesity, class III obesity and pre-obesity (e.g., being
"over-weight") as defined by the World Health Organization.
[0320] In certain embodiments, the condition associated with
aberrant activity of a kinase is a CNS disorder. Exemplary CNS
disorders include, but are not limited to, neurotoxicity and/or
neurotrauma, stroke, multiple sclerosis, spinal cord injury,
epilepsy, a mental disorder, a sleep condition, a movement
disorder, nausea and/or emesis, amyotrophic lateral sclerosis,
Alzheimer's disease and drug addiction.
[0321] In certain embodiments, the CNS disorder is neurotoxicity
and/or neurotrauma, e.g., for example, as a result of acute
neuronal injury (e.g., tramatic brain injury (TBI), stroke,
epilepsy) or a chronic neurodegenerative disorder (e.g., multiple
sclerosis, Parkinson's disease, Huntington's disease, amyotrophic
lateral sclerosis, Alzheimer's disease).
[0322] In certain embodiments, the CNS disorder is a mental
disorder, e.g., for example, depression, anxiety or anxiety-related
conditions, a learning disability or schizophrenia.
[0323] In certain embodiments, the CNS disorder is depression.
"Depression," as used herein, includes, but is not limited to,
depressive disorders or conditions, such as, for example, major
depressive disorders (e.g., unipolar depression), dysthymic
disorders (e.g., chronic, mild depression), bipolar disorders
(e.g., manic-depression), seasonal affective disorder, and/or
depression associated with drug addiction (e.g., withdrawal). The
depression can be clinical or subclinical depression. The
depression can be associated with or premenstrual syndrome and/or
premenstrual dysphoric disorder.
[0324] In certain embodiments, the CNS disorder is anxiety.
"Anxiety," as used herein, includes, but is not limited to anxiety
and anxiety-related conditions, such as, for example, clinical
anxiety, panic disorder, agoraphobia, generalized anxiety disorder,
specific phobia, social phobia, obsessive-compulsive disorder,
acute stress disorder, post-traumatic stress disorder, adjustment
disorders with anxious features, anxiety disorder associated with
depression, anxiety disorder due to general medical conditions, and
substance-induced anxiety disorders, anxiety associated with drug
addiction (e.g., withdrawal, dependence, reinstatement) and anxiety
associated with nausea and/or emesis. This treatment may also be to
induce or promote sleep in a subject (e.g., for example, a subject
with anxiety).
[0325] In certain embodiments, the CNS disorder is a learning
disorder (e.g., attention deficit disorder (ADD)).
[0326] In certain embodiments, the CNS disorder is
Schizophrenia.
[0327] In certain embodiments, the CNS disorder is a sleep
condition. "Sleep conditions" include, but are not limited to,
insomnia, narcolepsy, sleep apnea, restless legs syndrome (RLS),
delayed sleep phase syndrome (DSPS), periodic limb movement
disorder (PLMD), hypopnea syndrome, rapid eye movement behavior
disorder (RBD), shift work sleep condition (SWSD), and sleep
problems (e.g., parasomnias) such as nightmares, night terrors,
sleep talking, head banging, snoring, and clenched jaw and/or
grinding of teeth (bruxism).
[0328] In certain embodiments, the CNS disorder is a movement
disorder, e.g., basal ganglia disorders, such as, for example,
Parkinson's disease, levodopa-induced dyskinesia, Huntington's
disease, Gilles de Ia Tourette's syndrome, tardive diskinesia and
dystonia.
[0329] In certain embodiments, the CNS disorder is Alzheimer's
disease.
[0330] In certain embodiments, the CNS disorder is amyotrophic
lateral sclerosis (ALS).
[0331] In certain embodiments, the CNS disorder is nausea and/or
emesis.
[0332] In certain embodiments, the CNS disorder is drug addiction
(e.g., for instance, addiction to opiates, nicotine, cocaine,
psychostimulants or alcohol).
[0333] In certain embodiments, the condition associated with
aberrant activity of a kinase is a viral infection.
[0334] In certain embodiments of Formula (I) and (II), the kinase
is Her3 protein kinase. In this instance, in certain embodiments,
the condition associated with aberrant activity of Her3 protein
kinase is a proliferative disorder. In certain embodiments, the
proliferative disorder associated with aberrant activity of Her3
protein kinase is cancer. In certain embodiments, the cancer
associated with aberrant activity of Her3 protein kinase is breast
cancer, lung cancer, or ovarian cancer. In certain embodiments, the
breast cancer associated with aberrant activity of Her3 protein
kinase is Her2 driven breast cancer. In certain embodiments, the
lung cancer associated with aberrant activity of Her3 protein
kinase is gefitinib resistant lung cancer. In certain embodiments,
the lung cancer is NSCLC.
[0335] Compounds of Formula (I) or (II) may be formulated in dosage
unit form for ease of administration and uniformity of dosage. It
will be understood, however, that the total daily usage of the
compositions comprising a compound of Formula (I) or (II) will be
decided by the attending physician within the scope of sound
medical judgment. The specific therapeutically effective dose level
for any particular subject or organism will depend upon a variety
of factors including the disease, disorder, or condition being
treated and the severity of the disorder; the activity of the
specific active ingredient employed; the specific composition
employed; the age, body weight, general health, sex and diet of the
subject; the time of administration, route of administration, and
rate of excretion of the specific active ingredient employed; the
duration of the treatment; drugs used in combination or
coincidental with the specific active ingredient employed; and like
factors well known in the medical arts.
[0336] The compounds and compositions provided herein can be
administered by any route, including enteral (e.g., oral),
parenteral, intravenous, intramuscular, intra-arterial,
intramedullary, intrathecal, subcutaneous, intraventricular,
transdermal, interdermal, rectal, intravaginal, intraperitoneal,
topical (as by powders, ointments, creams, and/or drops), mucosal,
nasal, bucal, sublingual; by intratracheal instillation, bronchial
instillation, and/or inhalation; and/or as an oral spray, nasal
spray, and/or aerosol. Specifically contemplated routes are oral
administration, intravenous administration (e.g., systemic
intravenous injection), regional administration via blood and/or
lymph supply, and/or direct administration to an affected site. In
general the most appropriate route of administration will depend
upon a variety of factors including the nature of the agent (e.g.,
its stability in the environment of the gastrointestinal tract),
the condition of the subject (e.g., whether the subject is able to
tolerate oral administration).
[0337] The exact amount of a compound required to achieve an
effective amount will vary from subject to subject, depending, for
example, on species, age, and general condition of a subject,
severity of the side effects or disorder, identity of the
particular compound(s), mode of administration, and the like. The
desired dosage can be delivered three times a day, two times a day,
once a day, every other day, every third day, every week, every two
weeks, every three weeks, or every four weeks. In certain
embodiments, the desired dosage can be delivered using multiple
administrations (e.g., two, three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, or more
administrations).
[0338] In certain embodiments, an effective amount of a compound
for administration one or more times a day to a 70 kg adult human
may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to
about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to
about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to
about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100
mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg,
of a compound per unit dosage form.
[0339] In certain embodiments, the compounds of the invention may
be administered orally or parenterally at dosage levels sufficient
to deliver from about 0.001 mg/kg to about 100 mg/kg, from about
0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to
about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg,
from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to
about 10 mg/kg, and more preferably from about 1 mg/kg to about 25
mg/kg, of subject body weight per day, one or more times a day, to
obtain the desired therapeutic effect.
[0340] It will be appreciated that dose ranges as described herein
provide guidance for the administration of provided pharmaceutical
compositions to an adult. The amount to be administered to, for
example, a child or an adolescent can be determined by a medical
practitioner or person skilled in the art and can be lower or the
same as that administered to an adult.
[0341] It will be also appreciated that a compound or composition,
as described herein, can be administered in combination with one or
more additional therapeutically active agents. The compounds or
compositions can be administered in combination with additional
therapeutically active agents that improve their bioavailability,
reduce and/or modify their metabolism, inhibit their excretion,
and/or modify their distribution within the body. It will also be
appreciated that the therapy employed may achieve a desired effect
for the same disorder (for example, a compound can be administered
in combination with an anti-inflammatory agent, anti-cancer agent,
etc.), and/or it may achieve different effects (e.g., control of
adverse side-effects, e.g., emesis controlled by an
anti-emetic).
[0342] The compound or composition can be administered concurrently
with, prior to, or subsequent to, one or more additional
therapeutically active agents. In general, each agent will be
administered at a dose and/or on a time schedule determined for
that agent. In will further be appreciated that the additional
therapeutically active agent utilized in this combination can be
administered together in a single composition or administered
separately in different compositions. The particular combination to
employ in a regimen will take into account compatibility of the
inventive compound with the additional therapeutically active agent
and/or the desired therapeutic effect to be achieved. In general,
it is expected that additional therapeutically active agents
utilized in combination be utilized at levels that do not exceed
the levels at which they are utilized individually. In some
embodiments, the levels utilized in combination will be lower than
those utilized individually. Additional therapeutically active
agents include, but are not limited to, small organic molecules
such as drug compounds (e.g., compounds approved by the Food and
Drugs Administration as provided in the Code of Federal Regulations
(CFR)), peptides, proteins, carbohydrates, monosaccharides,
oligosaccharides, polysaccharides, nucleoproteins, mucoproteins,
lipoproteins, synthetic polypeptides or proteins, small molecules
linked to proteins, glycoproteins, steroids, nucleic acids, DNAs,
RNAs, nucleotides, nucleosides, oligonucleotides, antisense
oligonucleotides, lipids, hormones, vitamins and cells. In certain
embodiments, the additional therapeutically agent is a cancer agent
(e.g., a biotherapeutic or chemotherapeutic cancer agent). In other
embodiments, the additional therapeutically active agent is an
anti-inflammatory agent.
Methods of Preparation
[0343] Compounds of the present invention may be prepared by
coupling a compound substituted with a group -L.sup.3-X* with a
compound of formula Y*-L.sup.4-R.sup.H, wherein X* and Y* react
together to form a group A, thus providing a compound substituted
with a group of formula -L.sup.3-A-L.sup.4-R.sup.H. It should be
understood that the group of formula -L.sup.3-A-L.sup.4- is
encompassed by the group of formula -L.sup.1- as defined
herein.
##STR00100##
[0344] It should also be understood that, for a compound of Formula
(P-I) or (P-II), the group Y* of the compound of formula
Y*-L.sup.4-R.sup.H, should be complimentary and reactive with the
group X* present on the precursor compound in order to form the
compound of Formula (I'') or (II''). For example, if the group Y*
is a nucleophilic group, the group X* must be a electrophilic
group. Likewise, if the group Y* is an electrophilic group, the
group X* must be a nucleophilic group. While X* and Y* are defined
the same in the present invention, it is thus understood that such
groups are paired compliments.
[0345] In certain embodiments, the coupling of a compound
substituted with a group -L.sup.3-X* with a compound of formula
Y*-L.sup.4-R.sup.H is via "click chemistry." Click chemistry is a
chemical philosophy introduced by Sharpless in 2001 and describes
chemistry tailored to generate substances quickly and reliably by
joining small units together. See, e.g., Kolb, Finn and Sharpless,
Angewandte Chemie International Edition (2001) 40: 2004-2021;
Evans, Australian Journal of Chemistry (2007) 60: 384-395.
Exemplary coupling reactions (some of which may be classified as
"click chemistry") include, but are not limited to, formation of
esters, thioesters, amides (e.g., such as peptide coupling) from
activated acids or acyl halides; nucleophilic displacement
reactions (e.g., such as nucleophilic displacement of a halide or
ring opening of strained ring systems); azide-alkyne Huisgen
cycloaddition; thiol-yne addition; imine formation; and Michael
additions (e.g., maleimide addition).
[0346] In any of the above and below embodiments, L.sup.3 and
L.sup.4 represent a bond or a linker selected from the group
consisting of substituted and unsubstituted alkylene; substituted
and unsubstituted alkenylene; substituted and unsubstituted
alkynylene; substituted and unsubstituted heteroalkylene;
substituted and unsubstituted heteroalkenylene; substituted and
unsubstituted heteroalkynylene; substituted and unsubstituted
heterocyclylene; substituted and unsubstituted carbocyclylene;
substituted and unsubstituted arylene; substituted and
unsubstituted heteroarylene; and combinations thereof. Groups of
formula A, X*, and Y* are further defined herein.
[0347] In any of the embodiments herein, X* and Y* independently
represent a group --SH, --OH, --NH.sub.2, --NH--NH.sub.2,
--N.sub.3, --O--NH.sub.2, halogen (or other leaving group),
##STR00101##
wherein:
[0348] R.sup.X1 is hydrogen, halogen, or --OR.sup.X2, wherein
R.sup.X2 is hydrogen, substituted or unsubstituted alkyl,
substituted or unsubstituted alkyl; substituted or unsubstituted
alkenyl; substituted or unsubstituted alkynyl; substituted or
unsubstituted heteroalkyl; substituted or unsubstituted
heteroalkenyl; substituted or unsubstituted heteroalkynyl;
substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or an oxygen protecting
group;
[0349] W is O, S, or NR.sup.W1;
[0350] R.sup.W1 is hydrogen, substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; or a nitrogen protecting
group; and
[0351] R.sup.W2 is hydrogen, substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl; or
substituted or unsubstituted heteroaryl, or two R.sup.W2 groups are
joined to form a 5-6 membered ring.
[0352] In certain embodiments, Y* is --SH. In certain embodiments,
X* is --SH.
[0353] In certain embodiments, Y* is --OH. In certain embodiments,
X* is --OH.
[0354] In certain embodiments, Y* is --NH.sub.2. In certain
embodiments, X* is --NH.sub.2.
[0355] In certain embodiments, Y* is --NH--NH.sub.2. In certain
embodiments, X* is --NH--NH.sub.2.
[0356] In certain embodiments, Y* is --O--NH.sub.2. In certain
embodiments, X* is --O--NH.sub.2.
[0357] In certain embodiments, Y* is --N.sub.3. In certain
embodiments, X* is --N.sub.3.
[0358] In certain embodiments, Y* is halogen, e.g., --Cl, --Br, or
--I. In certain embodiments, X* is halogen, e.g., --Cl, --Br, or
--I.
[0359] In certain embodiments, Y* is --C(.dbd.O)R.sup.X1, wherein
R.sup.X1 is hydrogen, i.e., to provide Y* as an aldehyde --CHO. In
certain embodiments, X* is --C(.dbd.O)R.sup.X1, wherein R.sup.X1 is
hydrogen, i.e., to provide X* as an aldehyde --CHO.
[0360] In certain embodiments, Y* is --C(.dbd.O)R.sup.X1, wherein
R.sup.X1 is halogen (e.g., "Hal" representing --Cl, --Br, and --I),
i.e., to provide Y* as an acyl halide --C(.dbd.O)--Hal.
[0361] In certain embodiments, X* is --C(.dbd.O)R.sup.X1, wherein
R.sup.X1 is halogen (e.g., "Hal" representing --Cl, --Br, and --I),
i.e., to provide X* as an acyl halide --C(.dbd.O)--Hal.
[0362] In certain embodiments, Y* is --C(.dbd.O)R.sup.X1, wherein
R.sup.X1 is --OR.sup.X2, and wherein R.sup.X2 is hydrogen, i.e., to
provide Y* as a carboxylic acid --C(.dbd.O)OH.
[0363] In certain embodiments, X* is --C(.dbd.O)R.sup.X1, wherein
R.sup.X1 is --OR.sup.X2, and wherein R.sup.X2 is hydrogen, i.e., to
provide X* as a carboxylic acid --C(.dbd.O)OH.
[0364] In certain embodiments, Y* is --C(.dbd.O)R.sup.X1, wherein
R.sup.Z1 is --OR.sup.X2, and wherein R.sup.X2 is substituted or
unsubstituted alkyl; substituted or unsubstituted alkenyl;
substituted or unsubstituted alkynyl; substituted or unsubstituted
heteroalkyl; substituted or unsubstituted heteroalkenyl;
substituted or unsubstituted heteroalkynyl; substituted or
unsubstituted carbocyclyl; substituted or unsubstituted
heterocyclyl; substituted or unsubstituted aryl; substituted or
unsubstituted heteroaryl; or an oxygen protecting group, i.e., to
provide Y* as an ester --C(.dbd.O)OR.sup.X2
[0365] In certain embodiments, X* is --C(.dbd.O)R.sup.X1, wherein
R.sup.Z1 is --OR.sup.X2, and wherein R.sup.X2 is substituted or
unsubstituted alkyl; substituted or unsubstituted alkenyl;
substituted or unsubstituted alkynyl; substituted or unsubstituted
heteroalkyl; substituted or unsubstituted heteroalkenyl;
substituted or unsubstituted heteroalkynyl; substituted or
unsubstituted carbocyclyl; substituted or unsubstituted
heterocyclyl; substituted or unsubstituted aryl; substituted or
unsubstituted heteroaryl; or an oxygen protecting group, i.e., to
provide X* as an ester --C(.dbd.O)OR.sup.X2
[0366] In certain embodiments, X* or Y* is an oxiranyl of
formula:
##STR00102##
[0367] In certain embodiments, X* or Y* is ethynyl:
##STR00103##
[0368] In certain embodiments, X* or Y* is ethenyl:
##STR00104##
[0369] In certain embodiments, X* or Y* is an
.alpha.,.beta.-unsaturated carbonyl:
##STR00105##
[0370] In certain embodiments, X* or Y* is a maleimide group:
##STR00106##
[0371] Furthermore, as generally understood herein, X* and Y* may
react together to form a group A, wherein A is a group of the
formula:
##STR00107##
wherein:
[0372] Q is --NH--, --NH--NH--, --O--NH--, --NH--O--, --S--,
--O--;
[0373] W is O, S, or NR.sup.W1;
[0374] R.sup.W1 is hydrogen, substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; a nitrogen protecting
group if attached to a nitrogen atom, or an oxygen group if
attached to an oxygen atom; and
[0375] R.sup.W2 is hydrogen, substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl; substituted or unsubstituted
alkynyl; substituted or unsubstituted carbocyclyl; substituted or
unsubstituted heterocyclyl; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl, or two R.sup.W2 groups are
joined to form a 5-6 membered ring;
[0376] In certain embodiments, A is --NH--.
[0377] In certain embodiments, A is --NH--NH--.
[0378] In certain embodiments, A is --S--.
[0379] In certain embodiments, A is --O--.
[0380] In certain embodiments, A is a disulfide group
##STR00108##
[0381] In certain embodiments, A is
##STR00109##
wherein Q is --NH--, --NH--NH--, --O--NH--, --NH--O--, --S--,
--O--. For example, in certain embodiments, wherein Q is --NH--, A
is an amide group of the formula
##STR00110##
In certain embodiments, wherein Q is --NH--NH--, A is an amide
hydrazide group of the formula
##STR00111##
In certain embodiments, wherein Q is --S--, A is an thioester group
of the formula
##STR00112##
[0382] In certain embodiments, wherein Q is --O--, A is an ester
group of the formula
##STR00113##
[0383] In certain embodiments, A is
##STR00114##
In certain embodiments, R.sup.W2 is alkyl, e.g., methyl.
[0384] In certain embodiments, A is
##STR00115##
In certain embodiments, R.sup.W2 is alkyl, e.g., methyl. In certain
embodiments, R.sup.W1 is hydrogen.
[0385] In certain embodiments, A is
##STR00116##
In certain embodiments, R.sup.W2 is alkyl, e.g., methyl.
[0386] In certain embodiments, A is:
##STR00117##
[0387] In certain embodiments, A is:
##STR00118##
wherein R.sup.W1 is hydrogen, substituted or unsubstituted alkyl,
or an amino protecting group; and Q is --NH--, --NH--NH--,
--O--NH--, --NH--O--, --S--, --O--. In certain embodiments, Q is
--NH--. In certain embodiments, Q is --NH--NH--. In certain
embodiments, Q is --S--. In certain embodiments, Q is --O--.
[0388] In certain embodiments, A is:
##STR00119##
wherein Q is --NH--, --NH--NH--, --O--NH--, --NH--O--, --S--, or
--O--. In certain embodiments, Q is --NH--. In certain embodiments,
Q is --NH--NH--. In certain embodiments, Q is --S--. In certain
embodiments, Q is --O--.
[0389] In certain embodiments, A is:
##STR00120##
wherein Q is --NH--, --NH--NH--, --O--NH--, --NH--O--, --S--, or
--O--. In certain embodiments, Q is --NH--. In certain embodiments,
Q is --NH--NH--. In certain embodiments, Q is --S--. In certain
embodiments, Q is --O--.
[0390] In certain embodiments, A is:
##STR00121##
wherein W is O, S, or NR.sup.W1, R.sup.W1 is hydrogen, substituted
or unsubstituted alkyl, or an amino protecting group; and Q is
--NH--, --NH--NH--, --O--NH--, --NH--O--, --S--, or --O--. In
certain embodiments, W is O. In certain embodiments, W is S. In
certain embodiments, W is NR.sup.W1. In certain embodiments, Q is
--NH--. In certain embodiments, Q is --NH--NH--. In certain
embodiments, Q is --S--. In certain embodiments, Q is --O--.
[0391] In one aspect, provided is a method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, the method comprising coupling of a precursor compound of
Formula (P-I) or (P-II) or pharmaceutically acceptable salt thereof
with a compound of formula Y*-L.sup.4-R.sup.H
[0392] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling a precursor compound of Formula (P-I)
or (P-II), or pharmaceutically acceptable salt thereof, with a
compound of formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is
--C(.dbd.O)R.sup.X1, wherein R.sup.X1 is halogen or --OR.sup.X2 and
one of X* and Y* is --SH, --OH, --NH.sub.2, or --NH--NH.sub.2 to
provide a compound of Formula (I'') or (II''), wherein A is an
amide, thioester, or ester group. See, e.g., Table 2.
TABLE-US-00002 TABLE 2 R.sup.X1 Y* X* A --C(.dbd.O)Q--,
--QC(.dbd.O)-- halogen or --OR.sup.X2 --SH --C(.dbd.O)S-- --SH
--SC(.dbd.O)-- --OH --C(.dbd.O)O-- --OH --OC(.dbd.O)-- --NH.sub.2
--C(.dbd.O)NH-- --NH.sub.2 --NHC(.dbd.O)-- --NH--NH.sub.2
--C(.dbd.O)NHNH-- --NH--NH.sub.2 --NHNHC(.dbd.O)--
[0393] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling a precursor compound of Formula (P-I)
or (P-II), or pharmaceutically acceptable salt thereof, with a
compound of formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is
halogen or another leaving group, and one of X* and Y* is --SH,
--OH, --NH.sub.2, or --NH--NH.sub.2 to provide a compound of
Formula (I') or (II'), wherein A is, respectively, --S--, --O--,
--NH--, or --NH--NH--. See, e.g., Table 3.
TABLE-US-00003 TABLE 3 Y* X* A Hal or other leaving group --SH
--S-- --OH --O-- --NH.sub.2 --NH-- --NH--NH.sub.2 --NH--NH--
--O--NH.sub.2 --O--NH-- --SH Hal or other leaving group --S-- --OH
--O-- --NH.sub.2 --NH-- --NH--NH.sub.2 --NH--NH-- --O--NH.sub.2
--NH--O--
[0394] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling (azide-alkyne Huisgen cycloaddition of)
a precursor compound of Formula (P-I) or (P-II), or
pharmaceutically acceptable salt thereof, with a compound of
formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is
##STR00122##
and one of X* and Y* is --N.sub.3. See, e.g., Table 4.
TABLE-US-00004 [0395] TABLE 4 A X* Y* 1,4-adduct 1,5-adduct --
--N.sub.3 ##STR00123## ##STR00124## --N.sub.3 -- ##STR00125##
##STR00126##
[0396] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling (via thiol-yne addition of) a precursor
compound of Formula (P-I) or (P-II), or pharmaceutically acceptable
salt thereof, with a compound of formula Y*-L.sup.4-R.sup.H,
wherein one of X* and Y* is
##STR00127##
and one of X* and Y* is --SH. See, e.g., Table 5.
TABLE-US-00005 [0397] TABLE 5 X* Y* A -- --SH ##STR00128## --SH --
##STR00129##
[0398] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling a precursor compound of Formula (P-I)
or (P-II), or pharmaceutically acceptable salt thereof, with a
compound of formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is
an aldehyde --CHO or ketone, and one of X* and Y* is --NH.sub.2,
--NH--NH.sub.2, or --O--NH.sub.2. See, e.g., Table 6.
TABLE-US-00006 TABLE 6 X* Y* A -- --NH.sub.2 ##STR00130## --
--NH--NH.sub.2 ##STR00131## -- --O--NH.sub.2 ##STR00132##
--NH.sub.2 -- ##STR00133## --NH--NH.sub.2 -- ##STR00134##
--O--NH.sub.2 -- ##STR00135##
[0399] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling a precursor compound of Formula (P-I)
or (P-II), or pharmaceutically acceptable salt thereof, with a
compound of formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is
an .alpha.,.beta.-unsaturated carbonyl, and one of X* and Y* is
--OH, --SH, --NH.sub.2, --NHNH.sub.2, or --O--NH.sub.2. See, e.g.,
Table 7.
TABLE-US-00007 TABLE 7 X* Y* A ##STR00136## --OH, --SH, --NH.sub.2,
--NHNH.sub.2, --O--NH.sub.2 ##STR00137## --OH, --SH, --NH.sub.2,
--NHNH.sub.2, --O--NH.sub.2 ##STR00138## ##STR00139##
[0400] In certain embodiments, the method of preparing a compound
of Formula (I') or (II') or pharmaceutically acceptable salt
thereof comprises coupling a precursor compound of Formula (P-I) or
(P-II) or pharmaceutically acceptable salt thereof with a compound
of formula Y*-L.sup.4-R.sup.H, wherein one of X* and Y* is a
maleimide group, and one of X* and Y* is --OH, --SH, --NH.sub.2,
--NHNH.sub.2, or --O--NH.sub.2. See, e.g., Table 8.
TABLE-US-00008 TABLE 8 X* Y* A ##STR00140## --OH, --SH, --NH.sub.2,
--NHNH.sub.2, --O--NH.sub.2 ##STR00141## ##STR00142## --OH, --SH,
--NH.sub.2, --NHNH.sub.2, --O--NH.sub.2 ##STR00143## --OH, --SH,
--NH.sub.2, --NHNH.sub.2, --O--NH.sub.2 ##STR00144## ##STR00145##
--OH, --SH, --NH.sub.2, --NHNH.sub.2, --O--NH.sub.2 ##STR00146##
##STR00147##
[0401] In certain embodiments, the method of preparing a compound
of Formula (I'') or (II''), or pharmaceutically acceptable salt
thereof, comprises coupling a precursor compound of Formula (P-I)
or (P-II), or pharmaceutically acceptable salt thereof, with a
compound of formula Y*-L.sup.4-R.sup.H, wherein each of X* and Y*
is --SH to provide, upon treatment with an oxidant, a compound of
Formula (I') or (II'), or pharmaceutically acceptable salt thereof,
wherein A is a disulfide (--S--S--) bond.
Examples
[0402] In order that the invention described herein may be more
fully understood, the following examples are set forth. It should
be understood that these examples are for illustrative purposes
only and are not to be construed as limiting this invention in any
manner.
Synthetic Procedures
##STR00148##
[0403] Synthesis of Compound (2)
[0404] To a suspension of 1H-pyrazolo[3,4-d]pyrimidin-4-amine (1)
(2.8 g, 20.7 mmol) in DMF (12 mL) was added N-iodosuccinimide (5.59
g, 24.8 mmol) at ambient temperature. The reaction mixture was
heated to 80.degree. C. and stirred for 14 hr. The resulting solid
was collected by filtration, rinsed with ice-cold ethanol (20 mL),
and concentrated invacuo to provide
3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3.9 g, 72%) as an
off-white solid. MS m/z: 261.92 (M+1).
Synthesis of Compound (3)
[0405] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(531.8 mg, 2.04 mmol) in THF (12 mL) under argon atmosphere were
added 1,4-dioxaspiro[4.5]decan-8-ol (826.4 .mu.L, 6.11 mmol),
triphenylphosphine (1.07 g, 4.07 mmol) and diisopropyl
azodicarboxylate (802.3 .mu.L, 4.07 mmol) at ambient temperature in
this order. The reaction mixture was stirred at ambient temperature
for 16 hr and concentrated in vacuo. The crude mixture was taken up
in acetone (15 mL) and 6N HCl (5 mL) was added dropwise. The
solution was stirred at ambient temperature for 4 hr and
concentrated in vacuo. The residue was purified by flash-column
chromatography (5% methanol-dichloromethane) to provide
4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexanone
(337.2 mg, 46.3%) as a yellow oil. MS m/z: 357.90 (M).
Synthesis of Compound (4)
[0406] To a solution of
4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexanone
(168.5 mg, 0.47 mmol) in 1,2-dichloroethane (2.5 mL) was added
tert-butyl piperazine-1-carboxylate (158.2 mg, 0.85 mmol) at
0.degree. C. After 5 min, sodium triacetoxyborohydride (180.0 mg,
0.849 mmol) was added to the reaction mixture which was warmed up
to ambient temperature and stirred for 14 hr. The mixture was
diluted with dichloromethane (10 mL), washed with a saturated
aqueous sodium bicarbonate (10 mL) and brine (10 mL) and
concentrated invacuo. The residue was purified by flash-column
chromatography (10% methanol-dichloromethane) to provide
tert-butyl-4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohex-
yl)piperazine-1-carboxylate (89.5 mg, 36.0%) as a white solid. MS
m/z: 528.06 (M+1).
##STR00149##
Synthesis of Compound (5)
[0407] To a solution of
4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexanone
(168.5 mg, 0.47 mmol) in 1,2-dichloroethane (2.5 mL) was added
1-(piperazin-1-yl)ethanone (108.8 mg, 0.85 mmol) at 0.degree. C.
After 5 min, sodium triacetoxyborohydride (180.0 mg, 0.849 mmol)
was added to the reaction mixture which was warmed up to ambient
temperature and stirred for 14 hr. The mixture was diluted with
dichloromethane (10 mL), washed with a saturated aqueous sodium
bicarbonate (10 mL) and brine (10 mL) and concentrated invacuo. The
residue was purified by flash-column chromatography (10%
methanol-dichloromethane) to
cis-1-(4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)p-
iperazin-1-yl)ethanone (55 mg, 25%). .sup.1H NMR: (600 MHz,
DMSO-d.sub.6) .delta. (ppm): 8.31 (s, 1H); 6.05 (m, 2H); 4.83 (s,
1H); 3.65 (m, 5H); 2.58 (m, 4H); 2.39 (m, 3H); 2.10 (m, 8H); MS
m/z: 470.36 (M+1).
trans-1-(4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl-
)piperazin-1-yl)ethanone (78 mg, 35%). .sup.1H NMR: (600 MHz,
DMSO-d.sub.6) .delta. (ppm): 8.33 (s, 1H); 6.02 (m, 2H); 4.65 (s,
1H); 3.62 (m, 5H); 2.62 (m, 7H); 2.13 (m, 8H); MS m/z: 470.36
(M+1). MS m/z: 470.72 (M+1).
##STR00150##
Synthesis of Compound (6)
[0408] To a solution of
4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexanone
(168.5 mg, 0.47 mmol) in 1,2-dichloroethane (2.5 mL) was added
1-methylpiperazine (85 mg, 0.85 mmol) at 0.degree. C. After 5 min,
sodium triacetoxyborohydride (180.0 mg, 0.849 mmol) was added to
the reaction mixture which was warmed up to ambient temperature and
stirred for 14 hr. The mixture was diluted with dichloromethane (10
mL), washed with a saturated aqueous sodium bicarbonate (10 mL) and
brine (10 mL) and concentrated in vacuo. The residue was purified
by flash-column chromatography (10% methanol-dichloromethane) to
1-(4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piper-
azin-1-yl)ethanone (105 mg, 51%). MS m/z: 442.45 (M+1).
##STR00151##
Synthesis of Compound (7)
[0409] To a solution of tert-butyl
4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazi-
ne-1-carboxylate (360 mg, 0.68 mmol) in dioxane (6 mL) were added
(4-fluoro-3-nitrophenyl)boronic acid (177 mg, 0.96 mmol) and 1M
aqueous solution of sodium carbonate (2 mL) at ambient temperature.
The resulting suspension was degassed with argon for 3 min and
bis(triphenylphosphine)palladium(II) dichloride (35 mg, 0.05 mmol)
was added. The mixture was heated to 80.degree. C. and stirred for
2 hr. It was diluted with dichloromethane (30 mL), washed with
water (30 mL) and concentrated in vacuo. The residue was purified
by flash-column chromatography (10% methanol-dichloromethane) to
provide tert-butyl
4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl-
)cyclohexyl)piperazine-1-carboxylate (312 mg, 85%). MS m/z: 541.75
(M+1).
Synthesis of Compound (8)
[0410] To a solution of tert-butyl
4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl-
)cyclohexyl)piperazine-1-carboxylate (312 mg, 0.58 mmol) in
dimethylformamide (3 ml) were added phenol (81.7 mg 0.87 mmol) and
potassium carbonate (120 mg, 0.87 mmol) at ambient temperature. The
mixture was heated up to to 80.degree. C. and stirred overnight.
Worked up with dichloromethane and water, concentrated in vacuo.
The residue was purified by flash-column chromatography (10%
methanol-dichloromethane) to tert-butyl
4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-y-
l)cyclohexyl)piperazine-1-carboxylate (268.2 mg 75.4%). MS m/z:
615.49 (M+1).
##STR00152##
Synthesis of Compound (9)
[0411] To a solution of tert-butyl
4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazi-
ne-1-carboxylate (234 mg, 0.50 mmol) in dioxane (6 mL) were added
(4-fluoro-3-nitrophenyl)boronic acid (136 mg, 0.74 mmol) and 1M
aqueous solution of sodium carbonate (2 mL) at ambient temperature.
The resulting suspension was degassed with argon for 3 min and
bis(triphenylphosphine)palladium(II) dichloride (47 mg, 0.07 mmol)
was added. The mixture was heated to 80.degree. C. and stirred for
2 hr. It was diluted with dichloromethane (30 mL), washed with
water (30 mL) and concentrated in vacuo. The residue was purified
by flash-column chromatography (10% methanol-dichloromethane) to
1-(4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-
-yl)cyclohexyl)piperazin-1-yl)ethanone (188 mg, 78%). MS m/z:
482.63 (M+1).
##STR00153##
Synthesis of Compound (10)
[0412] To a solution of tert-butyl
4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl-
)cyclohexyl)piperazine-1-carboxylate (188 mg, 0.39 mmol) in
dimethylformamide (3 ml) were added phenol (56.4 mg 0.60 mmol) and
potassium carbonate (82.8 mg, 0.60 mmol) at ambient temperature.
The mixture was heated up to 80.degree. C. and stirred overnight.
The mixture was worked up with dichloromethane and water,
concentrated in vacuo. The residue was purified by flash-column
chromatography (10% methanol-dichloromethane) to
1-(4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin--
1-yl)cyclohexyl)piperazin-1-yl)ethanone (148.7 mg 68.4%). MS m/z:
557.59 (M+1).
##STR00154## ##STR00155##
Synthesis of Compound (11)
[0413] To a solution of tert-butyl
4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-y-
l)cyclohexyl)piperazine-1-carboxylate (268 mg, 0.44 mmol) in
tetrahydrofuran (5 mL) were added di-tert-butyl dicarbonate (477
mg, 2.1 mmol) and 4-dimethylaminopyridine (5.3 mg, 0.04 mmol) at
ambient temperature. The mixture was stirred for approximately 4
hours, concentrated in vacuo. The residue was purified by
flash-column chromatography (10% methanol-dichloromethane) to
tert-butyl
4-(4-(4-((tert-butoxycarbonyl)amino)-3-(3-nitro-4-phenoxyphenyl)-1H-pyraz-
olo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate (326
mg, 91%) MS m/z: 816.07 (M+1).
Synthesis of Compound (12)
[0414] To a solution of to tert-butyl
4-(4-(4-((tert-butoxycarbonyl)amino)-3-(3-nitro-4-phenoxyphenyl)-1H-pyraz-
olo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate (50
mg, 0.06 mmol) in methanol (4 mL) was added renay nichel (100 mg)
which was dispersed in methanol at ambient temperature. The round
bottom flash with the mixture was degrassed with vacuum and
inserted with hydrogen balloon. Repeat to degrass and supply
hydrogen for 3 times. The mixture was vigorously stirred for 2
hours, and filtered with celite. Celite was washed with methanol
quickly for 3 times. All elute solvent was collected and
concentration in vacu. tert-butyl
4-(4-(3-(3-amino-4-phenoxyphenyl)-4-((tert-butoxycarbonyl)amino)-1H-pyraz-
olo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate was
obtained. (45 mg, 95%) MS m/z: 786.28 (M+1).
Synthesis of Compound (13)
[0415] To a solution tert-butyl
4-(4-(3-(3-amino-4-phenoxyphenyl)-4-((tert-butoxycarbonyl)amino)-1H-pyraz-
olo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate (60
mg, 0.076 mmol) in dichloromethane (0.5 mL) were added acryloyl
chloride (8 .mu.L, 0.10 mmol) and 4-dimethylaminopyridine (4.0 mg,
0.033 mmol) at ambient temperature. The mixture was stirred for 2
hours. Then, trifluoroacetic acid (0.5 mL) was added and stirred
for another 2 hours at ambient temperature and concentrated.
N-(5-(4-amino-1-(4-(piperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidi-
n-3-yl)-2-phenoxyphenyl)acrylamide was obtained (35 mg, 85%) MS
m/z: 540.07 (M+1).
##STR00156##
Synthesis of Compound (14)
[0416] To a solution of
1-(4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin--
1-yl)cyclohexyl)piperazin-1-yl)ethanone (148.7 mg, 0.267 mmol) in
tetrahydrofuran (5 mL) were added di-tert-butyl dicarbonate (238
mg, 1.1 mmol) and 4-dimethylaminopyridine (5.3 mg, 0.04 mmol) at
ambient temperature. The mixture was stirred for approximately 4
hours, concentrated in vacuo. The residue was purified by
flash-column chromatography (10% methanol-dichloromethane) to
tert-butyl
(1-(4-(4-acetylpiperazin-1-yl)cyclohexyl)-3-(3-nitro-4-phenoxyphenyl)-1H--
pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (188 mg, 93%) MS m/z:
757.91 (M+1).
##STR00157##
Synthesis of Compound (15)
[0417] To a solution of to tert-butyl
(1-(4-(4-acetylpiperazin-1-yl)cyclohexyl)-3-(3-nitro-4-phenoxyphenyl)-1H--
pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (50 mg, 0.066 mmol) in
methanol (4 mL) was added renay nichel (100 mg) which was dispersed
in methanol at ambient temperature. The round bottom flash with the
mixture was degrassed with vacuum and inserted with hydrogen
balloon. Repeat to degrass and supply hydrogen for 3 times. The
mixture was vigorously stirred for 2 hours, and filtered with
celite. Celite was washed with methanol quickly for 3 times. All
elute solvent was collected and concentration in vacu. tert-butyl
(1-(4-(4-acetylpiperazin-1-yl)cyclohexyl)-3-(3-amino-4-phenoxyphenyl)-1H--
pyrazolo[3,4-d]pyrimidin-4-yl)carbamate was obtained (48 mg, 98%)
MS m/z: 728.04 (M+1).
##STR00158##
Synthesis of Compound (16)
[0418] To a tert-butyl
(1-(4-(4-acetylpiperazin-1-yl)cyclohexyl)-3-(3-amino-4-phenoxyphenyl)-1H--
pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (30 mg, 0.041 mmol) in
dichloromethane (0.5 mL) were added acryloyl chloride (4 .mu.L,
0.05 mmol) and 4-dimethylaminopyridine (4.0 mg, 0.033 mmol) at
ambient temperature. The mixture was stirred for 2 hours. Then,
trifluoroacetic acid (0.5 mL) was added and stirred for another 2
hours at ambient temperature and concentrated. The crude mixture
was diluted with dimethyl sulfoxide DMSO (1 mL) and directly
purified by preparative reverse-phase HPLC (methanol/water
gradient) to provide
N-(5-(4-amino-1-(4-(piperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidi-
n-3-yl)-2-phenoxyphenyl)acrylamide as a TFA salt. (TX1-85-1) (12
mg, 50%) 1H NMR: (600 MHz, DMSO-d.sub.6) .delta. (ppm): 9.94 (s,
1H); 8.38 (s, 1H); 8.32 (s, 2H); 8.23 (s, 1H); 7.37 (m, 3H); 7.06
(d, J=8.4 Hz, 2H); 6.96 (d, J=8.4 Hz, 2H); 6.64 (dd, J=17.4 and
10.8 Hz, 1H); 6.19 (dd, J=17.4 and 1.8 Hz, 1H); 5.69 (dd, J=10.8
and 1.8 Hz, 1H); 4.91 (s, 1H); 3.42 (br m, 5H); 2.56 (br m, 4H);
2.39 (s, 3H); 2.05 (m, 4H); 1.91 (br m, 4H); MS m/z: 581.43
(M+1)
##STR00159## ##STR00160##
Synthesis of Compound (17)
[0419] To a solution of 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(1g, 3.83 mmol) in dimethylformamide (15 ml) were added tert-butyl
4-bromopiperidine-1-carboxylate (1.5 g, 5.68 mmol) and potassium
carbonate (1g, 7.25 mmol) at ambient temperature. The mixture was
heated up to 80.degree. C. and stirred overnight. The mixture was
worked up with dichloromethane and water, concentrated in vacuo.
The residue was purified by flash-column chromatography
(methanol-dichloromethane) to tert-butyl
4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxyla-
te (918.5 mg 53.8%). MS m/z: 445.76 (M+1).
##STR00161## ##STR00162##
Synthesis of Compound (21)
[0420] To a solution of
3-(3-nitro-4-phenoxyphenyl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidi-
n-4-amine (100 mg, 0.23 mmol) in dimethylformamide (3 mL) were
added tert-butyl (2-bromoethyl)carbamate (78 mg, 0.35 mmol) and
potassium carbonate (128 mg, 0.93 mmol) at ambient temperature. The
reaction mixture was heated to 80.degree. C. stirred at ambient
temperature overnight. The crude was worked up with dichloromethane
and water. The product was purified by flash-column chromatography
(8% methanol-dichloromethane) to provide tert-butyl
(2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1--
yl)piperidin-1-yl)ethyl)carbamate (135.2 mg, 67.2%) as a yellow
solid. MS m/z: 575.62 (M+1).
Synthesis of Compounds (22) and (23)
[0421] To a solution of tert-butyl
(2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1--
yl)piperidin-1-yl)ethyl)carbamate (30 mg, 0.05 mmol) in
dichloromethane (1.2 mL) was added trifluoroacetic acid (500 .mu.L)
at ambient temperature. The reaction mixture was stirred at ambient
temperature for 2 hr and concentrated invacuo. The crude product
was taken up in dimethylformamide (1.0 mL), and to that solution
were added (2R)-4-((1r,3S)-adamantan-1-yl)-2-methylbutanoic acid
(10 mg, 0.042 mmol), N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide
hydrochloride (30.8 mg, 0.16 mmol) and 4-(dimethylamino)pyridine (4
mg, 0.03 mmol) at ambient temperature in this order. The reaction
mixture was stirred at ambient temperature for 3 hr. The residue
was purified by flash-column chromatography
(methanol-dichloromethane) to provide
(R)-4-((3R,5R,7R)-adamantan-1-yl)-N-(2-(4-(4-amino-3-(3-nitro-4-phenoxyph-
enyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)yl)ethylbutanamide
(17.4 mg 50.2%). MS m/z: 693.45 (M+1).
##STR00163## ##STR00164##
Synthesis of Compound (26)
[0422] Following synthetic procedures described above,
(R)--N-(2-(4-(3-(3-acrylamido-4-phenoxyphenyl)-4-amino-1H-pyrazolo[3,4-d]-
pyrimidin-1-yl)piperidin-1-yl)ethyl)-4-((3R,5R,7R)-adamantan-1-yl)-2-methy-
lbutanamide (7.3 mg) ((R)-TX2-121-1) was purified by preparative
reverse-phase HPLC (methanol/water gradient). .sup.1H NMR: (600
MHz, DMSO-d.sub.6) .delta. (ppm): 9.94 (s, 1H); 9.74 (s, 1H); 8.33
(s, 1H); 8.22 (s, 1H); 7.37 (t, J=8.4 Hz, 2H); 7.33 (dd, J=8.4 Hz
and 1.8 Hz, 1H); 7.11 (d, J=8.4 Hz, 1H); 7.07 (d, J=8.4 Hz, 2H);
6.96 (d, J=8.4 Hz, 1H); 6.64 (dd, J=17.4 and 10.8 Hz, 1H); 6.19
(dd, J=17.4 and 1.8 Hz, 1H); 5.69 (dd, J=10.8 and 1.8 Hz, 1H); 4.91
(s, 1H); 3.42 (br m, 5H); 2.56 (br m, 4H); 2.39 (s, 3H); 2.05 (m,
4H); 1.91 (br m, 4H); MS m/z: 717.42 (M+1).
##STR00165##
Synthesis of Compound (36)
[0423] Following synthetic procedures described above, but using
propionyl chloride instead of acryloyl chloride, compound 36
((R)-TX2-121-3) was prepared.
##STR00166##
Synthesis of Compound (27)
[0424] N-(5-(1-(1-(2-(2-((1
s,3s)-adamantan-1-yl)acetamido)ethyl)piperidin-4-yl)-4-amino-1H-pyrazolo[-
3,4-d]pyrimidin-3-yl)-2-phenoxyphenyl)acrylamide (15.8 mg)
(TX2-112-1) was purified by preparative reverse-phase HPLC
(methanol/water gradient). .sup.1H NMR: (600 MHz, DMSO-d.sub.6)
.delta. (ppm): 9.95 (s, 1H); 9.50 (br s, 1H); 8.37 (s, 1H); 8.29
(s, 1H); 7.37 (t, J=8.4 Hz, 2H); 7.33 (dd, J=8.4 Hz and 1.8 Hz,
1H); 7.13 (d, J=8.4 Hz, 1H); 7.07 (d, J=8.4 Hz, 2H); 6.76 (d, J=8.4
Hz, 1H); 6.64 (dd, J=17.4 and 10.8 Hz, 1H); 6.20 (dd, J=17.4 and
1.8 Hz, 1H); 5.70 (dd, J=10.8 and 1.8 Hz, 1H); 4.99 (br m, 1H);
3.66 (m, 5H); 3.38 (br m); 3.24 (br m); 2.43 (s, 3H); 2.35 (m);
2.14 (br m); 1.85 (br m); MS m/z: 675.41 (M+1).
##STR00167##
Synthesis of Compound (28)
[0425] N-(5-(1-(1-(2-(2-(2-((1
s,3s)-adamantan-1-yl)acetamido)ethoxy)ethyl)piperidin-4-yl)-4-amino-1H-py-
razolo[3,4-d]pyrimidin-3-yl)-2-phenoxyphenyl)acrylamide (12.3 mg)
(TX2-114-1) was purified by preparative reverse-phase HPLC
(methanol/water gradient). 1H NMR: (600 MHz, DMSO-d.sub.6) .delta.
(ppm): 10.0 (s, 1H); 9.66 (br s, 1H); 8.47 (s, 1H); 8.38 (s, 1H);
7.47 (t, J=8.4 Hz, 2H); 7.42 (dd, J=8.4 Hz and 1.8 Hz, 1H); 7.23
(t, J=8.4 Hz, 1H); 7.16 (d, J=8.4 Hz, 2H); 7.05 (d, J=8.4 Hz, 1H);
6.74 (dd, J=17.4 and 10.8 Hz, 1H); 6.30 (dd, J=17.4 and 1.8 Hz,
1H); 5.79 (dd, J=10.8 and 1.8 Hz, 1H); 5.10 (br m, 1H); 3.80 (m,
5H); 3.73 (br m, 4H); 3.51 (br m, 4H); 3.27 (br m) 2.57 (s); 2.23
(m); 1.90 (br m); MS m/z: 719.44 (M+1).
##STR00168##
Synthesis of Compound (29)
[0426]
N-(5-(4-amino-1-(1-methylpiperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidi-
n-3-yl)-2-phenoxyphenyl)acrylamide (5.0 mg) (TX2-120-1) was
purified by preparative reverse-phase HPLC (methanol/water
gradient). 1H NMR: (600 MHz, DMSO-d.sub.6) .delta. (ppm): 10.0 (s,
1H); 9.56 (br s, 1H); 8.42 (s, 1H); 8.30 (s, 1H); 7.473 (t, J=8.4
Hz, 2H); 7.39 (dd, J=8.4 Hz and 1.8 Hz, 1H); 7.19 (t, J=8.4 Hz,
1H); 7.11 (d, J=8.4 Hz, 2H); 7.03 (d, J=8.4 Hz, 1H); 6.70 (dd,
J=17.4 and 10.8 Hz, 1H); 6.26 (dd, J=17.4 and 1.8 Hz, 1H); 5.76
(dd, J=10.8 and 1.8 Hz, 1H); 5.05 (br m, 1H); 3.80 (m); 3.70 (br
m); 3.16 (br m); 2.49 (s); MS m/z: 470.34 (M+1).
##STR00169##
Synthesis of Compound (32)
[0427] To a solution of 1-methyl-1H-indole-2-carboxylic acid (75.0
mg, 0.43 mmol) in dichloromethane (1.2 mL) were added oxalyl
chloride (44.8 .mu.L, 0.51 mmol) and a catalytic amount of
dimethylformamide at ambient temperature. The reaction mixture was
stirred at ambient temperature for 2 h, and concentrated invacuo.
The crude material was taken up with dichloromethane (2.0 mL), and
to that solution were added 4-amino-3-methoxyphenylboronic acid
pinacol ester (106.6 mg, 0.43 mmol), N,N-diisopropylethylamine
(111.9 .mu.L, 0.64 mmol) and 4-(dimethylamino)pyridine (5.2 mg,
0.043 mmol) sequentially. The reaction mixture was stirred at
ambient temperature for 3 hr. The mixture was diluted with
dichloromethane (10 mL), washed with water and concentrated
invacuo. The residue was directly used for the next step without
further purification. MS m/z: 406.98 (M).
##STR00170##
Synthesis of Compound (33)
[0428] To a solution of
tert-butyl-4-(4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohex-
yl)piperazine-1-carboxylate (64.0 mg, 0.12 mmol) in dioxane (1.94
mL) were added
N-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-
-1-methyl-1H-indole-2-carboxamide (59.5 mg, 0.15 mmol) and 1M
aqueous solution of sodium carbonate (485 .mu.L) at ambient
temperature. The resulting suspension was degassed with argon for 3
min and bis(triphenylphosphine)palladium(II) dichloride (8.5 mg,
0.012 mmol) was added. The mixture was heated to 80.degree. C. and
stirred for 2 hr. It was diluted with dichloromethane (10 mL),
washed with water (10 mL) and concentrated invacuo. The residue was
purified by flash-column chromatography (10%
methanol-dichloromethane) to provide tert-butyl
4-(4-(4-amino-3-(3-methoxy-4-(1-methyl-1H-indole-2-carboxamido)phenyl)-1H-
-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate
(55.2 mg, 66.9%) as a brown solid. MS m/z: 680.30 (M+1).
Synthesis of Compound (34)
[0429] To a solution of tert-butyl
4-(4-(4-amino-3-(3-methoxy-4-(1-methyl-1H-indole-2-carboxamido)phenyl)-1H-
-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazine-1-carboxylate
(33.1 mg, 0.049 mmol) in dichloromethane (1.1 mL) was added
trifluoroacetic acid (250 .mu.L) at ambient temperature. The
reaction mixture was stirred at ambient temperature for 2 hr and
concentrated. The crude product was taken up in acetonitrile (1.2
mL), and to that solution were added tert-Butyl
N-(2-bromoethyl)carbamate (16.4 mg, 0.073 mmol) and potassium
carbonate (26.9 mg, 0.20 mmol) sequentially. The mixture was heated
to reflux and stirred for 1 hr. The residual solid was filtered and
washed with ethyl acetate (10 mL), and the filtrated was
concentrated invacuo. This residue was purified by flash-column
chromatography (8% methanol-dichloromethane) to provide tert-butyl
(2-(4-(4-(4-amino-3-(3-methoxy-4-(1-methyl-1H-indole-2-carboxamido)phenyl-
)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethyl)carbama-
te (21.6 mg, 61.6%) as a yellow solid. MS m/z: 723.33 (M+1).
Synthesis of Compound (35)
[0430] To a solution of tert-butyl
(2-(4-(4-(4-amino-3-(3-methoxy-4-(1-methyl-1H-indole-2-carboxamido)phenyl-
)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethyl)carbama-
te (21.6 mg, 0.03 mmol) in dichloromethane (1.2 mL) was added
trifluoroacetic acid (300 .mu.L) at ambient temperature. The
reaction mixture was stirred at ambient temperature for 2 hr and
concentrated invacuo. The crude product was taken up in
dimethylformamide (1.0 mL), and to that solution were added
4-(adamantan-1-yl)-2-methylbutanoic acid (8.5 mg, 0.036 mmol),
N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (17.3
mg, 0.09 mmol) and 4-(dimethylamino)pyridine (0.4 mg, 0.003 mmol)
at ambient temperature in this order. The reaction mixture was
stirred at ambient temperature for 3 hr. The crude mixture was
diluted with water (1 mL) and directly purified by preparative
reverse-phase HPLC (methanol/water gradient) to provide
(R)--N-(4-(1-(4-(4-(2-(4-(adamantan-1-yl)-2-methylbutanamido)ethyl)pipera-
zin-1-yl)cyclohexyl)-4-amino-1H-pyrazolo
[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide
(SML-11-124-1) as a mixture of cis/trans isomers (6.3 mg, 25.0%) as
a TFA salt. MS m/z: 841.38 (M+1).
Biological Assays
Invitrogen LanthaScreen.TM. Eu Kinase Binding Assay
[0431] FIG. 2 depicts binding affinity data for exemplary compounds
of Formula (II). Binding affinity (IC.sub.50) was measured by
Invitrogen LanthaScreen.TM. Eu kinase binding assay which is based
on the binding and displacement of Alexa Fluor 647 labeled
ATP-competitive kinase inhibitor scaffold (Kinase Tracer 178).
Binding of the tracer to the kinase is detected using a
europium-labeled anti-tag antibody (anti-GST). The binding of both
the tracer and antibody to the kinase results in a high degree of
FRET (fluorescenece resonance energy transfer) from the europium
donor fluorophore to the Alexa Fluor 647 acceptor fluoropore on the
kinase tracer. Binding of an inhibitor to the kinase competes for
binding with the tracer, resulting in a loss of FRET. The typical
experiment procedure is shown below: [0432] (1) Purified
ErbB3(667-1053) protein was obtained from Invitrogen at a
concentration of 1.19 mg/ml. The buffer is 50 mM Tris (pH 7.5), 150
mM NaCl, 0.5 mM EDTA, 0.02% Triton.RTM. X-100, 2 mM DTT, 50%
Glycerol. Dilute to 30 nM with Kinase Buffer A (50 mM HEPES ph 7.5,
10 mM MgCl.sub.2, 1 mM EGTA, 0.01% Brij-35). [0433] (2) 1 to 1 mix
ErbB3 protein with 12 nM LanthaScreen.TM. Eu-anti-GST antibody
solution which was also dilute in Kinase Buffer A. Prior to use,
the antibody tube should be thawed and centrifuged at approximately
10,000g for 5 minutes, and the solution needed for the assay should
be aspirated from the top of the solution. This centrifugation step
will eliminate spurious data points that can arise on occasion due
to any particulates in the product. [0434] (3) Add 5 ul the mixture
of ErbB3 protein and Eu-anti-GST to 5 ul test compound solution per
well in coming 384 plates. [0435] (4) Add 5 ul tracer 178 at
concentration of 39 nM per well. [0436] (5) Incubate for 3 hours at
4.degree. C. and read plate with Perkin Elmer EnVision.
CellTiter-Glo.RTM. Luminescent Assay
[0437] FIG. 3 depicts anti-proliferation data for exemplary
compounds of Formula (II). The anti-proliferation assay was carried
out by using 96 well white bottom plates. 2000-4000 cells were
seeded per well, and the medium volume per well was about 100 ul.
Incubate for 3 days after adding and titrating indicated
concentration of compounds. The cell viability was test by
CellTiter-Glo.RTM. Luminescent Assay. In a typical experiment, add
10 ul CellTiter-Glo.RTM. reagent per well. Mix and shake the plate
for 2 minutes to induce cell lysis at room temperature. Allow the
plate to incubate at room temperature for approximately 10 minutes
to stabilize luminescent signal. Read plate with Perkin Elmer
EnVision. The cell numbers were normalized by the DMSO control. And
the EC.sub.50s were calculated by GraphPad Prism.
Electrophoretic Gel (SDS-PAGE)
[0438] FIGS. 4A and 4B depict electrophoretic gel image (SDS-PAGE)
results of compounds TX2-112-1, TX2-113-1, TX2-114-1, TX2-120-1,
and TX2-121-1 (FIG. 4A) and SML-11-124-1 and TX2-126-1 (FIG. 4B)
immunoblotted against various antibodies; line 1: ErbB3 antibody;
line 2: Phospho-Akt (Ser473) antibody; line 3: p44/42 MAPK
(p-Erk1/2) antibody; line 4: T-Akt antibody; and line 5:
Phospho-p44/42 MAPK (T-Erk1/2) (Thr202/Thr204) antibody. The
general procedure for running this gel is provided below.
[0439] PC9 Gefitinib Resistant 4 (GR4) cells were cultured in 60 mm
plate with 10% fetal bovine serum (FBS), Roswell Park Memorial
Institute medium (RPMI) medium. When the confluence reached 80%,
cells were treated with compounds in indicated concentration. After
4 hours, wash cells with medium for three times. Cells were
cultured for another 4 hours, followed by 3 times PBS washes. Cells
were lysed with lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1
mM EDTA, 1% NP-40, 5% glycerol, Roche PhosSTOP phosphatase
inhibitor cocktail tablets and Roche Complete Protease inhibitor
cocktail tablets). The cell lysate was rotated end-to-end for
approximately 30 min, centrifuged at 10,000g for 15 minutes at
4.degree. C. The supernatant was transferred to new tubes. The
total protein concentration was measure by Pierce BCA protein
assay: BCA reagent A and B were mixed with the ration of 20:1.
Pipette 1 ml the mixture to each disposal plastic cuvette, add 2 ul
lysate. Incubate at 37.degree. C. for approximately 30 minutes.
Cool all tubes to room temperature.
[0440] With the spectrophotometer set to 562 nm, zero the
instrument on a cuvette filled only with water. Subsequently,
measure the absorbance of all the samples with 10 minutes. Subtract
the average 562 nm absorbance measurement of the Blank standard
replicates from the 562 nm absorbance measurement of all other
individual standard and unknown sample replicates. Prepare a
standard curve by plotting the average Blank-corrected 562 nm
measurement for each BSA standard vs. its concentration. Use the
standard curve to determine the protein concentration of each
unknown sample. Dilute all samples to 1.0 mg/ml with lysis buffer.
Add same volume 1:1 loading buffer to samples, heat samples at
95.degree. C. for 10 min. Run samples on an SDS-PAGE gel at
110V.
[0441] After transferred, the membrane was immunoblotted with
antibodies: ErbB3 antibody, Santa Cruz sc-285; Phospho-Akt (Ser473)
antibody, Cell Signaling 4058; Akt antibody, Cell Signaling 4685;
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Thr204), Cell Signaling 4377;
p44/42 MAPK (Erk1/2), Cell Signaling 4695.
OTHER EMBODIMENTS
[0442] In the claims articles such as "a," "an," and "the" may mean
one or more than one unless indicated to the contrary or otherwise
evident from the context. Claims or descriptions that include "or"
between one or more members of a group are considered satisfied if
one, more than one, or all of the group members are present in,
employed in, or otherwise relevant to a given product or process
unless indicated to the contrary or otherwise evident from the
context. The invention includes embodiments in which exactly one
member of the group is present in, employed in, or otherwise
relevant to a given product or process. The invention includes
embodiments in which more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product
or process.
[0443] Furthermore, the invention encompasses all variations,
combinations, and permutations in which one or more limitations,
elements, clauses, and descriptive terms from one or more of the
listed claims is introduced into another claim. For example, any
claim that is dependent on another claim can be modified to include
one or more limitations found in any other claim that is dependent
on the same base claim. Where elements are presented as lists,
e.g., in Markush group format, each subgroup of the elements is
also disclosed, and any element(s) can be removed from the group.
It should it be understood that, in general, where the invention,
or aspects of the invention, is/are referred to as comprising
particular elements and/or features, certain embodiments of the
invention or aspects of the invention consist, or consist
essentially of, such elements and/or features. For purposes of
simplicity, those embodiments have not been specifically set forth
in haec verba herein. It is also noted that the terms "comprising"
and "containing" are intended to be open and permits the inclusion
of additional elements or steps. Where ranges are given, endpoints
are included. Furthermore, unless otherwise indicated or otherwise
evident from the context and understanding of one of ordinary skill
in the art, values that are expressed as ranges can assume any
specific value or sub-range within the stated ranges in different
embodiments of the invention, to the tenth of the unit of the lower
limit of the range, unless the context clearly dictates
otherwise.
[0444] This application refers to various issued patents, published
patent applications, journal articles, and other publications, all
of which are incorporated herein by reference. If there is a
conflict between any of the incorporated references and the instant
specification, the specification shall control. In addition, any
particular embodiment of the present invention that falls within
the prior art may be explicitly excluded from any one or more of
the claims. Because such embodiments are deemed to be known to one
of ordinary skill in the art, they may be excluded even if the
exclusion is not set forth explicitly herein. Any particular
embodiment of the invention can be excluded from any claim, for any
reason, whether or not related to the existence of prior art.
[0445] Those skilled in the art will recognize or be able to
ascertain using no more than routine experimentation many
equivalents to the specific embodiments described herein. The scope
of the present embodiments described herein is not intended to be
limited to the above Description, but rather is as set forth in the
appended claims. Those of ordinary skill in the art will appreciate
that various changes and modifications to this description may be
made without departing from the spirit or scope of the present
invention, as defined in the following claims.
* * * * *